Synthetic vaccines against francisella tularensis

Abstract

The present invention relates to a synthetic saccharide of general formula (I) that is related to O-antigen capsular polysaccharide of Francisella tularensis, a conjugate thereof and the use of said saccharide and conjugate for raising a protective immune response in a human and / or animal host. Furthermore, the synthetic saccharide of general formula (I) is useful as marker in immunological assays for detection of antibodies against Francisella tularensis bacteria type A and type B. Another aspect of the present invention is directed to a monoclonal antibody having specificity for a synthetic saccharide of general formula (I).

Description

[0001] -ABK>

[0002] 1

[0003] Synthetic vaccines against Francisella tularensis

[0004] Field of the invention

[0005] The present invention relates to a synthetic saccharide of general formula (I) that is related to O-antigen capsular polysaccharide of Francisella tularensis, a conjugate thereof and the use of said saccharide and conjugate for raising a protective immune response in a human and / or animal host. Furthermore, the synthetic saccharide of general formula (I) is useful as marker in immunological assays for detection of antibodies against Francisella tularensis bacteria. Another aspect of the present invention is directed to a monoclonal antibody having specificity for a synthetic saccharide of general formula (I).

[0006] Background of the invention

[0007] Francisella tularensis, the causative agent of tularemia (rabbit fever), is an aerobic, Gram-negative, facultative intracellular bacterium. As a zoonotic pathogen, it can affect a variety of animals and can be transmitted to humans in different ways with various clinical outcomes (see e.g. Appelt, S.; Faber, M.; Kdppen, K.; Jacob, D.; Grunow, R.; Heuner, K. Francisella tularensis Subspecies holarctica and Tularemia in Germany. Microorganisms 2020, 8, 1448). F. tularensis can be the result of infected insect bites (in Germany mainly ticks), inhalation, ingestion of contaminated food or water, or inoculation through a break in the skin. This highly virulent pathogen requires approximately ten organisms to cause disease in humans. The disease outcome depends on the virulence of the infecting organisms and the infection route, where pneumonic tularemia is the most severe form with a 30% to 60% mortality rate if left untreated (J. Sharon et al., Clinical and Vaccine Immunology 2014, 21 , 227- 233). Classified as a category A bioterrorism agent by the Center for Disease Control and Prevention (CDC), F. tularensis can be easily aerosolized for high infectivity in humans (A. Chong, J. Celli, Front. Microbiol. 2010, 1 , 138). The subspecies tularensis (type A) and holarctica (type B) mainly cause human tularemia, with type A being more severe and life-threatening, while type B is more prevalent (G. Stefanetti, N. Okan, A. Fink, E. Gardner, D. L. Kasper, Proc. Natl. Acad. Sci. U. S. A. 2019, 116, 7062-7070).

[0008] GAR-P04620W004 Application (final) docx - ABK> 2

[0009] A live attenuated vaccine strain of type B F. tularensis strain has been developed clinically but it did not provide complete protection against all forms of the infections especially against pulmonary infection caused by inhalation. A new defined subunit vaccine comprised of F. tularensis cell surface O-antigen components such as lipopolysaccharide (LPS), or O-antigen capsular polysaccharide (CPS) was developed (see R. W. Titball et al., Nat. Rev. Microbiol. 2004, 2, 967-978; and J. Sharon, Clinical and Vaccine Immunology 2014, 21 , 227-233). Mice vaccinated with O-antigen from mild acid hydrolysis of F. tularensis LPS, conjugated with bovine serum albumin (BSA), showed complete protection against intradermal challenge with highly virulent type B strain and partial protection against aerosol challenge with more severe type A strain. A highly branched synthetic hexasaccharide resembling inner core of F. tularensis LPS, unlike the full length LPS, did not elicit an antigenic response in mice (see G.-J. Boons, J. Am. Chem. Soc. 2012, 134, 14255-14262).

[0010] The O-antigen capsular polysaccharide of F. tularensis strain 15 is an alternative for the development of diagnostics and vaccines against tularemia. Both type A tularensis and type B holarctica subspecies share a common O-antigen capsular polysaccharide on their cell surfaces containing a tetrasaccharide repeating unit (RU), wherein one or two repeating units are sufficient to provide protection against tularemia.

[0011] -^2)- / 3-D-Quip4NFm-(1 -^4)-o-D-GalNAcAN-(1 -^4)-o-D-GalNAcAN-(1 -^3)- / 3-D- QuipNAc-(1 ^

[0012] Bacterial capsular polysaccharides are promising vaccine candidates against a number of pathogens given their presentation of unique glycans at the termini (P. H. Seeberger, Chem. Rev., 2021 , 121 , 3598-3626.). Nevertheless, the advancement of vaccines, diagnostics, or therapeutic tools necessitates a comprehensive structural understanding concerning the glycan motif that is recognized by protective antibodies (D. L. Kasper et al., Proc. Natl. Acad. Sci. U. S. A. 2019, 116, 7062-7070). Although

[0013] GAR-P04620W004 Application (final) docx -ABK-

[0014] 3 oligosaccharide fragments from F. tularensis can be obtained by mild hydrolysis of LPS, their isolation is hazardous (G.-J. Boons et al., J. Am. Chem. Soc. 2012, 134, 14255-14262.). Therefore, the chemical synthesis of oligosaccharide fragments resembling F. tularensis strains is an attractive alternative. The O-antigen repeating unit of F. tularensis strain 15 CPS consists of two rare deoxy amino sugars, A / -acetyl- D-quinovosamine (QuipNAc) and ZV-formyl-4-amino-D-quinovose (Quip4NFm), and two / V-acetyl-D-galactosamine uronamides (GalNAcAN). The presence of two different types of rare deoxy amino sugars, two oxidative centers in D-galactosamine derivatives, two consecutive 1 ,2-c / s a-glycosidic linkages, and three different A / -functional groups in the Rll provides a multitude of synthetic challenges.

[0015] Lu Zhaohua et al. (Clinical and Vaccine Immunology 2013, 21 (2)227-233) reports on mouse monoclonal antibodies specific to the O-polysaccharide of F. tularensis lipopolysaccharide (Qui4NFm-GalNAcAN-GalNAcAN-QuiNAc): The monoclonal antibody Ab63 recognizes a terminal epitope located at the non-reducing end of the native Francisella tularensis O-antigen tetrasaccharide, binding the terminal Qui4NFm residue together with part of the adjacent sugar within a defined three- dimensional conformation of the polysaccharide chain. Structural modeling revealed that Ab63 forms a compact aromatic pocket accommodating the terminal sugar moiety in its natural orientation. The second antibody, Ab52, binds a repeating internal epitope spanning two consecutive tetrasaccharide repeats (approximately a hexasaccharide), indicating interaction with a larger, extended region of the polymeric O-antigen.

[0016] The international patent application WO 2008 / 133645 A2 discloses conjugate vaccines comprising a Francisella tularensis O-antigen polysaccharide, particularly a tetrasaccharide repeat unit from the O-antigen chemically linked to immunogenic carriers such as tetanus toxoid, bovine serum albumin, or human serum albumin. The polysaccharides are obtained from Francisella tularensis bacteria by hydrolysis, extraction and purification from bacterial cultures, followed by optional fragmentation into smaller saccharide units such as tetrasaccharide, trisaccharide, disaccharide, and monosaccharide.

[0017] The article from Seeberger (Chemical Reviews 2021 , 121 (7), 3598-3626) reports advances in the development of semi-synthetic and fully synthetic carbohydrate- based vaccines against bacterial infections. Strategies are described for identifying protective carbohydrate antigens, assembling them either by chemical synthesis or by combining synthetic fragments with naturally derived components, and linking them to immunogenic carriers. These approaches enable precise control over

[0018] GAR-P04620W004 Application (final) docx -ABK>

[0019] 4 antigen structure and composition, offering potential for improved safety, efficacy, and scalability compared to vaccines based solely on isolated bacterial polysaccharides. The article also emphasizes the critical role of linker chemistry in creating glycoconjugates, ensuring selective and efficient coupling between the glycan and carrier protein while avoiding immunogenic linkers.

[0020] It is the objective of the present invention to provide a saccharide of general formula (I) that is related to the Francisella tularensis strain 15 O-antigen capsular polysaccharide, as well as a conjugate of the saccharide of general formula (I) with an immunogenic carrier, such as a carrier protein. The saccharide of general formula (I), and particularly the conjugate of said saccharide with an immunogenic carrier is able to raise a protective immune response against F. tularensis O-antigen CPS in a human and / or animal host. Thus, a vaccine composition for immunization against F. tularensis comprising the saccharide of general formula (I), and / or a conjugate thereof is provided. Furthermore, the synthetic saccharide of general formula (I) is useful as marker in immunological assays for detection of antibodies against F. tularensis bacteria.

[0021] The objective of the present invention is solved by the teaching of the independent claims. Further advantageous features, aspects and details of the invention are evident from the dependent claims, the description, the figures, and the examples of the present application.

[0022] Description of the invention

[0023] Definitions

[0024] The term “linker” as used herein encompasses molecular fragments capable of connecting the reducing-end monosaccharide of a saccharide with an immunogenic carrier or a solid support, optionally by binding to at least one interconnecting molecule. Thus, the function of the linker perse or together with the interconnecting molecule is to establish, keep and / or bridge a special distance between the reducing- end monosaccharide and an immunogenic carrier or a solid support. More specifically, one extremity of the linker is connected to the exocyclic oxygen atom at the anomeric center of the reducing-end monosaccharide and the other extremity is connected via the nitrogen atom with the interconnecting molecule, or directly with the immunogenic carrier or the solid support.

[0025] As used herein, the term “interconnecting molecule" refers to a bifunctional molecule containing functional group X and functional group Y, wherein functional group X is

[0026] GAR-P04620W004 Application (final) docx -ABK>

[0027] 5 capable of reacting with the terminal amino group on the linker L and the functional group Y is capable of reacting with a functionality present on an immunogenic carrier or on a solid support. Figure 2 displays examples of commercially available interconnecting molecules, but does not restrict the interconnecting molecules that can be used according to the present invention to the examples displayed herein.

[0028] The term “adjuvant’ as used herein refers to an immunological adjuvant i.e. a material used in a vaccine composition that modifies or augments the effects of said vaccine by enhancing the immune response to a given antigen contained in the vaccine without being antigenically related to it. For the person skilled in the art, classically recognized examples of adjuvants include:

[0029] - mineral-containing compositions, including calcium salts and aluminium salts (or mixtures thereof). Calcium salts include calcium phosphate. Aluminium salts include hydroxides, phosphates, sulfates, etc., with the salts taking any suitable form (e.g. gel, crystalline, amorphous, etc.). Adsorption to these salts is preferred. The mineral containing compositions may also be formulated as a particle of metal salt. The adjuvants known as aluminium hydroxide and aluminium phosphate may be also used. The invention can use any of the "hydroxide" or "phosphate" adjuvants that are in general used as adjuvants. The adjuvants known as "aluminium hydroxide" are typically aluminium oxyhydroxide salts, which are usually at least partially crystalline. The adjuvants known as "aluminium phosphate" are typically aluminium hydroxyphosphates, often also containing a small amount of sulfate (i. e. aluminium hydroxyphosphate sulfate). They may be obtained by precipitation, and the reaction conditions and concentrations during precipitation influence the degree of substitution of phosphate for hydroxyl in the salt. Mixtures of both an aluminium hydroxide and an aluminium phosphate can be employed in the formulation according to the present invention;

[0030] - saponins, which are a heterologous group of sterol glycosides and triterpenoid glycosides that are found in the bark, leaves, stems, roots and even flowers of a wide range of plant species. Saponins from the bark of the Quillaia saponaria, Molina tree have been widely studied as adjuvants. Saponins can also be commercially obtained from Smilax ornata (sarsaprilla), Gypsophilla paniculata (brides veil), and Saponaria oficianalis (soap root). Saponin adjuvant formulations include purified formulations, such as QS21 , as well as lipid formulations, such as ISCOMs. Saponin compositions have been purified using HPLC and RP-HPLC. Specific purified fractions using these techniques have been identified, including QS7, QS 17, QS 18, QS2 1 , QH-A, QH-B and QH-C. Saponin formulations may also comprise a sterol, such as cholesterol. Combinations of saponins and cholesterols can be used to form unique particles called immunostimulating complexes (ISCOMs).

[0031] GAR-P04620W004 Application (final) docx -ABK>

[0032] 6

[0033] ISCOMs generally include a phospholipid such as phosphatidylethanolamine or phosphatidylcholine. Any known saponin can be used in ISCOMs. Preferably, the ISCOM includes one or more of QuilA, QHA & QHC;

[0034] - microparticles (i.e. a particle of 100 nm to 150 pm in diameter, more preferably 200 nm to 30 pm in diameter, or 500 nm to 10 pm in diameter) formed from materials that are biodegradable and non-toxic. Such non-toxic and biodegradable materials include, but are not restricted to poly(a-hydroxy acid), polyhydroxybutyric acid, polyorthoester, polyanhydride, polycaprolactone;

[0035] - CD1d ligands, such as an a-glycosylceramide, phytosphingosine-containing a-glycosylceramides, OCH, KRN7000 [(2S,3S,4R)-1-O-(a-D-galactopyranosyl)-2-( / V- hexacosanoylamino)-1 ,3,4-octadecanetriol], CRONY- 101 , 3"-sulfo-galactosyl- ceramide;

[0036] - immunostimulatory oligonucleotides, such CpG motif containing ones (a dinucleotide sequence containing an unmethylated cytosine residue linked by a phosphate bond to a guanosine residue), or CpI motif containing ones (a dinucleotide sequence containing cytosine linked to inosine), or a double-stranded RNA, or an oligonucleotide containing a palindromic sequence, or an oligonucleotide containing a poly(dG) sequence. Immunostimulatory oligonucleotides can include nucleotide modifications / analogs such as phosphorothioate modifications and can be doublestranded or (except for RNA) single-stranded;

[0037] - compounds containing lipids linked to a phosphate-containing acyclic backbone, such as the TLR4 antagonist E5564;

[0038] - oil emulsions (e.g. Freund's adjuvant).

[0039] Theoretically, each molecule or substance that is able to favor or amplify a particular situation in the cascade of immunological events, ultimately leading to a more pronounced immunological response, can be defined as an adjuvant.

[0040] In principle, through the use of adjuvants in vaccine formulations, one can

[0041] - direct and optimize immune responses that are appropriate or desirable for the vaccine;

[0042] - enable mucosal delivery of vaccines, i.e. administration that results in contact of the vaccine with a mucosal surface such as buccal or gastric or lung epithelium and the associated lymphoid tissue;

[0043] - promote cell-mediated immune responses;

[0044] - enhance the immunogenicity of weaker immunogens, such as highly purified or recombinant antigens;

[0045] - reduce the amount of antigen or the frequency of immunization required to provide protective immunity; and

[0046] GAR-P04620W004 Application (final) docx -ABK>

[0047] 7

[0048] - improve the efficacy of vaccines in individuals with reduced or weakened immune responses, such as newborns, the aged, and immunocompromised vaccine recipients.

[0049] Although little is known about their mode of action, it is currently believed that adjuvants augment immune responses by one of the following mechanisms:

[0050] - increasing the biological or immunologic half-life of antigens;

[0051] - improving antigen delivery to antigen-presenting cells (APCs), as well as antigen processing and presentation by the APCs e.g., by enabling antigen to cross endosomal membranes into the cytosol after ingestion of antigen-adjuvant complexes by APC;

[0052] - mimicking danger inducing signals from stressed or damaged cells, which serve to initiate an immune response;

[0053] - inducing the production of immunomodulatory cytokines;

[0054] - biasing the immune response towards a specific subset of the immune system; and

[0055] - blocking the rapid dispersal of the antigen challenge.

[0056] Saccharides are known by the person skilled in the art as TI-2 (T cell independent-2) antigens and poor immunogens. Therefore, to produce a saccharide-based vaccine, said saccharide is conjugated to an immunogenic carrier to provide a conjugate, which presents an increased immunogenicity in comparison with the saccharide. In this context the term “immunogenic carrier” is defined as a structure, which is conjugated to the saccharide to form a conjugate that presents an increased immunogenicity in comparison with the saccharide per se. Thus, the conjugation of the saccharides to the immunogenic carrier has as effect the stimulation of the immune response against said saccharide, without inducing an immune response against the said immunogenic carrier.

[0057] Surprisingly, it was found that a pure saccharide of general formula (I) according to the present invention contains a protective immunogenic glycan epitope and is able to induce a protective immune response against Francisella tularensis bacteria in a human and / or animal host. The saccharide of general formula (I) elicits antibodies that are cross-reacting with the F. tularensis strain 15 O-antigen CPS, recognize specifically F. tularensis bacteria of type A and type B.

[0058] In immunization studies using the semisynthetic glycoconjugates I3-CRM197 and 18- CRM197 in mice, the inventors could demonstrate a strong and specific immune response against the Francisella tularensis O-antigen fragments (see Figure 10 to Figure 14). Both conjugates induced robust IgM and IgG production, confirming

[0059] GAR-P04620W004 Application (final) docx -ABK>

[0060] 8 effective B-cell activation and class switching. Remarkably, I3-CRM197 elicited IgG antibodies that not only recognized glycan 13 but also cross-reacted with structurally related glycans, while I8-CRM197 produced a highly specific response towards glycan 18. Monoclonal antibodies derived from these immunizations bound selectively to the respective synthetic glycans and, in the case of mAb 13, exhibited strong reactivity to several F. tularensis subspecies. These findings were unexpected, as minimal synthetic saccharide conjugates were not anticipated to induce such pronounced isotype switching and affinity maturation comparable to that of native polysaccharide antigens. The results clearly demonstrate that the designed synthetic antigens effectively mimic the natural O-antigen epitopes, resulting in a mature, high-affinity immune response with potential for both diagnostic and protective applications, and underscores the immunological potency and practical advantage of the semisynthetic design over naturally derived conjugates.

[0061] Thus, the present invention relates to a saccharide of general formula (I)

[0062] H-Ux+1-Ux-T-O-L-NH2

[0063] (I) wherein x is an integer selected from 1 , 2, 3, and 4;

[0064] -T- represents a bond, -Ux+3-, -Ux+3-Ux+2-, -Ux+3-Ux+2-Ux+i-, or

[0065] - [Ux+3- Ux+2- Ux+i- Ux]n- with n being an integer selected from 1 , 2 and 3;

[0066] R1represents -CH2OH or -CONH2;

[0067] L represents a linker; or a pharmaceutically acceptable salt thereof

[0068] -L- is defined as a linker and is part of the fragment -O-L-NH2. Thus, the linker -L- is bound to an oxygen atom and to the nitrogen atom of the NH2-group. It is preferred that at least two carbon atoms of the linker are between the oxygen atom and the NH2-group, like -O-C-C-NH2. The linker -L- can be an aliphatic chain,

[0069] GAR-P04620W004 Application (final) docx -ABK>

[0070] 9 wherein the aliphatic chain can optionally include an aromatic chain inserted in it, or a number of heteroatoms oscillating from 0 to 10.

[0071] The linker L preferably contains between 2 and 40 carbon atoms (including the carbon atoms of optional side chains), more preferably between 2 and 30, more preferably between 2 and 20, more preferably between 2 and 14, more preferably between 2 and 12, and still more preferably between 2 and 10 carbon atoms.

[0072] The shortest atom chain between the oxygen atom (i.e. the oxygen of -O-L-NH2) and the NH2-group consists preferably of 2 to 14 atoms, more preferably of 2 to 12 atoms, more preferably of 2 to 10 atoms, more preferably of 2 to 8 atoms. In case the shortest chain (which is the shortest possible connection between the oxygen at the anomeric center and the NH2-group) consists of 2 to 6 atoms, these are preferably carbon atoms. In case the shortest chain consists of 4 to 8 atoms, the chain may contain 1 , 2 or 3 heteroatoms selected from O, N and S. In case the shortest chain consists of 9 to 14 atoms, the chain may contain 1 , 2, 3, 4, 5, or 6 heteroatoms selected from O, N and S.

[0073] It is also preferred that the linker -L-, or the shortest chain is fully or partially fluorinated. The linker -L- may contain a 3-membered or a 4-membered or a 5- membered or a 6-membered saturated carbocycle or a 5-membered partly unsaturated (and not aromatic) carbocycle or a 4-membered or a 5-membered or a 6-membered saturated oxygen heterocycle or a 4-membered or a 5-membered or a 6-membered saturated nitrogen heterocycle or a 6-membered aromatic carbocycle.

[0074] The linker -L- may also contain amide (-NH-CO-, -CO-NH-) and / or urea (-NH-CO-NH-) residues and preferably only one amide or urea residue. The linker may also contain substituents and preferably two substituents, such as R10and R11, or four substituents such as R10, R11, R15and R14, which have the meanings as defined herein and which are preferably selected from: -F, -Cl, -CH3, -C2H5, -C3H7, -C5H9, -C6Hi3, -OCH3, -OC2H5, -CH2F, -CHF2, -CF3,

[0075] -C(O)-NH2I-SCH3I-SC2H5, -NHC(O)CH3, -N(CH3)2, and -N(C2H5)2;

[0076] In case the linker -L- is fluorinated, more than two substituents -F are preferred. A perfluorination (i.e. a complete fluorination of the linker, especially of the alkyl linker) is also preferred.

[0077] Preferably the linker -L- is selected from: -CH2-, -(CH2)2-, -(CH2)3-, -(CH2)4-, — (CH2)s— , -(CH2)6-, — (CH2)7— , -(CH2)8- -(CH2)9-, -(CH2)IO-, -CF2-,

[0078] GAR-P04620W004 Application (final) docx -ABK>

[0079] GAR-P04620W004 Application (final) docx -ABK> -NHC(O)CH3, -N(CH3)2and -N(C2H5)2; o, q, p1 and p2 are independently of each other an integer selected from 1 , 2, 3, 4, 5, 6, 7, 8, 9, and 10.

[0080] GAR-P04620W004 Application (final) docx -ABK>

[0081] 12

[0082] Preferably, the linker -L- is selected from: -La- — La— Le— , -La-Lb-Le- and

[0083] -La-Ld-Le-

[0084] -La- represents -(CH2)0- -(CH^CH^O)o-C2H4- -(CH2-CH2-O)o-CH2-;

[0085] -Lb- represents -O-; -NH-CO-NH-, -NH-CO-CH2-NH- -NH-CO-;

[0086] -Ld- represents -(CH2)q- -(CF2)q- -(CH2-CH2-O)q-C2H4-, or

[0087] -(CH2-CH2-O)q-CH2-;

[0088] -Le- represents -(CH2)PI- — (CF2)pi— , -C2H4-(O-CH2-CH2)PI-

[0089] -CH2-(O-CH2-CH2)PI- or -(CH2)pi-O-(CH2)p2-; o, q, p1 and p2 are independently of each other an integer selected from 1 , 2, 3, 4, 5, and 6.

[0090] Preferably, the linker -L- represents -(CH2)O- and o is an integer selected from 1 , 2, 3, 4, 5, 6, 7 and 8.

[0091] The saccharides of the present invention bear basic and / or acidic substituents and they may form salts with organic or inorganic acids or bases.

[0092] Examples of suitable acids for such acid addition salt formation are hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, acetic acid, citric acid, oxalic acid, malonic acid, salicylic acid, p-aminosalicylic acid, malic acid, fumaric acid, succinic acid, ascorbic acid, maleic acid, sulfonic acid, phosphonic acid, perchloric acid, nitric acid, formic acid, propionic acid, gluconic acid, lactic acid, tartaric acid, hydroxymaleic acid, pyruvic acid, phenylacetic acid, benzoic acid, p-aminobenzoic acid, p-hydroxybenzoic acid, methanesulfonic acid, ethanesulfonic acid, nitrous acid, hydroxyethanesulfonic acid, ethylenesulfonic acid, p-toluenesulfonic acid, naphthylsulfonic acid, sulfanilic acid, camphorsulfonic acid, china acid, mandelic acid, o-methylmandelic acid, hydrogen-benzenesulfonic acid, picric acid, adipic acid, d-o- tolyltartaric acid, tartronic acid, (o, m, p)-toluic acid, naphthylamine sulfonic acid, and other mineral or carboxylic acids well known to those skilled in the art. The salts are prepared by contacting the free base form with a sufficient amount of the desired acid to produce a salt in the conventional manner.

[0093] Examples of suitable inorganic or organic bases are, for example, NaOH, KOH, NH4OH, tetraalkylammonium hydroxide, lysine or arginine and the like. Salts may be prepared in a conventional manner using methods well known in the art, for example by treatment of a solution of the compound of the general formula (I) with a solution of a base, selected out of the group mentioned above.

[0094] GAR-P04620W004 Application (final) docx -ABK>

[0095] 13

[0096] It is clear for the skilled person in the art of carbohydrate chemistry that the saccharides of general (I) are not containing -O-O- bonds and or sugar fragments (Ux, Ux+i, Ux+2, Ux+3) connected or bound to each other via their anomeric or C-1 carbons. It is also clear for the person skilled in the art that the stereochemistry of the glycosidic bond is the stereochemistry indicated for the anomeric center of the sugar fragment in the general formula. Hence, the stereochemistry of the anomeric center for sugar fragment U1 and U4 is a, for sugar fragment U2 and Ue is (3, for sugar fragment U3 and U7 is [3 and for sugar fragment Us is a.

[0097] The saccharide of general formula (I) contains an immunogenic epitope and is able to induce an immune response against F. tularensis bacteria in a human and / or animal host. The saccharide of general formula (I) elicits antibodies that are crossreacting with the F. tularensis strain 15 O-antigen capsular polysaccharide, recognize specifically F. tularensis bacteria of type A and type B. Additionally, the inventive saccharides have the advantage that these are pure synthesized compounds, which can be easily manufactured in accordance with GMP regulations.

[0098] Thus, the vaccine composition of the present invention contains most preferably only one single compound of the general formula (I) bound to an immunogenic carrier, preferably a carrier protein and more preferably CRM197. Thus, the compound of the general formula (I) is useful for the preparation of well defined, well characterized and pure vaccines containing only one synthetically prepared and well characterized tri-, tetra-, penta-, hexa-, hepta- or octasaccharide preferably linked to an immunogenic carrier, preferably a carrier protein and more preferably CRM197. Consequently, the vaccines of the present invention contain only one synthetically synthesized compound of general formulae (I) preferably linked to an immunogenic carrier, preferably a carrier protein and more preferably CRM197.

[0099] Preferred is a saccharide of general formula (I)

[0100] H-Ux+1-Ux-T-O-L-NH2

[0101] (I) wherein x is an integer selected from 1 and 2;

[0102] GAR-P04620W004 Application (final) docx -ABK>

[0103] -T- represents a bond, -Ux+3-, -Ux+3-Ux+2-, -Ux+3-Ux+2-Ux+i-, or

[0104] - [Ux+3- Ux+2- Ux+i- Ux]n- with n being an integer selected from 1 , 2 and 3;

[0105] R1represents -CH2OH or -CONH2;

[0106] L represents a linker; or a pharmaceutically acceptable salt thereof.

[0107] Preferred is a saccharide of general formula (I), wherein x represents 1 and a pharmaceutically acceptable salt thereof. Hence, a saccharide of general formula (l-a) with L, T, and R1having the meaning defined herein, or a pharmaceutically acceptable salt thereof is particularly preferred.

[0108] Also preferred is a saccharide of general formula (I), wherein x represents 2, and a pharmaceutically acceptable salt thereof. Thus, a saccharide of general formula (l-b), with L, T, and R1having the meaning defined herein, or a pharmaceutically acceptable salt thereof is also preferred.

[0109] GAR-P04620W004 Application (final) docx -ABK>

[0110] 15

[0111] Also preferred is a saccharide of general formula (I), wherein x represents 3, and a pharmaceutically acceptable salt thereof. Thus, a saccharide of general formula (l-c), with L, T, and R1having the meaning defined herein, or a pharmaceutically acceptable salt thereof is also preferred.

[0112] Also preferred is a saccharide of general formula (I), wherein x represents 4, and a pharmaceutically acceptable salt thereof. Thus, a saccharide of general formula (l-d), with L, T, and R1having the meaning defined herein, or a pharmaceutically acceptable salt thereof is also preferred.

[0113] Preferably, T represents a bond, -Ux+3-, -Ux+3-Ux+2-, or -Ux+3-Ux+2-Ux+i-. Thus, a saccharide of general formula (I), (l-a), (l-b), (l-c), or (l-d), wherein T represents a bond, -Ux+3-, - Ux+3- Ux+2- , or -Ux+3-Ux+2-Ux+i- is preferred.

[0114] Particularly preferred is a saccharide of general formula (I), wherein T represents -Ux+3-, and a pharmaceutically acceptable salt thereof. Thus, a saccharide of general formulae (ll-a), (ll-b), (ll-c) and (ll-d),

[0115] GAR-P04620W004 Application (final) docx with L and R1having the meaning defined herein, or a pharmaceutically acceptable salt thereof is also preferred.

[0116] Also preferred is a saccharide of general formula (I), wherein T represents -Ux+3-Ux+2-, and a pharmaceutically acceptable salt thereof. Thus, a saccharide of general formulae (lll-a), (lll-b), (lll-c) and (lll-d),

[0117] GAR-P04620W004 Application (final) docx

[0118] with L and R1having the meaning defined herein, or a pharmaceutically acceptable salt thereof is also preferred. Also preferred is a saccharide of general formula (I), wherein T represents -a bond, and a pharmaceutically acceptable salt thereof. Thus, a saccharide of general formulae (IV-a), (IV-b), (IV-c) and (IV-d),

[0119] GAR-P04620W004 Application (final) docx -ABK>

[0120] 18 with L and R1having the meaning defined herein, or a pharmaceutically acceptable salt thereof is also preferred.

[0121] Also, preferred is a saccharide of general formula (V),

[0122] H-Ux+1-Ux-[Ux+3-Ux+2-Ux+i-Ux]n-O-L-NH2

[0123] (V) wherein Ux, Ux+i, Ux+2, Ux+3, x, L, and n have the meanings as defined herein.

[0124] Particularly preferred is a saccharide of general formula (V), wherein n represents 1 .

[0125] In a preferred embodiment, R1represents -CH2OH, Thus, a saccharide of general formula (I), (l-a), (l-b), (l-c), (l-d), (ll-a), (ll-b), (ll-c), (ll-d), (lll-a), (lll-b), (lll-c), (lll-d), (IV-a), (IV-b), (IV-c), (IV-d), and (V) wherein R1represents -CH2OH is also preferred.

[0126] In a preferred embodiment, R1represents -CONH2, Thus, a saccharide of general formula (I), (l-a), (l-b), (l-c), (l-d), (ll-a), (ll-b), (ll-c), (ll-d), (lll-a), (lll-b), (lll-c), (lll-d), (IV-a), (IV-b), (IV-c), (IV-d), and (V) wherein R1represents -CH2OH is also preferred.

[0127] Preferably the linker -L- represents -La-, -La-Le-, -La-Lb-Le-, or -La-Ld-Le- -La- represents -(CH2)o-, -(CH^CH^O)o-C2H4-, or -(CH^CH^O)o-CH2;

[0128] -Lb- represents -O-, -NH-CO-NH-, -NH-CO-CH^NH-, -NH-CO-; -Ld- represents -(CH2)q-, -(CH(OH))q- — (CF2)q— , -(CH^CH^O)q-C2H4-, or -(CH^CH^O)q-CH^ ;

[0129] -Le- represents -(CH2)PI-, — (CF2)pi— , -C2H4-(O-CH2-CH2)PI-,

[0130] -CH2-(O-CH2-CH2)PI- or -(CH2)Pi-O-(CH2)P2- ; and o, q, p1 and p2 are independently of each other an integer selected from 1 , 2, 3, 4, 5, and 6.

[0131] Therefore, a saccharide of general formula (I), (l-a), (l-b), (l-c), (l-d), (ll-a), (ll-b), (ll-c), (ll-d), (lll-a), (lll-b), (lll-c), (lll-d), (IV-a), (IV-b), (IV-c), (IV-d), or (V), wherein -L- represents -La-, — La— Le— , -La-Lb-Le-, or -La-Ld-Le- ;

[0132] GAR-P04620W004 Application (final) docx - ABK> 19

[0133] -La- represents -(CH2)0- -(CH^CH^O)O-C2H4- or -(CH^CH^O)o-CH2;

[0134] -Lb- represents -O-, -NH-C0-NH-, -NH-CO-CH^NH- -NH-CO-;

[0135] -Ld- represents -(CH2)q- -(CH(OH))q- -(CF2)q- -(CH^CH^O)q-C2H4- or -(CH^CH^O)q-CH^ ;

[0136] -Le- represents -(CH2)PI- — (CF2)PI— , -C2H4-(O-CH2-CH2)PI-

[0137] -CH2-(O-CH2-CH2)PI- or -(CH2)pi-O-(CH2)p2- ; and o, q, p1 and p2 are independently of each other an integer selected from 1 , 2, 3, 4, 5, and 6 is especially preferred.

[0138] It is particularly preferred that -L- represents -(CH2)O- and o is an integer selected from 2, 3, 4, 5, 6, 7 and 8. Thus, a particularly preferred saccharide is a saccharide of general formula (I), (l-a), (l-b), (l-c), (l-d), (ll-a), (ll-b), (ll-c), (ll-d), (lll-a), (lll-b), (lll-c), (lll-d), (IV-a), (IV-b), (IV-c), (IV-d), or (V), wherein-L- represents -(CH2)O- and o is an integer selected from 2, 3, 4, 5, 6, 7 and 8.

[0139] Preferably, the inventive saccharide is selected from: 4-amino butyl 4-formamido- / 3-D- quinovopyranosyl-(1 — >4)-a-D- / V-acetylgalactopyranoside; 5-amino pentyl

[0140] 4-formamido- / 3-D-quinovopyranosyl-(1 — >4)-cr-D- / V-acetylgalactopyranoside; 6-amino hexyl 4-formamido- / 3-D-quinovopyranosyl-(1 — >4)-cr-D- / V-acetylgalactopyranoside;

[0141] 7-amino heptyl 4-formamido- / 3-D-quinovopyranosyl-(1 -^4)-a-D- / V-acetylgalacto- pyranoside; 4-amino butyl / 3-D- / V-acetylquinovopyranoside-(1 — >2)-4-formamido- / 3-D- quinovopyranoside; 5-amino pentyl / 3-D- / V-acetylquinovopyranoside-(1 — >2)-4- formamido- / 3-D-quinovopyranoside; 6-amino hexyl / 3-D- / V-acetyl-quinovosamine- pyranoside-(1 ^2)-4-formamido- / 3-D-quinovopyranoside; 7-amino pentyl 3-D- / V- acetylquinovosaminepyranoside-(1 ^2)-4-formamido- / 3-D-quinovo-pyranoside.

[0142] Preferably, the inventive saccharide is selected from: 5-amino-pentanyl 4- / V-formamido-4,6-dideoxy- / 3-D-glucopyranosyl-(1 — >4)-2- acetamido-2- deoxy-a-D-galactouronamide; 5-amino-pentanyl 4- / V-formamido-4,6-dideoxy- / 3-D-glucopyranosyl-(1 — >4)-2- acetamido-2-deoxy-o-D-galactopyranoside; 5-amino-pentanyl 2-acetamido-2,6-dideoxy-o-D-glucopyranosyl-(1^2)-4- / \ / - formamido-4,6-dideoxy- / 3-D-glucopyranoside; 5-amino-pentanyl 2-acetamido-o-D-galactopyranosyl uronamide-(1 -^3)-2-acetamido- 2,6-dideoxy-[3-D-glucopyranoside 5-amino-pentanyl 2-acetamido-o-D-galactopyranosyl-(1 ^3)-2-acetamido-2,6- dideoxy- / 3-D-glucopyranoside; 5-am ino-pentanyl 2-acetam ido-o-D-galactopyranosyl-( 1 -^4)-2-acetam ido-a-D- galactopyranosyl-(1 ^3)-2-acetamido-2,6-dideoxy- / 3-D-glucopyranoside

[0143] GAR-P04620W004 Application (final) docx -ABK>

[0144] 20

[0145] 5-amino-pentanyl 4-acetamido-4,6-dideoxy- / 3-D-glucopyranosyl-(1 ^2)-2- acetamido-a-D-galactopyranosyl-(1 — >4)-2-acetamido-a-D-galactopyranosyl-(1 — >3)- 2-acetamido-2,6-dideoxy- / 3-D-glucopyranoside;

[0146] 5-amino-pentanyl 2-acetamido-a-D-galactopyranosyl uronamide-(1 — >4)-2- acetamido-a-D-galactopyranosyl uronamide-(1 ^3)-2-acetamido-2,6-dideoxy- / 3-D- glucopyranoside; and

[0147] 5-amino-pentanyl 4- / V-formamido-4,6-dideoxy- / 3-D-glucopyranosyl-(1 — >4)-2- acetam ido-2-deoxy-a-D-galactopyranosyl uronam ide-( 1 -^4)-2-acetam ido-a-D- galactopyranosyluronamide-(1 ^3)-2-acetamido-2,6-dideoxy- / 3-D-glucopyranoside.

[0148] Conjugate

[0149] Another aspect of the present invention is directed to a conjugate comprising a synthetic saccharide of general formula (I) covalently bound or covalently linked to an immunogenic carrier through the nitrogen atom of the -O-L-NH2 group. In other words, another aspect of the present invention is directed to a saccharide of any of the general formulae (I), (l-a), (l-b), (l-c), (l-d), (ll-a), (ll-b), (ll-c), (ll-d), (lll-a), (lll-b), (lll-c), (lll-d), (IV-a), (IV-b), (IV-c), (IV-d), or (V) conjugated with an immunogenic carrier through the nitrogen atom of the -O-L-NH2 group. The inventive conjugate comprising a synthetic saccharide of the general formula (I), (l-a), (l-b), (l-c), (l-d), (ll-a), (ll-b), (ll-c), (ll-d), (lll-a), (lll-b), (lll-c), (lll-d), (IV-a), (IV-b), (IV-c), (IV-d), or (V) covalently bound or covalently linked to an immunogenic carrier through the nitrogen atom of the -O-L-NH2 group is also defined as a conjugate obtained by reacting a saccharide of any of the general formulae (I), (l-a), (l-b), (l-c), (l-d), (ll-a), (ll-b), (ll-c), (ll-d), (lll-a), (lll-b), (lll-c), (lll-d), (IV-a), (IV-b), (IV-c), (IV-d), or (V) with an immunogenic carrier. Said conjugate proved to be efficient as a vaccine for immunization against diseases associated with Francisella tularensis bacteria.

[0150] Saccharides are known by the person skilled in the art as generally TI-2 (T cell independent-2) antigens and poor immunogens. TI-2 antigens are antigens, which are recognized only by mature B cells through the cross linking of surface exposed immunoglobulin receptors. Without T cell help, no immunological memory is generated and neither isotype switching from IgM to other IgG subclasses, nor B cells affinity maturation occurs. Moreover, saccharides are known as poor immunogens in humans due to the structural homology to human glycolipids and glycoproteins. Due to their poor immunogenic properties, saccharides manifest poor ability to produce both antibody production by B cells, as well as the formation of memory cells, features which are essential for the production of potent vaccines.

[0151] GAR-P04620W004 Application (final) docx -ABK>

[0152] 21

[0153] Therefore, to produce a potent saccharide-based vaccine, a saccharide of general formula (I), (l-a), (l-b), (l-c), (l-d), (ll-a), (ll-b), (ll-c), (ll-d), (lll-a), (lll-b), (lll-c), (lll-d), (IV-a), (IV-b), (IV-c), (IV-d), or (V) is conjugated to an immunogenic carrier to provide a conjugate presenting increased immunogenicity in comparison with the saccharide.

[0154] Said conjugate consists of at least one synthetic saccharide of the general (I), (l-a), (l-b), (l-c), (l-d), (ll-a), (ll-b), (ll-c), (ll-d), (lll-a), (lll-b), (lll-c), (lll-d), (IV-a), (IV-b), (IV-c), (IV-d), or (V) and an immunogenic carrier to which the at least one saccharide of the general formula (I), (l-a), (l-b), (l-c), (l-d), (ll-a), (ll-b), (ll-c), (ll-d), (lll-a), (lll-b), (lll-c), (lll-d), (IV-a), (IV-b), (IV-c), (IV-d), or (V) is covalently bound.

[0155] Surprisingly, it was found that immunization with a conjugate according to the present invention results in the production of high titers of antibodies specific to the carbohydrate part of the saccharide according to the present invention. Said antibodies are cross-reacting with the natural Francisella tularensis O-antigen capsular polysaccharide, thus conferring protection against Francisella tularensis bacteria of type A and type B.

[0156] In this context the term “immunogenic carrier” is defined as a structure, which is conjugated to the saccharide to form a conjugate that presents an increased immunogenicity in comparison with the saccharide per se. Thus, the conjugation of a saccharide of the general formula (I), (l-a), (l-b), (l-c), (l-d), (ll-a), (ll-b), (ll-c), (ll-d), (lll-a), (lll-b), (lll-c), (lll-d), (Vl-a), (Vl-b), (Vl-c), (Vl-d), or (V) to the immunogenic carrier has as effect the stimulation of the immune response against the saccharide of the general formula (I), (l-a), (l-b), (l-c), (l-d), (ll-a), (ll-b), (ll-c), (ll-d), (lll-a), (lll-b), (lll-c), (lll-d), (IV-a), (IV-b), (IV-c), (IV-d), or (V) without inducing an immune response against the said immunogenic carrier.

[0157] Preferred immunogenic carriers are carrier proteins or glycosphingolipids with immunomodulatory properties. For the person skilled in the art, a carrier protein is a protein selected from the group comprising or consisting of: a diphtheria toxoid, a mutated diphtheria toxoid, a modified diphtheria toxoid, a mutated and modified diphtheria toxoid, a tetanus toxoid, a modified tetanus toxoid, a mutated tetanus toxoid, outer membrane protein (OMP), bovine serum albumin (BSA), keyhole limpet hemocyanine (KLH), cholera toxoid (CT) and protein D (a non-typeable Haemophilus influenzae protein).

[0158] The term “toxoid” as used herein refers to a bacterial toxin (usually an exotoxin), whose toxicity has been inactivated or suppressed either by chemical (formalin) or

[0159] GAR-P04620W004 Application (final) docx -ABK>

[0160] 22 heat treatment, while other properties, typically immunogenicity, are maintained. A mutated toxoid as used herein is a recombinant bacterial toxin, which has been amended to be less toxic or even non-toxic by amending the wild-type amino acid sequence. Such a mutation could be a substitution of one or more amino acids. Such a mutated toxoid presents on its surface a functionality that can react with the functional group Y of the interconnecting molecule to provide a modified toxoid. Said functionality is known to the person skilled in the art and includes but is not restricted to the primary amino functionality of a lysine residue that can react with activated esters, an isocyanate group or an aldehyde in presence of a reducing agent, to the carboxylate functionality of a glutamate or aspartate residue that can be activated by carbodiimides or to the thiol functionality of a cysteine residue.

[0161] Activated esters include, but are not restricted to N-(y-maleimidobutyryloxy) sulfosuccinimide ester (sulfo-GMBS), succinimidyl (4-iodoacetyl) aminobenzoate (sulfo-SIAB), succinimidyl-3-(bromoacetamido)propionate (SBAP), disuccinimidyl glutarate (DSG), disuccinimidyl adipate (DSA), 2-pyridyldithiol-tetraoxatetradecane- / V-hydroxysuccinimide (PEG-4-SPDP), bis-(4-nitrophenyl) adipate and bis-(4- nitrophenyl) succinate (see Figure 2). Preferred activated esters are disuccinimidyl adipate (DSA), disuccinimidyl glutarate (DSG), bis-(4-nitrophenyl) adipate and bis-(4- nitrophenyl) succinate.

[0162] Preferred is a conjugate of general formula (IV)

[0163] [H-Ux+i-Ux-T-O-L-NH-W]m-IM (VI) wherein m is comprised between about 2 and about 18; a represents an integer from 1 to 10; b represents an integer from 1 to 4; IM represents an immunogenic carrier, and

[0164] Ux, Ux+i, T, x, n and L have the meanings defined herein.

[0165] As well known to the skilled person, “m” in structure VI corresponds to the average load of saccharide units per unit of immunogenic carrier as determined by MALDI-

[0166] GAR-P04620W004 Application (final) docx -ABK>

[0167] 23

[0168] TOF MS method using the molecular weight of the immunogenic carrier as reference. By varying the reaction conditions for the coupling of the saccharide according to the present invention to the immunogenic carrier any conjugate of structure VI with m being comprised between about 2 and about 18 can be obtained.

[0169] Preferably, the linker -L- is selected from: -La- — La— Le— , -La-Lb-Le- and -La-Ld-Le- and o, q, p1 and p2 are independently of each other an integer selected from 1 , 2, 3, 4, 5, and 6.

[0170] It is also preferred that -W- represents o o and a is an integer selected from 2, 3, 4, 5 and 6 is especially preferred .

[0171] Hence, a conjugate of general formula (VI), wherein the linker -L- is selected from: -La-, — La— Le— , -La-Lb-Le-, and -La-Ld-Le- -La- represents -(CH2)O-, -(CH2-CH2-O)O-C2H4- or -(CH2-CH2-O)O-CH2; -Lb- represents -O-, -NH-CO-NH-, -NH-CO-CH2-NH-, -NH-CO-; -Ld- represents -(CH2)q- -(CH(OH))q-, -(CF2)q- -(CH2-CH2-O)q-C2H4-, or -(CH2-CH2-O)q-CH2- ;

[0172] -Le- represents — (CH2)pi— , — (CF2)pi— , -C2H4-(O-CH2-CH2)pi-

[0173] -CH2-(O-CH2-CH2)pi- or -(CH2)pi-O-(CH2)p2- ; o, q, p1 and p2 are independently of each other an integer selected from 1 , 2, 3, 4, 5, and 6; o o and a is an integer selected from 2, 3, 4, 5

[0174] -W- represents and 6 is especially preferred.

[0175] Preferred is also conjugate of general formula (Via)

[0176] [H-Ux+i-Ux-T-O-L-N H-W]m-CP (Via) wherein m is comprised between about 2 and about 18;

[0177] GAR-P04620W004 Application (final) docx -ABK;

[0178] 24

[0179] -W- is selected from: a represents an integer from 1 to 10; b represents an integer from 1 to 4;

[0180] CP represents a carrier protein, and

[0181] Ux, Ux+i, T, x, n and L have the meanings defined herein.

[0182] As well known to the skilled person, “m” in structure Via corresponds to the average load of saccharide units per unit of carrier protein as determined by MALDI-TOF MS method using the molecular weight of carrier protein as reference. By varying the reaction conditions for the coupling of the saccharide according to the present invention to the carrier protein any conjugate of structure Via with m being comprised between about 2 and about 18 can be obtained.

[0183] Preferably, the linker -L- is selected from: -La-, — La— Le— , -La-Lb-Le-, and -La-Ld-Le-

[0184] -La- represents -(CH2)o-, -(CH2-CH2-O)o-C2H4-, or -(CH2-CH2-O)o-CH2; -Lb- represents -O-, -NH-CO-NH-, -NH-CO-CH2-NH-, -NH-CO-; -Ld- represents -(CH2)q-, -(CH(OH))q-, -(CF2)q-, -(CH2-CH2-O)q-C2H4-, or -(CH2-CH2-O)q-CH2- ;

[0185] -Le- represents — (CH2)P1— , — (CF2)P1— , -C2H4-(O-CH2-CH2)pi-,

[0186] -CH2-(O-CH2-CH2)pi- or -(CH2)pi-O-(CH2)p2- ; and o, q, p1 and p2 are independently of each other an integer selected from 1 , 2, 3, 4, 5, and 6.

[0187] It is also preferred that -W- represents and a is an integer selected from 2, 3, 4, 5 and 6 is especially preferred.

[0188] Hence, a conjugate of general formula (VI), wherein the linker -L- is selected from: -La-, — La— Le— , -La-Lb-Le-, and -La-Ld-Le-

[0189] GAR-P04620W004 Application (final) docx -ABK>

[0190] 25 o, q, p1 and p2 are independently of each other an integer selected from 1 , 2, 3, 4, 5, and 6; and a is an integer selected from 2, 3, 4, 5

[0191] -W- represents and 6 is especially preferred.

[0192] The cysteine residue on the carrier protein can be converted to the corresponding dehydroalanine that can be further reacted with a suitable interconnecting molecule to provide modified carrier protein having on their surface the functional group X of the interconnecting molecule.

[0193] It is especially preferred that the inventive saccharides described herein are conjugated to the non-toxic mutated diphtheria toxin CRM197 presenting as a functionality a primary amine functionality of a lysine residue.

[0194] CRM197 like wild-type diphtheria toxin is a single polypeptide chain of 535 amino acids (58 kD) consisting of two subunits linked by disulfide bridges having a single amino acid substitution of glutamic acid for glycine. It is utilized as a carrier protein in a number of approved conjugate vaccines for diseases such as Prevnar®.

[0195] Thus, in a preferred embodiment of the present invention the carrier protein presents on its surface primary amino functionalities of lysine residues that are able to react with the functional group Y of the interconnecting molecule to provide modified carrier protein having on their surface said functional group X of the interconnecting molecule, which is able to react with the terminal amino group of the linker functionalizing the inventive saccharides.

[0196] Said functional group X of the interconnecting molecules is selected from the group comprising or consisting of maleimide; a-iodoacetyl; a-bromoacetyl; and / V- hydroxysuccinimide ester (NHS), aldehyde, imidoester, carboxylic acid, alkyl sulfonate, sulfonyl chloride, epoxide, anhydride, carbonate (see Figure 3).

[0197] Even more preferred is a conjugate of general formula (VII),

[0198] GAR-P04620W004 Application (final) docx -ABK>

[0199] [H-Ux+i-Ux-T-O-L-NH-W]m-CRMi97 (VII) wherein m is comprised between about 2 and about 18;

[0200] -W- is selected from: a represents an integer from 1 to 10; b represents an integer from 1 to 4, and

[0201] Ux, Ux+i, T, x, n and L have the meanings defined herein.

[0202] Also preferred is a conjugate of general formula (VII), wherein x represents 1 , 2, 3 or 4. Thus, a conjugate of general formula (Vll-a), (Vll-b), (Vll-c), or (Vll-d),

[0203] GAR-P04620W004 Application (final) docx -ABK; wherein m is comprised between about 2 and about 18;

[0204] -W- is selected from: a represents an integer from 1 to 10; b represents an integer from 1 to 4;

[0205] T, L, and R1have the meaning defined herein, is also preferred.

[0206] Also preferred is a conjugate of general formula (VII), wherein T represents a bond, - Ux+3- , or - Ux+3- Ux+2- . Thus, a conjugate of general formula (Vlll-a), (Vlll-b), (Vlll-c), (Vlll-d), (IX-a), (IX-b), (IX-c), (IX-d), (X-a), (X-b), (X-c), or (X-d)

[0207] GAR-P04620W004 Application (final) docx "ABK-

[0208] 28

[0209] GAR-P04620W004 Application (final) docx

[0210]

[0211] GAR-P04620W004 Application (final) docx -ABK> wherein m is comprised between about 2 and about 18;

[0212] -W- is selected from: a represents an integer from 1 to 10; b represents an integer from 1 to 4;

[0213] L, and R1have the meaning defined herein, is also preferred.

[0214] Also preferred is a conjugate of general formula (Vlll-a), (Vlll-b), (Vlll-c), (IX-d), or

[0215] GAR-P04620W004 Application (final) docx -ABK> wherein m is comprised between about 2 and about 18;

[0216] -W- is selected from:

[0217] GAR-P04620W004 Application (final) docx -ABK; a represents an integer from 1 to 10; b represents an integer from 1 to 4;

[0218] L, and R1have the meaning defined herein, is also preferred.

[0219] Preferably, in general formulae (VII), (Vll-a), (Vll-b), (Vll-c), (Vll-d), (Vlll-a), (Vlll-b), (Vlll-c), (Vlll-d), (IX-a), (IX-b), (IX-c), (IX-d), (X-a), (X-b), (X-c), and (X-d) the linker -L- is selected from: -La-, — La— Le— , -La-Lb-Le-, and -La-Ld-Le- -La- represents -(CH2)0- -(CH^CH^O)o-C2H4-, or -(CH^CH^O)O-CH2;

[0220] -Lb- represents -O-, -NH-CO-NH-, -NH-CO-CH^NH-, -NH-CO-; -Ld- represents -(CH2)q- -(CH(OH))q- -(CF2)q-, -(CH^CH^O)q-C2H4-, or -(CH^CH^O)q-CH^ ;

[0221] -Le- represents -(CH2)PI-, — (CF2)PI— , -C2H4-(O-CH2-CH2)PI-

[0222] -CH2-(O-CH2-CH2)PI- or -(CH2)pi-O-(CH2)p2- ; o, q, p1 and p2 are independently of each other an integer selected from 1 , 2, 3, 4, 5, and 6; o o nd a is an integer selected from 2, 3, 4, 5 and -W- represents

[0223] Especially preferred is a conjugate of general formula (VII), (Vll-a), (Vll-b), (Vll-c), (Vll-d), (Vlll-a), (Vlll-b), (Vlll-c), (Vlll-d), (IX-a), (IX-b), (IX-c), (IX-d), (X-a), (X-b), (X-c), or (X-d), wherein the linker -L- represents -(CH2)O- , o is an integer selected from 2, 3, 4, 5, 6, 7 and 8; o o nd a is an integer selected from 2, 3, 4, 5 and -W- represents

[0224] Preferably m is comprised between about 2 and about 18, more preferably between about 5 and about 15, even more preferably between about 8 and about 12.

[0225] In another embodiment, said immunogenic carrier is preferably a glycosphingolipid with immunomodulatory properties, and more preferably (2S,3S,4R)-1-(a-D- galactopyranosyl)-2-hexacosanoylaminooctadecane-3,4-diol. The term glycosphingolipid with immunomodulatory properties, as used herein, refers to a suitable

[0226] GAR-P04620W004 Application (final) docx - ABK> 33 glycosphingolipid capable of stimulating the immune system's response to a target antigen, but which does not in itself confer immunity as defined above.

[0227] Glycosphingolipids as used herein are compounds containing a carbohydrate moiety a-linked to a sphingolipid. Preferably, the carbohydrate moiety is a hexopyranose and most preferably is a-D-galactopyranose. For the person skilled in the art, sphingolipids are a class of lipids containing a C18 amino alcohol connected via an amide bond to a fatty acid. The C18 amino alcohol is preferably mono-, di- or polysubstituted with hydroxyl groups. Especially preferred, the C18 amino alcohol is phytosphingosine. The fatty acid is preferably a monocarboxylic acid having a saturated alkyl chain of a number of carbons ranging from 16 to 28 and more preferably from 18 to 26. Glycosphingolipids with immunomodulatory properties include, but they are not restricted to (2S,3S,4R)-1-(a-D-galactopyranosyl)-2- hexacosanoylaminooctadecane-3,4-diol, which can stimulate natural killer (NK) activity and cytokine production by natural killer T (NKT) cells and exhibits potent antitumor activity in vivo (Proc. Natl Acad. Sci. USA, 1998, 95, 5690).

[0228] The conjugates of the inventive saccharides with a glycosphingolipid with immunomodulatory properties have the advantage of being heat stable. To be suitable for conjugation, on the glycosphingolipid with immunomodulatory properties a functionality is introduced. Said functionality is prone to react directly with the terminal amino group of the linker of the inventive to provide conjugates of the saccharides or with the functional group Y of the interconnecting molecule to provide the modified glycosphingolipid with immunomodulatory properties.

[0229] Preferably, said functionality is introduced at the C6 of the carbohydrate moiety of the glycosphingolipid with immunomodulatory properties. Thus, the glycosphingolipid with immunomodulatory properties is functionalized with a functionality, which is prone of reacting with the terminal amino group of the saccharides or with the functional group Y of the interconnecting molecule. A functionality prone to react with an amino group includes, but it is not restricted to activated ester, isocyanate group, aldehyde, epoxide, imidoester, carboxylic acid, alkyl sulfonate and sulfonyl chloride. A functionality prone to react with the functional group Y of the interconnecting molecule so that to provide the modified glycosphingolipid with immunomodulatory properties presenting the functional group X of the interconnecting molecule includes, but it is not restricted to amine, alcohol, thiol, activated ester, isocyanate group, aldehyde, epoxide, vinyl, imidoester, carboxylic acid, alkyl sulfonate, sulfonyl chloride, vinyl group, alkynyl group and azido group.

[0230] GAR-P04620W004 Application (final) docx -ABK>

[0231] 34

[0232] Preferably, the functionality introduced at the C-6 position of the carbohydrate moiety of the glycosphingolipid with immunomodulatory properties is selected from the group comprising or containing an amine, a thiol, an alcohol, a carboxylic acid, a vinyl, maleimide, a-iodoacetyl, a-bromoacetyl, / V-hydroxysuccinimide ester (NHS), 2- pyridyldithiols.

[0233] Said functional group X of the interconnecting molecules is selected from the group comprising or consisting of maleimide, a-iodoacetyl, a-bromoacetyl, / V- hydroxysuccinimide ester (NHS), aldehyde, carboxylic acid, epoxyde, alkyl sulfonate, sulfonyl chloride, anhydride, carbonate.

[0234] Preferably, di( / V-succinimidyl) adipate or bis(4-nitrophenyl) adipate is first reacted with a synthetic saccharide having a primary amino group. Activated saccharide is subsequently condensed with a glycosphingolipid, which is modified at C-6 position by an interconnecting molecule having a terminal amino functionality in order to afford the conjugate.

[0235] As used herein, the term “interconnecting molecule” refers to a bifunctional molecule containing functional group X and functional group Y, wherein functional group X is capable of reacting with the terminal amino group on the linker -L- and the functional group Y is capable of reacting with a functionality present on the immunogenic carrier.

[0236] As used herein, the term “interconnecting molecule” refers to a bifunctional molecule containing functional group X and functional group Y, wherein functional group X is capable of reacting with the terminal amino group on the linker -L- and the functional group Y is capable of reacting with a functionality present on the immunogenic carrier.

[0237] Thus, in another preferred embodiment the conjugate has the structure of general formula (XI)

[0238] H— Ux+i—Ux—T— O-L-NH-W -GSL (XI)

[0239] -W- represents -L2-NH-L3- ;

[0240] L3represents -L3-L3-L3- or -L3-L3- or and

[0241] L3, L3, and L3are independently of each other selected from: -CH2- -C2H4-, -C3H6-, -C4H8-, -C5H10-, -CeHi2-, -C7H14-, -CsHie-, -C9H18- -C10H20-,

[0242] GAR-P04620W004 Application (final) docx -ABK>

[0243] -CR23R24-, -CR25R26-, -CR27R28- CR29R30-, -CR31R32-,-CR33R34

[0244] -(CH2-CH2-0)O-; -O-C6H4- — m— C6H4— , — p— C6H4— ,

[0245] -CH2-S-CH2- -CH2-O-CH2-, -S-, -O-; L2is selected from: -C(O)-, -E-, -C(O)-NH-NH-C(O)-

[0246] GAR-P04620W004 Application (final) docx

[0247] E is selected from m, n, p represent independently of each other an integer from 0 to 30;

[0248] GSL represents a glycosphingolipid,

[0249] R23- R34are independently of each other selected from: -H, -F, -Cl, -CH3, -C2H5, -C3H7, -C5H9, -C6Hi3, -OCH3, -OC2H5, -CH2F, -CHF2, -CF3, -C(O)-NH2I-SCH3I-SC2H5, -NHC(O)CH3, -N(CH3)2, and -N(C2H5)2; and Ux, Ux+1, Ux+2, Ux+3, x, and L have the meanings defined herein.

[0250] In a preferred embodiment of the conjugate of general formula (XI), L2is selected from: and m and n represent independently of each other an integer from 0 to 30.

[0251] GAR-P04620W004 Application (final) docx In a further preferred embodiment the glycosphingolipid GSL has the following structure: wherein R2is selected from

[0252] R3is -(X1)pi-(X2)p2-(X3)p3-X4;

[0253] R4and R5are selected from -H and -OH and cannot be simultaneously the same;

[0254] R6is -(Y1)mi-(Y2)m2-(Y3)m3-Y4;

[0255] GAR-P04620W004 Application (final) docx "ABK-

[0256] 38

[0257] 5 p1 , p2, p3, ml , m2 and m3 represent independently of each other an integer from 0 to 30;

[0258] GAR-P04620W004 Application (final) docx -ABK>

[0259] 39

[0260] In a particularly preferred embodiment, the glycosphingolipid is (2S,3S,4R)-1-(a-D- galactopyranosyl)-2-hexacosanoylaminooctadecane-3,4-diol (a-galactosylceramide).

[0261] Also preferred is a conjugate of general of general formula (Xl-a), (Xl-b), (Xl-c), (Xl-d), (Xll-a), (Xll-b), (Xll-c), (Xll-d), (Xlll-a) (Xlll-b), (Xlll-c), (Xlll-d) wherein GSL represents a glycosphingolipid as defined herein

[0262] GAR-P04620W004 Application (final) docx -ABK>

[0263] GAR-P04620W004 Application (final) docx -ABK> wherein R1, W, L and GSL have the meanings as defined herein.

[0264] It was found that the saccharide of general formula (I), (l-a), (l-b), (l-c), (l-d), (ll-a), (ll-b), (ll-c), (ll-d), (lll-a), (lll-b), (lll-c), (lll-d), (IV-a), (IV-b), (IV-c), (IV-d), or (V) covalently linked or covalently bound to an immunogenic carrier through the nitrogen atom of the -O-L-NH2 group or in other words the conjugate obtained by reacting a saccharide of general formula (I), (l-a), (l-b), (l-c), (l-d), (ll-a), (ll-b), (ll-c), (ll-d), (lll-a), (lll-b), (lll-c), (lll-d), (IV-a), (IV-b), (IV-c), (IV-d), or (V) with an immunogenic carrier, and especially a conjugate of general formula (VI), (Via), (VII), (Vll-a), (Vll-b), (Vll-c), (Vll-d), (Vlll-a), (Vlll-b), (Vlll-c), (Vlll-d), (IX-a), (IX-b), (IX-c), (IX-d), (X-a), (X-b), (X-c), (X-d), (XI), (Xl-a), (Xl-b), (Xl-c), (Xl-d), (Xll-a), (Xll-b), (Xll-c), (Xll-d), (Xlll-a), (Xlll-b), (Xlll-c), or (Xlll-d), elicits an immune response in a human and / or animal host, and therefore is useful in the prevention and / or treatment of a disease caused by F. tularensis. Such disease includes tularemia, particularly

[0265] GAR-P04620W004 Application (final) docx -ABK>

[0266] 42 ulceroglandular tularemia, glandular tularemia, oculoglandular tularemia, oropharyngeal tularemia, pneumonic tularemia, or typhoidal tularemia.

[0267] It was also found that the saccharide of general formula (I), (l-a), (l-b), (l-c), (l-d), (II- a), (ll-b), (ll-c), (ll-d), (lll-a), (lll-b), (lll-c), (lll-d), (IV-a), (IV-b), (IV-c), (IV-d), or (V) covalently linked or covalently bound to an immunogenic carrier through the nitrogen atom of the -O-L-NH2 group or in other words the conjugate obtained by reacting a saccharide of general formula (I), (l-a), (l-b), (l-c), (l-d), (ll-a), (ll-b), (ll-c), (ll-d), (lll-a), (lll-b), (lll-c), (lll-d), (IV-a), (IV-b), (IV-c), (IV-d), or (V) with an immunogenic carrier, and especially a conjugate of general formula (VI), (Via), (VII), (Vll-a), (Vll-b), (Vll-c), (Vll-d), (Vlll-a), (Vlll-b), (Vlll-c), (Vlll-d), (IX-a), (IX-b), (IX-c), (IX-d), (X-a), (X-b), (X-c), (X-d), (XI), (Xl-a), (Xl-b), (Xl-c), (Xl-d), (Xll-a), (Xll-b), (Xll-c), (Xll-d), (Xlll-a), (Xlll-b), (Xlll-c), or (Xlll-d), elicits an immune response in an animal host susceptible to a Francisella tularensis infection, and therefore is useful in the prevention and / or treatment of a disease in an animal caused by F. tularensis, particularly tularemia.

[0268] Animals susceptible to a Francisella tularensis infection include, but are not limited to, rodents, rabbits, hares, horses, cats, cheetahs, and dogs.

[0269] Pharmaceutical composition

[0270] A further aspect of the present invention relates to a pharmaceutical composition or a vaccine containing at least one synthetic saccharide and / or a pharmaceutically acceptable salt thereof according to the present invention and / or a conjugate comprising a saccharide according to the present invention covalently linked to an immunogenic carrier, preferably to CRM197 carrier protein, through the nitrogen atom of the -O-L-NH2 group together with at least one pharmaceutically acceptable adjuvant and / or excipient.

[0271] The term “adjuvant” as used herein refers to an immunological adjuvant i.e. a material used in a pharmaceutical composition or vaccine that modifies or augments the effects of said pharmaceutical composition or said vaccine by enhancing the immune response to a given antigen contained in the pharmaceutical composition or vaccine without being antigenically related to it. For the persons skilled in the art, classically recognized examples of immunological adjuvants include, but are not restricted to oil emulsions (e.g. Freund's adjuvant), saponins, aluminium or calcium salts (e.g. alum), non-ionic block polymer surfactants, and many others.

[0272] GAR-P04620W004 Application (final) docx -ABK>

[0273] 43

[0274] Pharmaceutical compositions or vaccines are preferably in aqueous form, particularly at the point of administration, but they can also be presented in non-aqueous liquid forms or in dried forms e.g. as gelatin capsules, or as lyophilisates, etc..

[0275] Pharmaceutical compositions or vaccines may include one or more preservatives, such as thiomersal or 2-phenoxyethanol. Mercury-free compositions are preferred, and preservative-free vaccines can be prepared.

[0276] Pharmaceutical compositions or vaccines may include a physiological salt, such as a sodium salt e.g. to control tonicity. Sodium chloride (NaCI) is typical and may be present at between 1 and 20 mg / ml. Other salts that may be present include potassium chloride, potassium dihydrogen phosphate, disodium phosphate dehydrate, magnesium chloride, calcium chloride, etc.

[0277] Pharmaceutical compositions or vaccines can have an osmolality of between 200 mOsm / kg and 400 mOsm / kg.

[0278] Pharmaceutical compositions or vaccines may include compounds (with or without an insoluble metal salt) in plain water (e.g. w.f.i.), but will usually include one or more buffers. Typical buffers include: a phosphate buffer; a Tris buffer; a borate buffer; a succinate buffer; a histidine buffer (particularly with an aluminium hydroxide adjuvant); or a citrate buffer. Buffer salts will typically be included in the 5-20 mM range.

[0279] Pharmaceutical compositions or vaccines typically have a pH between 5.0 and 9.5, e.g. between 6.0 and 8.0.

[0280] Pharmaceutical compositions or vaccines are preferably sterile and gluten free.

[0281] Pharmaceutical compositions or vaccines are suitable for administration to animal (and, in particular, human) patients, and thus include both human and veterinary uses. They may be used in a method of raising an immune response in a patient, comprising the step of administering the composition to the patient.

[0282] The pharmaceutical compositions or vaccines of the present invention may be administered before a subject is exposed to Francisella tularensis and / or after a subject is exposed to Francisella tularensis.

[0283] Pharmaceutical compositions or vaccines may be prepared in unit dose form. In some embodiments a unit dose may have a volume of between 0.1 -1.0 mL e.g. about 0.5 mL.

[0284] GAR-P04620W004 Application (final) docx - ABK> 44

[0285] Pharmaceutical compositions or vaccines of the invention may be prepared in various forms. For example, the pharmaceutical compositions or vaccines may be prepared as injectables, either as liquid solutions or suspensions. Solid forms suitable for solution in, or suspension in, liquid vehicles prior to injection can also be prepared (e.g. a lyophilized composition or a spray-freeze dried composition). The composition may be prepared for topical administration e.g. as an ointment, cream or powder. The composition may be prepared for oral administration e.g. as a tablet or capsule, as a spray, or as a syrup (optionally flavored). The composition may be prepared for pulmonary administration e.g. by an inhaler, using a fine powder or a spray. The composition may be prepared as a suppository. The composition may be prepared for nasal, aural or ocular administration e.g. as a spray or drops. Injectables for intramuscular administration are typical.

[0286] A therapeutically effective dosage of one conjugate according to the present invention or of one saccharide of general formula (I) refers to that amount of the compound that results in an at least a partial immunization against a disease. Toxicity and therapeutic efficacy of such compounds can be determined by standard pharmaceutical, pharmacological, and toxicological procedures in cell cultures or experimental animals. The dose ratio between toxic and therapeutic effect is the therapeutic index. The actual amount of the composition administered will be dependent on the subject being treated, on the subject's weight, the severity of the affliction, the manner of administration and the judgement of the prescribing physician.

[0287] Antibody

[0288] A further embodiment of the present invention relates to a monoclonal antibody having specificity for the saccharide of general formula (I) or a fragment thereof. Said antibody is able to prevent and treat diseases caused by Francisella tularensis. Thus, the monoclonal antibody is useful for passive immunization against Francisella tularensis infections by providing a fast immune response in any subject. The monoclonal antibody is particularly useful for passive immunization against Francisella tularensis infections in a subject having a deficient immune response and who does not respond to active immunization. Thus, the present invention also relates to a monoclonal antibody recognizing the O-antigen capsular polysaccharide of Francisella tularensis type A and type B.

[0289] The term fragment of a saccharide of general formula (I) refers to constituting subunits of a saccharide of general formula (I). For example, if the saccharide of general formula (I) is a hexasaccharide, then a fragment thereof includes penta-,

[0290] GAR-P04620W004 Application (final) docx -ABK>

[0291] 45 tetra-, tri-, di- and monosaccharides, which are the constituting units of the hexasaccharide.

[0292] The term “antibody” as used herein encompasses polyclonal and monoclonal antibody preparations, as well as preparations including hybrid antibodies, F(ab’)2 fragments, F(ab) molecules, single domain antibodies and functional fragments thereof, which exhibit immunological binding properties of the parent antibody molecule. The antibody disclosed herein may be a monoclonal antibody.

[0293] Preferably, the monoclonal antibody or a fragment thereof has specificity for a saccharide of general formula (I) as described herein, wherein x represents an integer selected from 1 or 2,

[0294] -T- represents a bond,

[0295] R1represents -CH2OH, and L, Ux, and Ux+i have the meanings as defined herein.

[0296] Preferably, the monoclonal antibody or a fragment thereof has specificity for a saccharide of general formula (I) as described herein, wherein x represents 1 ,

[0297] -T- represents a bond,

[0298] R1represents -CH2OH, and L, Ux, and Ux+ihave the meanings as defined herein.

[0299] Preferably, the monoclonal antibody or a fragment thereof has specificity for a saccharide of general formula (I) as described herein, wherein x represents 2,

[0300] -T- represents a bond,

[0301] R1represents -CH2OH, and L, Ux, and Ux+ihave the meanings as defined herein.

[0302] Preferably, the monoclonal antibody or a fragment thereof has specificity for a saccharide of general formula (I) as described herein, wherein x represents an integer selected from 1 or 2,

[0303] -T- represents a bond,

[0304] R1represents -CH2OH,

[0305] -L- represents -La-, -La-Le-, -La-Lb-Le-, or -La-Ld-Le- ;

[0306] -La- represents -(CH2)o-, -(CH2-CH2-O)o-C2H4-, or -(CH2-CH2-O)o-CH2;

[0307] GAR-P04620W004 Application (final) docx - ABK> 46

[0308] -Lb- represents -0-, -NH-CO-NH-, -NH-CO-CH2-NH-, -NH-CO-; -Ld- represents -(CH2)q- -(CH(OH))q- -(CF2)q- -(CH2-CH2-O)q-C2H4- or -(CH2-CH2-O)q-CH2- ;

[0309] -Le- represents -(CH2)PI- — (CF2)PI— , -C2H4-(O-CH2-CH2)PI-

[0310] -CH2-(O-CH2-CH2)PI- or -(CH2)pi-O-(CH2)p2- ; and o, q, p1 and P2 are independently of each other an integer selected from 1 , 2, 3, 4, 5, and 6 and Ux, and Ux+i have the meanings as defined herein.

[0311] Preferably, the monoclonal antibody or a fragment thereof has specificity for a saccharide of general formula (I) as described herein, wherein x represents an integer selected from 1 or 2, -T- represents a bond, R1represents -CH2OH, -L- represents -(CH2)0- and o is an integer selected from 2, 3, 4, 5, 6, 7, and 8 and Ux, and Ux+i have the meanings as defined herein.

[0312] Preferably, the monoclonal antibody or a fragment thereof has specificity for a saccharide of general formula (I) selected from 4-amino butyl 4-formamido- / 3-D- quinovopyranosyl-(1 — >4)-a-D- / V-acetylgalactopyranoside; 5-amino pentyl

[0313] 4-formamido- / 3-D-quinovopyranosyl-(1 — >4)-cr-D- / V-acetylgalactopyranoside; 6-amino hexyl 4-formamido- / 3-D-quinovopyranosyl-(1 — >4)-cr-D- / V-acetylgalactopyranoside;

[0314] 7-amino heptyl 4-formamido- / 3-D-quinovopyranosyl-(1 -^4)-a-D- / V-acetylgalacto- pyranoside; 4-amino butyl / 3-D- / V-acetylquinovopyranoside-(1 — >2)-4-formamido- / 3-D- quinovopyranoside; 5-amino pentyl / 3-D- / V-acetylquinovopyranoside-(1 — >2)-4- formamido- / 3-D-quinovopyranoside; 6-amino hexyl / 3-D- / V-acetyl-quinovosamine- pyranoside-(1 ^2)-4-formamido- / 3-D-quinovopyranoside; 7-amino pentyl 3-D- / V- acetylquinovosaminepyranoside-(1 ^2)-4-formamido- / 3-D-quinovo-pyranoside.

[0315] Preferably, the monoclonal antibody or a fragment thereof has specificity for a saccharide of general formula (I) selected from

[0316] 5-amino-pentanyl 4- / V-formamido-4,6-dideoxy- / 3-D-glucopyranosyl-(1 — >4)-2- acetamido-2- deoxy-a-D-galactouronamide;

[0317] 5-amino-pentanyl 4- / V-formamido-4,6-dideoxy- / 3-D-glucopyranosyl-(1 — >4)-2- acetamido-2-deoxy-o-D-galactopyranoside;

[0318] 5-amino-pentanyl 2-acetamido-2,6-dideoxy-o-D-glucopyranosyl-(1^2)-4- / \ / - formamido-4,6-dideoxy- / 3-D-glucopyranoside;

[0319] 5-amino-pentanyl 2-acetamido-o-D-galactopyranosyl uronamide-(1 -^3)-2-acetamido- 2,6-dideoxy-[3-D-glucopyranoside

[0320] GAR-P04620W004 Application (final) docx - ABK> 47

[0321] 5-amino-pentanyl 2-acetam ido-a-D-galactopyranosyl-(1^3)-2-acetamido-2, 6- dideoxy- / 3-D-glucopyranoside;

[0322] 5-am ino-pentanyl 2-acetam ido-a-D-galactopyranosyl-( 1 -^4)-2-acetam ido-a-D- galactopyranosyl-(1— >3)-2-acetamido-2,6-dideoxy- / 3-D-glucopyranoside 5-amino-pentanyl 4-acetamido-4,6-dideoxy- / 3-D-glucopyranosyl-(1^2)-2- acetamido-o-D-galactopyranosyl-(1^4)-2-acetamido-o-D-galactopyranosyl-(1^3)- 2-acetamido-2,6-dideoxy- / 3-D-glucopyranoside;

[0323] 5-amino-pentanyl 2-acetam ido-a-D-galactopyranosyl uronamide-(1 — >4)-2- acetamido-a-D-galactopyranosyl uronamide-(1^3)-2-acetamido-2,6-dideoxy- / 3-D- glucopyranoside; and

[0324] 5-amino-pentanyl 4- / V-formamido-4,6-dideoxy- / 3-D-glucopyranosyl-(1— >4)-2- acetam ido-2-deoxy-a-D-galactopyranosyl uronam ide-( 1 -^4)-2-acetam ido-a-D- galactopyranosyluronamide-(1^3)-2-acetamido-2,6-dideoxy- / 3-D-glucopyranoside.

[0325] Preferably, the monoclonal antibody or a fragment thereof has specificity for a saccharide of general formula (I) selected from

[0326] 5-amino-pentanyl 4- / V-formamido-4,6-dideoxy- / 3-D-glucopyranosyl-(1— >4)-2- acetam ido-2-deoxy-o-D-galactopyranoside; and

[0327] 5-amino-pentanyl 2-acetamido-2,6-dideoxy-o-D-glucopyranosyl-(1^2)-4- / \ / - formamido-4,6-dideoxy- / 3-D-glucopyranoside.

[0328] The monoclonal antibodies of the invention were produced using hybridoma technology following standard immunological methods. Splenocytes were isolated from C57BL / 6NRj mice (6-8 weeks old) that had been immunized with the synthetic glycoconjugate vaccines 13-CRMI97or I8-CRM197 as described in Example E. After the final booster immunization, spleen cells were fused with SP2 / 0-Ag14 mouse myeloma cells using polyethylene glycol (PEG 1500) to generate hybridoma cell lines secreting antibodies specific for the Francisella tularensis O-antigen saccharide fragments.

[0329] Hybridoma mAb 13 secretes an lgG2b (K light chain) monoclonal antibody that binds specifically to the synthetic disaccharide glycan 13 and also cross-reacts with O-antigens of several F. tularensis subspecies.

[0330] Hybridomas mAb 18_1 , mAb 18_2, and mAb 18_3 secrete lgG1 (K light chain) monoclonal antibodies exhibiting high-affinity and specific binding to the corresponding synthetic glycan 18.

[0331] GAR-P04620W004 Application (final) docx -ABK-

[0332] 48

[0333] The hybridoma clones were selected by enzyme-linked immunosorbent assay (ELISA) and glycan microarray screening against the respective synthetic glycans and against native F. tularensis lipopolysaccharide (LPS). All selected hybridomas secrete antibodies that recognize the natural O-antigen epitopes with high specificity and affinity.

[0334] Each hybridoma grows as an adherent-independent cell line in RPMI-1640 medium supplemented with 10 % fetal calf serum, 2 mM L-glutamine, 1 mM sodium pyruvate, and 50 pM 2-mercaptoethanol at 37 °C and 5 % CO2. The hybridomas can be maintained by routine sub-culturing or cryopreserved in liquid nitrogen or at -80 °C using standard culture techniques.

[0335] The monoclonal antibodies secreted by these hybridomas can be purified from culture supernatants using protein A / G affinity chromatography followed by buffer exchange into phosphate-buffered saline (PBS).

[0336] Thus, In one embodiment, the invention provides a hybridoma cell line producing a monoclonal antibody specifically binding to a saccharide of general formula (I) H- Ux+i- Ux- T- O— L- NH2, wherein Ux, Ux+i, T, and L have the meanings as defined herein. Preferred are hybridoma cell lines producing a monoclonal antibody specifically binding to a saccharide of general formula (I) selected from

[0337] 5-amino-pentanyl 4- / V-formamido-4,6-dideoxy- / 3-D-glucopyranosyl-(1 — >4)-2- acetamido-2- deoxy-a-D-galactouronamide;

[0338] 5-amino-pentanyl 4- / V-formamido-4,6-dideoxy- / 3-D-glucopyranosyl-(1 — >4)-2- acetamido-2-deoxy-o-D-galactopyranoside; 5-amino-pentanyl 2-acetamido-2,6-dideoxy-o-D-glucopyranosyl-(1^2)-4- / \ / - formamido-4,6-dideoxy- / 3-D-glucopyranoside; 5-amino-pentanyl 2-acetamido-o-D-galactopyranosyl uronamide-(1 -^3)-2-acetamido- 2,6-dideoxy-[3-D-glucopyranoside 5-amino-pentanyl 2-acetam ido-o-D-galactopyranosyl-(1 ^3)-2-acetamido-2, 6- dideoxy- / 3-D-glucopyranoside; 5-am ino-pentanyl 2-acetam ido-o-D-galactopyranosyl-( 1 -^4)-2-acetam ido-a-D- galactopyranosyl-(1 ^3)-2-acetamido-2,6-dideoxy- / 3-D-glucopyranoside 5-amino-pentanyl 4-acetamido-4,6-dideoxy- / 3-D-glucopyranosyl-(1 ^2)-2- acetamido-o-D-galactopyranosyl-(1 ^4)-2-acetamido-o-D-galactopyranosyl-(1 ^3)- 2-acetamido-2,6-dideoxy- / 3-D-glucopyranoside;

[0339] 5-amino-pentanyl 2-acetam ido-a-D-galactopyranosyl uronamide-(1 — >4)-2- acetamido-o-D-galactopyranosyl uronamide-(1 ^3)-2-acetamido-2,6-dideoxy- / 3-D- glucopyranoside; and

[0340] GAR-P04620W004 Application (final) docx - ABK> 49

[0341] 5-amino-pentanyl 4- / V-formamido-4,6-dideoxy- / 3-D-glucopyranosyl-(1— >4)-2- acetam ido-2-deoxy-o-D-galactopyranosyl uronam ide-( 1 -^4)-2-acetam ido-a-D- galactopyranosyluronamide-(1^3)-2-acetamido-2,6-dideoxy- / 3-D-glucopyranoside.

[0342] Preferred are hybridoma cell lines producing a monoclonal antibody specifically binding to a saccharide of general formula (I), wherein x represents an integer selected from 1 or 2, -T- represents a bond, R1represents -CH2OH, and L, Ux, and Ux+i have the meanings as defined herein.

[0343] In a preferred embodiment, the invention provides a hybridoma cell line designated mAb 13, which produces a monoclonal lgG2b (K light chain) antibody specifically binding to a synthetic Francisella tularensis O-antigen disaccharide 13 (5-amino- pentanyl 4- / V-formamido-4,6-dideoxy- / 3-D-glucopyranosyl-(1— >4)-2-acetamido-2- deoxy-o-D-galactopyranoside).

[0344] In another embodiment, the invention provides hybridoma cell lines designated mAb 18_1 , mAb 18_2, and mAb 18_3, each of which produces a monoclonal lgG1 (K light chain) antibody specifically binding to the synthetic F. tularensis O-antigen disaccharide corresponding to glycan 18 (5-amino-pentanyl 2-acetamido-2,6-dideoxy- o-D-glucopyranosyl-(1— >2)-4- / V-formamido-4,6-dideoxy- / 3-D-glucopyranoside).

[0345] Also disclosed herein is a vaccine composition comprising a monoclonal antibody having specificity for the saccharide of general formula (I) or a fragment thereof, and a pharmaceutically acceptable carrier.

[0346] The vaccine composition typically includes one or more pharmaceutically acceptable carriers (e.g., sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like). Water is a more typical carrier when the pharmaceutical composition is administered intravenously. Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid carriers, particularly for injectable solutions. Suitable pharmaceutical excipients include, for example, starch, glucose, lactose, sucrose, gelatine, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skimmilk, glycerol, propylene glycol, water, ethanol, and the like. The vaccine composition, if desired, can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents. These compositions can take the form of solutions, suspensions, emulsion, tablets, pills, capsules, powders, sustained-release formulations and the like.

[0347] GAR-P04620W004 Application (final) docx - ABK> 50

[0348] For prophylactic treatment against Francisella tularensis infection, the monoclonal antibody or the vaccine composition can be administered prior to exposure of a subject to the bacteria so that the resulting immune response can inhibit or reduce the severity of the bacterial infection such that the bacteria can be eliminated from said subject.

[0349] Also, the monoclonal antibody or the vaccine composition can be administered post infection or after presumed infection, exposure or manifestation of clinical symptoms. In an aspect thereof, the monoclonal antibody or the vaccine composition can be administered in a time period up to 8 hours post infection. Alternatively, the monoclonal antibody combination is administered in a time period up to 24 hours post infection. In a further alternative, the monoclonal antibody combination is administered in a time period up to 48 hours post infection.

[0350] The monoclonal antibody or the vaccine composition may be administered, including as a single dose or in multiple sequential doses, up to 8 hours post infection (8hpi), 12hpi, 18hpi, 24hpi, 36hpi, 48hpi, 72hpi, 1 day post infection, 2 days post infection, 3 days post infection, 4 days post infection, 5 days post infection, 6 days post infection 7 days post infection, a week post infection, 10 days post infection, 2 weeks post infection, 3 weeks post infection, 4 weeks post infection, a month post infection, months post infection.

[0351] Various delivery systems are known and can be used to administer the monoclonal antibody. Methods of introduction include but are not limited to intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, epidural, intrarectal, and oral routes. The therapeutic agent can be administered, for example by infusion or bolus injection, by absorption through epithelial or mucocutaneous linings (e.g., oral mucosa, rectal and intestinal mucosa, and the like).

[0352] Immunological assay

[0353] A further embodiment of the present invention is directed to a saccharide according to the present invention for use as marker in immunological assays for detection of antibodies against Francisella tularensis. Such assays comprise, for instance, microarray and ELISA.

[0354] Hence, the inventive saccharide can be used for diagnosis of diseases caused by Francisella tularensis. An assay conducted for diagnostic purposes according to the invention may be an immune assay like a solid-phase enzyme immunoassay (EIA), an enzyme linked immunosorbent assay (ELISA), especially an “indirect" ELISA or a

[0355] GAR-P04620W004 Application (final) docx -ABK>

[0356] 51 radioimmune assay (RIA). Preferably, the saccharide according to the present invention is covalently linked on the solid support through an interconnecting molecule. Thus, the saccharide according to the present invention can be covalently linked on the solid support directly or indirectly through the nitrogen atom of the -O-L-NH2 group. The solid support is preferably selected from the group comprising or consisting of: a glass slide, a microtitre plate, test tubes, microspheres, nanoparticle or beads.

[0357] Thus, the saccharides of the present invention can be easily conjugated to solid supports for providing immunological assays useful for detection of antibodies against Francisella tularensis. Said solid supports present on their surface a functionality that is prone to react with the amino group of saccharides of general formula (I) or with the functional group Y of the interconnecting molecule to provide modified solid supports, presenting on their surface the functional group X of the interconnecting molecule that can further react with the amino group of saccharides of general formula (I). In an embodiment according to the present invention the solid supports are microarray slides, which present on their surface a functionality that is prone to react with the functional group Y of the interconnecting molecule to provide modified microarray slides, presenting of their surface the functional group X of the interconnecting molecule. Examples of such microarray slides include, but are not restricted to Coming® epoxide coated slides or Corning® GAPS™ II coated slides.

[0358] It is particularly preferred that the solid support is a glass slide or a microtitre plate. A microtitre plate or microplate or microwell plate is a flat plate with multiple "wells" used as small test tubes. Typically, a microtitre plate having 6, 24, 96, 384 or even 1536 sample wells can be used. Microplates are produced from many different materials, like polycarbonate for microtitre plate used for PCR. The most common is polystyrene as used for most optical detection microplates. It can be colored white by the addition of titanium dioxide for optical absorbance or luminescence detection or black by the addition of carbon for fluorescent biological assays.

[0359] Thus, another aspect of the present invention is directed to a diagnostic test kit for conducting an immunological assay for detection of antibodies against Francisella tularensis comprising at least one saccharide of formula (I) immobilized on a solid support.

[0360] A further embodiment of the present invention is directed to a monoclonal antibody having specificity for the saccharide of general formula (I) or a fragment thereof for use as specific binder in immunological assays for detection of Francisella tularensis

[0361] GAR-P04620W004 Application (final) docx - ABK> 52 bacteria in a specimen. Such assays comprise, for instance, ELISA (direct ELISA, indirect ELISA, and Sandwich ELISA), lateral flow immunoassay, Western Blot, immunofluorescence assay, immunohistochemistry, flow cytometry, immunomagnetic separation, chemiluminescence immunoassay, and surface plasmon resonance.

[0362] Hence, the inventive monoclonal antibody can be used for detection of the presence of Francisella tularensis in a specimen. An assay conducted for detection purposes according to the invention may be an immune assay like a solid-phase enzyme immunoassay (EIA), an enzyme linked immunosorbent assay (ELISA), especially an “indirect" ELISA or a radioimmune assay (RIA). Preferably, the monoclonal antibody according to the present invention is covalently linked on the solid support. Preferably, the monoclonal antibody according to the present invention is present in a solution. The solid support is preferably selected from the group comprising or consisting of: a glass slide, a microtitre plate, test tubes, microspheres, nanoparticle or beads.

[0363] Thus, another aspect of the present invention is directed to a diagnostic kit for detection of Francisella tularensis bacteria in a specimen comprising a monoclonal antibody having specificity for the saccharide of general formula (I) or a fragment thereof.

[0364] In a preferred embodiment, the diagnostic kit for detection of Francisella tularensis bacteria in a specimen comprises a monoclonal antibody having specificity for the saccharide of general formula (I) or a fragment thereof on a solid support.

[0365] In a preferred embodiment, the diagnostic kit further comprises a detection antibody for visualizing the antigen-antibody interaction. To this extent, the detection antibody has a detection label for labeling the Francisella tularensis O-antigen capsular polysaccharide in the specimen. Thus, in a preferred embodiment, the diagnostic kit for detection of Francisella tularensis bacteria in a specimen comprises a monoclonal antibody having specificity for the saccharide of general formula (I) or a fragment thereof, and a detection antibody having a detection label for labeling the Francisella tularensis O-antigen capsular polysaccharide in the specimen.

[0366] In a preferred embodiment, the diagnostic kit comprises a monoclonal antibody or a fragment thereof having specificity for a saccharide of general formula (I) as described herein, wherein x represents an integer selected from 1 or 2,

[0367] -T- represents a bond,

[0368] GAR-P04620W004 Application (final) docx -ABK>

[0369] 53

[0370] R1represents -CH2OH, and L, Ux, and Ux+i have the meanings as defined herein.

[0371] In a preferred embodiment, the diagnostic kit comprises a monoclonal antibody or a fragment thereof having specificity for a saccharide of general formula (I) as described herein, wherein x represents 1 ,

[0372] -T- represents a bond, R1represents -CH2OH, and L, Ux, and Ux+ihave the meanings as defined herein.

[0373] In a preferred embodiment, the diagnostic kit comprises a monoclonal antibody or a fragment thereof having specificity for a saccharide of general formula (I) as described herein, wherein x represents 2,

[0374] -T- represents a bond, R1represents -CH2OH, and L, Ux, and Ux+ihave the meanings as defined herein.

[0375] In a preferred embodiment, the diagnostic kit comprises a monoclonal antibody or a fragment thereof having specificity for a saccharide of general formula (I) selected from

[0376] 5-amino-pentanyl 4- / V-formamido-4,6-dideoxy- / 3-D-glucopyranosyl-(1 — >4)-2- acetamido-2- deoxy-a-D-galactouronamide; 5-amino-pentanyl 4- / V-formamido-4,6-dideoxy- / 3-D-glucopyranosyl-(1 — >4)-2- acetamido-2-deoxy-o-D-galactopyranoside; 5-amino-pentanyl 2-acetamido-2,6-dideoxy-o-D-glucopyranosyl-(1^2)-4- / \ / - formamido-4,6-dideoxy- / 3-D-glucopyranoside;

[0377] 5-amino-pentanyl 2-acetamido-o-D-galactopyranosyl uronamide-(1 -^3)-2-acetamido- 2,6-dideoxy-[3-D-glucopyranoside

[0378] 5-amino-pentanyl 2-acetam ido-o-D-galactopyranosyl-(1 ^3)-2-acetamido-2, 6- dideoxy- / 3-D-glucopyranoside;

[0379] 5-am ino-pentanyl 2-acetam ido-o-D-galactopyranosyl-( 1 -^4)-2-acetam ido-a-D- galactopyranosyl-(1 ^3)-2-acetamido-2,6-dideoxy- / 3-D-glucopyranoside 5-amino-pentanyl 4-acetamido-4,6-dideoxy- / 3-D-glucopyranosyl-(1 ^2)-2- acetamido-o-D-galactopyranosyl-(1 ^4)-2-acetamido-o-D-galactopyranosyl-(1 ^3)- 2-acetamido-2,6-dideoxy- / 3-D-glucopyranoside;

[0380] 5-amino-pentanyl 2-acetam ido-a-D-galactopyranosyl uronamide-(1 — >4)-2- acetamido-o-D-galactopyranosyl uronamide-(1 ^3)-2-acetamido-2,6-dideoxy- / 3-D-

[0381] GAR-P04620W004 Application (final) docx -ABK-

[0382] 54 glucopyranoside; and

[0383] 5-amino-pentanyl 4- / V-formamido-4,6-dideoxy- / 3-D-glucopyranosyl-(1— >4)-2- acetam ido-2-deoxy-a-D-galactopyranosyl uronam ide-( 1 -^4)-2-acetam ido-a-D- galactopyranosyluronamide-(1^3)-2-acetamido-2,6-dideoxy- / 3-D-glucopyranoside.

[0384] In a preferred embodiment, the diagnostic kit comprises a monoclonal antibody or a fragment thereof having specificity for a saccharide of general formula (I) selected from

[0385] 5-amino-pentanyl 4- / V-formamido-4,6-dideoxy- / 3-D-glucopyranosyl-(1— >4)-2- acetam ido-2-deoxy-o-D-galactopyranoside; and

[0386] 5-amino-pentanyl 2-acetamido-2,6-dideoxy-o-D-glucopyranosyl-(1^2)-4- / \ / - formamido-4,6-dideoxy- / 3-D-glucopyranoside.

[0387] In a preferred embodiment, the diagnostic kit comprises a monoclonal antibody or a fragment thereof having specificity for a saccharide of general formula (I) as described herein, wherein x represents an integer selected from 1 or 2,

[0388] -T- represents a bond,

[0389] R1represents -CH2OH,

[0390] -L- represents -La-, -La-Le-, -La-Lb-Le- or -La-Ld-Le- ;

[0391] -La- represents -(CH2)o-, -(CH2-CH2-O)o-C2H4-, or -(CH2-CH2-O)o-CH2;

[0392] -Lb- represents -O-, -NH-CO-NH-, -NH-CO-CH2-NH-, -NH-CO-;

[0393] -Ld- represents -(CH2)q-, -(CH(OH))q-, -(CF2)q-, -(CH2-CH2-O)q-C2H4-, or

[0394] -(CH2-CH2-O)q-CH2- ;

[0395] -Le- represents -(CH2)PI-, — (CF2)P1— , -C2H4-(O-CH2-CH2)pi-,

[0396] -CH2-(O-CH2-CH2)pi- or -(CH2)pi-O-(CH2)p2- ; and o, q, p1 and P2 are independently of each other an integer selected from 1 , 2, 3, 4,

[0397] 5, and 6 and Ux, and Ux+i have the meanings as defined herein.

[0398] In a preferred embodiment, the diagnostic kit comprises a monoclonal antibody or a fragment thereof having specificity for a saccharide of general formula (I) as described herein, wherein x represents an integer selected from 1 or 2,

[0399] -T- represents a bond,

[0400] R1represents -CH2OH,

[0401] -L- represents -(CH2)o- and o is an integer selected from 2, 3, 4, 5, 6, 7, and 8 and Ux, and Ux+i have the meanings as defined herein.

[0402] GAR-P04620W004 Application (final) docx -ABK>

[0403] 55

[0404] Description of the Figures

[0405] Figure 1: shows a repeating unit of the O-antigen of Francisella tularensis strain 15 O-antigen capsular polysaccharide.

[0406] Figure 2: Commercially available interconnecting molecules .

[0407] Figure 3: Examples of functional group X of the interconnecting molecule.

[0408] Figure 4: shows two CRM197 conjugates of the present invention.

[0409] Figure 5: shows structures of synthetic F. tularensis related glycans tested in glycan microarray analysis

[0410] Figure 6: shows (A) printing pattern of glycan microarray and (B) exemplary binding pattern of pig serum to immobilized synthetic glycans,

[0411] Figure 7: Mean Fluorescence Intensity of IgG antibody binding to synthetic glycans. The sera are derived from tularemia positive (pos.; dark grey) and negative (neg.; light grey) pigs. A serum dilution of 1 :100 was used. Values represent mean ± SEM. Differences were tested for significance to tularemia negative animals using multiple Mann-Whitney test with (***) p < 0.001 , (**) p < 0.01 and (*) p < 0.05.

[0412] Figure 8: Glycan microarray analysis of Francisella tularensis related glycans. Mean Fluorescence Intensity of IgG antibody binding to synthetic glycans. The sera are derived from tularemia positive (pos.; dark grey) and negative (neg.; light grey) horses (A), cats / cheetahs (B), dogs (C) and rabbits (D). A serum dilution of 1 :100 was used. Values represent mean ± SEM. Differences were tested for significance to tularemia negative animals using multiple Mann-Whitney test with (****) p < 0.0001 and (*) p < 0.05.

[0413] Figure 9: shows (A) MALDI-TOF-MS spectra of I3-CRM197 glycoconjugate and (B) MALDI-TOF-MS spectra of I8-CRM197 glycoconjugate,

[0414] GAR-P04620W004 Application (final) docx - ABK> 56

[0415] Figure 10: shows IgG antibody response from sera derived from the (A) 13- CRM197 vaccination against glycan 13 and (B) I8-CRM197 vaccination against glycan 18 measured by glycan microarrays. Serum samples from mice immunized on day 0, 14 and 28. Sera samples were collected on day -0, 14, 27 and 31 .

[0416] Figure 11: shows (A) IgM and (B) IgG antibody response from sera derived from I8-CRM197 vaccination on day 31 measured by glycan microarrays

[0417] Figure 12: shows (A) IgM and (B) IgG antibody response from sera derived from I8-CRM197 vaccination on day 31 measured by glycan microarrays

[0418] Figure 13: shows Antibody response from (A) one mAb 13 derived from I3-CRM197 and (B) three mAbs 18_1 - 18_3 derived from the I8-CRM197 immunization against the respective glycans measured by glycan microarrays.

[0419] Figure 14: shows Enzyme-linked immunosorbent assays (ELISA) of the mAb 13 derived from the vaccination of mice with I3-CRM197 on different Francisella tularensis subspecies. Values represent the mean ± SD of three assays with each three replicates.

[0420] The following examples are included to demonstrate preferred embodiments of the invention. It should be appreciated by those skilled in the art that the techniques disclosed in the examples, which follow represent techniques discovered by the inventor to function well in the practice of the invention, and thus can be considered to constitute preferred modes for its practice. However, those skilled in the art should, in light of the present disclosure, appreciate that many changes can be made in the specific embodiments, which are disclosed and still obtain a like or similar result.

[0421] Further modifications and alternative embodiments of various aspects of the invention will be apparent to those skilled in the art in view of this description. Accordingly, this description is to be construed as illustrative only and is for the purpose of teaching those skilled in the art the general manner of carrying out the invention. It is to be understood that the forms of the invention shown and described herein are to be taken as examples of embodiments. Elements and materials may be substituted for those illustrated and described herein, parts and processes may be

[0422] GAR-P04620W004 Application (final) docx reversed, and certain features of the invention may be utilized independently, all as would be apparent to one skilled in the art after having the benefit of this description of the invention.

[0423] GAR-P04620W004 Application (final) docx -ABK>

[0424] 58

[0425] Examples

[0426] A. Chemical synthesis

[0427] General Information

[0428] All the glassware were dried in the oven prior to reaction. Commercial grade solvents and reagents were used without further purification. Reactions sensitive to moisture were carried out under an atmosphere of nitrogen. Sodium iodide (Nal) used in the reaction was dried at 80 °C under vacuum. Anhydrous solvents were obtained from a solvent drying system (JCMeyer) or dried according to reported procedures. Analytical TLC was performed on Kieselgel 60 F254 glass (Macherey-Nagel). Spots were visualized with UV light (A: 254 nm), sulphuric acid stain [1 mL of 3-methoxyphenol in 1 L of EtOH and 30 mL H2SO4] or ceric ammonium molybdate stain [0.5 g Ce(NH4)4(SO4)4*2H2O, 12 g (NH4)6Mo7O24*4H2O and 15 mL H2SO4in 235 mL H2O]. Flash chromatography was performed on Kieselgel 60 230-400 mesh (Sigma-Aldrich). Preparative HPLC purifications were performed with an Agilent 1200 Series or Agilent 1260 Infinity II. NMR spectra were recorded on a Varian 400 MHz spectrometer (Agilent), Ascend 400 MHz (cryoprobe, Broker), Ascend 700 MHz (cryoprobe, Broker) or Varian 600 MHz (Agilent) at 25 °C unless indicated otherwise. Chemical shifts (5) are reported in parts per million (ppm) relative to the respective residual solvent peaks (CDCI3: 6 7.26 in1H and 77.16 in13C; D2O 5 4.79 in1H). Bidimensional and non-decoupled experiments were performed to assign identities of peaks showing relevant structural features. The following abbreviations are used to indicate peak multiplicities: s (singlet), d (doublet) dd (doublet of doublets), t (triplet), dt (doublet of triplets), td (triplet of doublets), q (quartet), p (pentet), m (multiplet). Additional descriptors b (broad signal) and app (apparent first-order multiplet) are also employed when required. Coupling constants (J) are reported in Hertz (Hz). NMR spectra were processed using MestreNova 14.1 (MestreLab Research). High- resolution mass spectra (ESI-HRMS) were recorded with a Xevo G2-XS Q-Tof (Waters).

[0429] Abbreviations

[0430] Ac Acetyl

[0431] AcOH Acetic acid

[0432] AC20 Acetic anhydride

[0433] BAIB Bisacetyliodobenzene

[0434] Bn Benzyl

[0435] GAR-P04620W004 Application (final) docxfBuOH t-Butanol Bz Benzoyl CAN Cericammonium nitrate Cbz Benzyloxycarbonyl CU(0AC)2 Copper(ll) acetate DBU 1 ,8-Diazabicyclo[5.4.0]undec-7-ene DCC / V, / V -Dicyclohexylcarbodiimide DCM Dichloromethane DMAP / V, / V-Dimethylaminopyridine DMF / V, / V -Dimethylformamide ESI Electrosprayionization Et3N Triethylamine Et Ethyl EtOAc Ethyl acetate FmocCI 9-Fluorenylmethylchloroformate g Grams h Hours HRMS High resolution mass spectrometry Lev Levulinyl min Minute mL Millilitre Me Methyl Mel Methyl iodide MeOH Methanol MP p-Methoxy phenyl MS Molecular sieves NaHCO3Sodium bicarbonate NaOH Sodium hydroxide NaOMe Sodium methoxide NIS A / -lodo succinimide NMR Nuclear magnetic resonance Pd / C Palladium on charcoal Ph Phenyl Pico Picoloyl CPS Capsular polysaccharide Py Pyridine RT Room temperature TCA Trichloroacetamide TEMPO 2,2,6,6-Tetramethylpiperidinyloxy

[0436] GAR-P04620W004 Application (final) docx -ABK-

[0437] 60

[0438] TfOH Trifluromethanesulfonic acid

[0439] TMSOTf T rimethylsilyltrifluromethanesulfonate

[0440] THF Tetrahydrofuran

[0441] Tol p-Tolyl

[0442] Example A: Chemical Synthesis of qlycans related to F. tularensis

[0443] 16 2.NaOMe, CH2CI2 / MeOH rt. 1 h. 78%

[0444] Scheme 1. Synthetic route to D-viosamine donor 5 and acceptor 16.

[0445] 4-Methyl phenyl 3-O-benzyl-2-O-benzoyl-6-deoxy-1 -thio- -D-galactopyranoside (S2) 66% over two steps

[0446] Dibutyltinoxide (Bu2SnO, 2.7 g, 10.81 mmol) was added to the solution of known compound S1 (2.7 g, 7.21 mmol) in anhydrous toluene (55 mL) and the reaction was kept stirring at 110 °C for 12 h. After that, the reaction mixture was concentrated under reduced pressure and dried under high vacuum for the next step.

[0447] The so formed tin acetal compound was dissolved in anhydrous toluene (50 mL). To this solution, tetrabutylammonium bromide (TBAB, 3.48 g, 10.81 mmol) and benzyl bromide (BnBr, 1.3 mL, 10.81 mmol) were added sequentially at room temperature. The reaction was then allowed to stir at 70 °C for 5 h. After completion of the reaction (indicated by TLC), the reaction mixture was diluted with EtOAc (200 mL) and washed with brine solution. The separated organic layer was dried over anhydrous Na2SO4, concentrated and purified by silica gel chromatography (3:7 Ethyl acetate: n-Hexane) to afford compound S2 (2.21 g, 66% over two steps) as a colorless sticky solid.

[0448] GAR-P04620W004 Application (final) docx - ABK> 61

[0449] 1H NMR (400 MHz, CDCI3) 57.83 (dd, J = 8.4, 1 .3 Hz, 2H, -ArH), 7.38 (ddd, J = 7.5, 5.5, 1.3 Hz, 1 H, -ArH), 7.24 (t, J = 7.7 Hz, 2H, -ArH), 7.16 (d, J = 8.2 Hz, 2H, -ArH), 7.00 - 6.87 (m, 5H, -ArH), 6.84 (d, J = 8.3 Hz, 2H, -ArH), 5.28 (t, J = 9.7 Hz, 1 H, H- 2), 4.53 - 4.40 (m, 2H, H-1 , -CHPh), 4.30 (d, J = 12.3 Hz, 1 H, -CHPh), 3.73 (d, J = 3.9 Hz, 1 H, H-4), 3.53 - 3.40 (m, 2H, H-3, H-5), 2.44 (s, 1 H, -OH), 2.07 (s, 3H, - CH3(STol)), 1 .22 (d, J = 6.5 Hz, 3H, H-6).

[0450] 13C NMR (101 MHz, CDCI3) 5 165.31 , 137.75, 137.06, 133.06, 132.80, 129.90, 129.76, 129.48, 129.41 , 128.30, 127.81 , 127.74, 86.69 (C-1 ), 79.56, 77.48, 77.16, 76.84, 74.43, 71.12, 69.62, 68.70, 21.05, 16.71.

[0451] HRMS (ESI): calculated for C27H28O5SNa [M+Na]+: 487.1549, found: 487.1550..

[0452] 4-Methyl phenyl 4-azido-3-O-benzyl-2-O-benzoyl-4,6-dideoxy-1 -thio-jB-D-gluco- pyranoside (5)

[0453] Bn

[0454] OBz 2. NaN3, DMF, rt, 3 h0Bz

[0455] 83% over two stepsgS2 °

[0456] Trifluoromethanesulfonic anhydride (Tf2O, 1.14 mL, 6.78 mmol) and anhydrous pyridine (1.1 mL, 13.56 mmol) were added dropwise to the stirred solution of compound S2 (2.1 g, 4.52 mmol) in anhydrous CH2CI2(21 mL) at 0 °C. The reaction was kept stirring at same temperature for 1 h. After completion of the reaction (monitored by TLC), the reaction mixture was diluted with CH2CI2(2x30 mL) washed with 1 M HCI and aq. NaHCOs solution. The separated organic layer was dried over anhydrous Na2SO4 and concentrated under reduced pressure to get triflated compound which was further treated with sodium azide (NaN3, 1.5 g, 22.6 mmol) in anhydrous DMF (27 mL) at room temperature for 3 h. After completion of reaction (indicated by TLC), the reaction mixture was diluted with EtOAc (2x30 mL) and washed with brine solution. Separated organic layer was dried over anhydrous Na2SO4, concentrated and purified by silica gel column chromatography (1 :9 Ethyl acetate: n-Hexane) to obtain 4-azido-4,6-dideoxy-D-glucose derivative 5 (1.84 g, 83% over two steps) as a white solid.

[0457] 1H NMR (400 MHz, CDCI3) 5 8.00 (d, J = 7.0 Hz, 2H, -ArH), 7.52 - 7.44 (m, 1 H, -ArH), 7.39 - 7.32 (m, 2H, -ArH), 7.29 - 7.23 (m, 2H, -ArH), 7.11 - 7.03 (m, 5H, -ArH), 6.97 (d, J = 8.2 Hz, 2H, -ArH), 5.18 (t, J = 9.5 Hz, 1 H, H-2), 4.66 - 4.58 (m, 2H, H-1 , -CHPh), 4.53 (d, J = 10.6 Hz, 1 H, -CHPh), 3.62 (t, J = 9.1 Hz, 1 H, H-3), 3.30 - 3.22 (m, 1 H, H-5), 3.17 (t, J = 9.6 Hz, 1 H, H-4), 2.20 (s, 3H, -CH3(STol)), 1.32 (d, J = 6.0 Hz, 3H, H-6).

[0458] GAR-P04620W004 Application (final) docx ABK.

[0459] 62

[0460] 13C NMR (101 MHz, CDCI3) 6 165.00, 138.23, 136.88, 133.32, 133.30, 129.78, 129.63, 129.57, 128.48, 128.46, 128.29, 128.24, 127.86, 86.22 (C-1 ), 82.47, 77.48, 77.16, 76.84, 75.10, 74.93, 72.46, 67.35, 21.08, 18.63.

[0461] HRMS (ESI): calculated for C27H27N3O4SNa [M+Na]+: 512.1614, found: 512.1617.

[0462] / V-(Benzyl)benzyloxycarbonyl-5-amino-pentanyl 4-azido-3-O-benzyl-4,6- dideoxy-jB-Dglucopyranoside (16) rt, 1 h, 78%

[0463] Anhydrous CH2CI2 (7 mL) was added to the mixture of 4-azido-D-viosamine donor 5 (0.202 g, 0.413 mmol), known linker acceptor S3 (0.09 g, 0.276 mmol) and 4A molecular sieves (500 mg) and the solution was kept stirring at room temperature for 0.5 h. Then NIS (93 mg, 0.413 mmol) and TMSOTf (5 juL, 0.027 mmol) were added to the stirring solution at 0°C and it was allowed to stir for 1 h. After completion of reaction (consumption of both donor and acceptor were monitored by TLC), Et3N was added and 4A molecular sieves was filtered out through celite bed and the reaction mixture was diluted with CH2CI2 (20 mL) and washed with saturated Na2S2O3solution. The separated organic layer was dried over anhydrous Na2SO4, concentrated and purified by silica gel column chromatography (1 :4 Ethyl acetate: n-Hexane) to give linker coupled D-viosamine compound (0.186 g, 98%) as colorless viscous liquid.

[0464] Sodium methoxide (54 mg, 0.99 mmol) was added to the stirring solution of linker coupled D-viosamine compound (0.15 g, 0.217 mmol) in Methanol / CH2Cl2 (1 / 1 , vlv, 5 mL). After 1 h, Amberlite IR120H+ was added to the solution and the reaction mixture was filtered out through celite, concentrated and purified by silica gel column chromatography (3:7 Ethyl acetate: n-Hexane) to get debenzoylated compound 16 (0.09 g, 78%) as white foam.

[0465] 1H NMR (600 MHz, CDCI3) 57.42 - 7.17 (m, 14H, -ArH), 7.17 - 7.06 (m, 1 H, -ArH), 5.14 (d, J = 19.7 Hz, 2H, -CH2Cbz), 4.97 - 4.88 (m, 1 H, -CHPh), 4.80 (d, J = 11.0 Hz, 1 H, -CHPh), 4.52 - 4.38 (m, 2H, -CH2Ph), 4.15 - 4.05 (m, 1 H, H-1 / 3), 3.87 - 3.68 (m, 1 H, -CH(linker)), 3.52 - 3.31 (m, 3H, H-2, H-3, -CH(linker)), 3.31 - 3.12 (m, 3H, H-5, - CH2(linker)), 3.09 (t, J = 9.6 Hz, 1 H, H-4), 1 .62 - 1 .43 (m, 4H, -CH2(linker)), 1 .30 (d, J = 6.1 Hz, 3H, H-6), 1 .24 (d, J = 16.3 Hz, 2H, -CH2(linker)).

[0466] 13CNMR (151 MHz, CDCI3) 5 156.88, 156.43, 138.18, 137.96, 136.97, 136.78, 128.66, 128.56, 128.38, 128.05, 127.97, 127.41 , 127.31 , 102.83, 102.58, 82.64,

[0467] GAR-P04620W004 Application (final) docx " ABK

[0468] 63

[0469] 77.37, 77.16, 76.95, 75.12, 75.08, 70.82, 70.17, 69.87, 67.43, 67.33, 50.56, 50.34, 47.10, 46.13, 29.81 , 29.29, 29.11 , 27.89, 27.35, 23.45, 23.25, 18.60.

[0470] HRMS (ESI): calculated for C33H41N4O6 [M+H]+: 589.3021 , found: 589.4294.

[0471] Scheme 2. Synthesis of D-galactosamine donor 6 and acceptor 8.

[0472] Phenyl-2-trichloroacetamido-3-O-benzyl-4,6-O-silylidene-2-deoxy-1-seleno-a-D- galactopyranoside (6)

[0473] (fBu)2SO

[0474] Q I

[0475] 1. Zn, AcOH, THF rt, 3 h IX-O

[0476] BnO -

[0477] 2. TCACI, NaHCO3TCAHN I THF, 0 °C, 1 h SePh 77% over two steps 6

[0478] Activated zinc (1.15 g) and acetic acid (AcOH, 1 mL) were added sequentially to the stirring solution of known compound 30 (1.0 g, 2.17 mmol) in THF (10 mL). After 3 h and complete consumption of starting material (indicated by TLC), the reaction mixture was diluted with ethyl acetate (30 mL). Zinc was filtered out through celite bed. Crude amine was directly concentrated under reduced pressure, azeotroped with toluene twice and dried under high vacuum for next step without purification.

[0479] The crude amine was dissolved in anhydrous THF (16 mL) and sodium bicarbonate (0.39 g, 4.66 mmol), TCACI (0.8 mL, 6.99 mmol) were added sequentially at 0 °C. The reaction was kept stirring at same temperature for 1 h. After conversion of the starting material, the crude was diluted with ethyl acetate (50 mL) and washed with brine, aq. NaHCOs solution. The separated organic layer was dried over anhydrous Na2SO4, concentrated and purified by silica gel column chromatography (1 :9 Ethyl acetate: n-Hexane) to give compound 6 (1.25 g, 77% over two steps) as a white solid.

[0480] GAR-P04620W004 Application (final) docx -ABK-

[0481] 64

[0482] 1H NMR (400 MHz, CDCI3) 5 7.42 (dd, J = 6.1 , 2.0 Hz, 2H), 7.27 (d, J = 4.5 Hz, 4H), 7.24 - 7.19 (m, 1 H), 7.19 - 7.13 (m, 3H), 6.80 (d, J = 7.1 Hz, 1 H, ), 6.04 (d, J = 4.8 Hz, 1 H), 4.71 - 4.63 (m, 2H, -CHPh, H-2), 4.60 (s, 1 H, H-4), 4.47 (d, J = 11.9 Hz, 1 H, -CHPh), 4.23 (dd, J = 12.7, 2.3 Hz, 1 H, H-6a), 4.07 (dd, J = 12.7, 1.7 Hz, 1 H, H-6b), 3.95 (s, 1 H, H-5), 3.41 (dd, J =11.0, 2.7 Hz, 1 H, H-3), 0.97 (d, J = 4.3 Hz, 18H, -C(CH3)3).

[0483] 13C NMR (101 MHz, CDCI3) 6 161.77, 137.47, 134.46, 129.47, 128.83, 128.61 , 128.26, 128.23, 127.92, 92.55, 89.22 (C-1 ), 77.48, 77.16, 76.84, 76.55, 70.94, 69.73, 69.07, 67.30, 51.03, 27.77, 27.42, 23.55, 20.93.

[0484] HRMS (ESI): calculated for C29H38Cl3NO5SeSiNa [M+Na]+: 716.0642, found: 716.0686.

[0485] N-(Benzyl)benzyloxycarbonyl-5-amino-pentanyl 2-trichloroacetamido-4-O- benzyl-a-Dgalactopyranoside (S5)

[0486] 1. Zn, AcOH, THF

[0487] (*BufeSi rt, 3 h

[0488] Activated zinc dust (900 mg) and AcOH (0.6 mL) were added sequentially to the stirring solution of known compound S4 (285 mg, 0.382 mmol) in THF (6 mL). After 3 h and complete conversion of azide to amine, zinc dust was removed by filtering through a celite bed. The crude was then concentrated under reduced pressure, azeotroped with toluene twice and dried under high vacuum for next step without purification.

[0489] The crude amine was dissolved in anhydrous THF (3 mL) and sodium bicarbonate (NaHCOs, 78 mg, 1.14 mmol), trichloroacetyl chloride (TCACI, 0.13 mL, 1.14 mmol) were added sequentially at 0 °C. The reaction was kept stirring at same temperature for 1 h. After conversion of starting material, crude was diluted with ethyl acetate (10 mL) and washed with brine, aq. NaHCOs solution. The separated organic layer was dried over anhydrous Na2SO4, concentrated and purified by silica gel column chromatography (3:7 Ethyl acetate: n-Hexane) to give linker coupled D-galactosamine derivative (254 mg, 77% over two steps) as a sticky white solid.

[0490] 1H NMR (400 MHz, CDCI3) 57.45 - 7.34 (m, 14H, -ArH), 7.26 - 7.25 (m, 1 H, -ArH), 6.91 - 6.80 (m, 1 H, -NH), 5.26 (d, J = 13.7 Hz, 2H, -CH2Cbz), 5.08 (s, 1 H, H-1 a), 4.83 (dd, J = 12.2, 3.3 Hz, 1 H, -CHPh), 4.69 (d, J = 8.6 Hz, 3H, H-2, H-5, -CHPh), 4.57 (s, 2H, -CH2Ph), 4.35 (d, J = 13.0 Hz, 1 H, H-6a), 4.24 (d, J = 13.1 Hz, 1 H, H-6b), 3.78 - 3.64 (m, 2H, H-3, H-4), 3.55 - 3.36 (m, 2H, -CH2(linker)), 3.36 - 3.16

[0491] GAR-P04620W004 Application (final) docx -ABK-

[0492] 65

[0493] (m, 2H, -CH2(linker)), 1.69-1.62 (m, 4H, -CH2(linker)), 1.38-1.28 (m, 2H, -CH2(linker)),

[0494] I .17 (s, 9H, -C(CH3)3), 1.16 (S, 9H, -C(CH3)3).

[0495] 13C NMR (151 MHz, CDCI3) 5 161.85, 156.35, 138.19, 137.98, 128.72, 128.61 , 128.12, 127.98, 127.88, 127.77, 127.51 , 127.35, 97.19 (C-1 a), 92.93, 77.37, 77.16, 77.04, 76.95, 75.46, 70.84, 70.35, 70.03, 69.93, 69.78, 68.25, 67.87, 67.41 , 67.35, 64.48, 50.44, 50.10, 47.21 , 46.22, 45.13, 29.11 , 27.80, 27.50, 26.66, 25.68, 23.59, 20.90.

[0496] HRMS (ESI): calculated for C43H57CI3N2O8SiNa [M+Na]+: 885.2842, found: 885.2913. To a solution of above formed linker coupled compound (126 mg, 0.146 mmol) in THF (3 mL), was added dropwise solution of HF*Py (70% in THF, 0.03 mL) at 0 °C. After 1 h, Et3N was added and crude was directly concentrated under reduced pressure, purified by silica gel column chromatography (1 :1 ethyl acetate: n-Hexane to 100% ethyl acetate) to get diol compound S5 (86 mg, 82%) as white foam. 400 MHz, CDCI3) 5 7.37 (d, J = 4.5 Hz, 1 H, -ArH), 7.31 (t, J = 4.5 Hz, ), 7.28 - 7.22 (m, 3H, -ArH), 7.17 (d, J = 7.0 Hz, 1 H, -ArH), 6.92 - 6.71 (m, 5.20-5.11 (m, 2H, -CH2Cbz), 4.92-4.87 (m, 1 H, H-1 aGalN), 4.70 (d, J = H, -CHPh), 4.58 - 4.43 (m, 4H, H-2, -CHPh, -CH2Ph), 4.21 (d, J = 2.9 Hz, 3.91 (dd, J = 11 .3, 5.9 Hz, 1 H, H-6a), 3.86 - 3.80 (m, 2H, H-5, H-6b), 3.75 - 3.67 (m, 2H, H-3, -CH(linker)), 3.67 - 3.56 (m, 1 H, -CH(linker)), 3.43 - 3.35 (m, 1 H, -OH), 3.31 (tt, J = 9.4, 5.5 Hz, 1 H, -CH(linker)), 3.19 (q, J = 6.5 Hz, 2H, -CH(linker), -OH), 1 .53 (ddd, J = 32.4, 15.1 , 7.9 Hz, 4H, -CH2(linker)), 1 .35 - 1 .26 (m, 2H, -CH2(linker)).

[0497] 13C NMR (101 MHz, CDCI3) 5 161.87, 156.78, 156.36, 137.77, 137.32, 136.83, 136.54, 128.64, 128.56, 128.50, 128.08, 128.03, 127.88, 127.84, 127.80, 127.72, 127.43, 127.24, 96.95 (C-1 a), 92.70, 77.50, 77.39, 77.18, 76.87, 76.09, 71.17, 70.04, 69.88, 67.87, 67.32, 66.19, 62.43, 60.50, 50.56, 50.32, 47.16, 46.09, 28.97, 28.76, 27.87, 27.15, 23.50, 21.13.

[0498] HRMS (ESI): calculated for C35H4iCI3N2O8Na [M+Na]+: 745.1820, found: 745.1926.

[0499] / V-(Benzyl)benzyloxycarbonyl-5-amino-pentanyl 2-trichloroacetamido-2-deoxy- 3-0-benzyl-6-0-tert-butyldiphenylsilyl-o-D-galactopyranoside (8)

[0500] Imidazole (Im, 21 mg, 0.304 mmol) and te / Y-butyldiphenylsilylchloride (TBDPSCI, 0.07 mL, 0.276 mmol) were added sequentially to the stirring solution of diol S5 (100 mg, 0.138 mmol) in CH3CN (4 mL) at 0 °C. After 1 h and complete consumption of

[0501] GAR-P04620W004 Application (final) docx - ABK - 66 starting material (monitored by TLC), the crude reaction mixture was diluted with EtOAc (20 mL) and washed with brine solution.

[0502] The separated organic layer was dried over anhydrous Na2SO4, concentrated and purified by silica gel column chromatography (3:7 Ethyl acetate: n-Hexane) to afford 4-OH acceptor 8 (117 mg, 88%) as a white sticky solid. 1 H NMR (400 MHz, CDCI3) 6 7.62 - 7.60 (m, 4H, -ArH), 7.38 -7.29 (m, 7H, -ArH), 7.28-7.23 (m, 10H, -ArH)), 7.21- 7.20 (m, 3H, -ArH)), 7.10 (d, J = 7.6 Hz, 1 H, -ArH), 6.80-6.62 (m, 1 H, -NH), 5.10 (d, J = 18.1 Hz, 2H, -CH2Cbz), 4.81-4.77 (m, 1 H, H-1 a), 4.62 (d, J = 12.0 Hz, 1 H, -CHPh), 4.53 (t, J = 12.7 Hz, 1 H, -CHPh), 4.47 - 4.32 (m, 3H, H-2, -CH2Ph), 4.06 (s, 1 H, H-4), 3.87 (dd, J = 10.5, 6.1 Hz, 1 H, -CH(linker)), 3.79 (dd, J = 10.5, 5.8 Hz, 1 H, -CH(linker)), 3.70 - 3.42 (m, 3H, H-3, H-5, H-6a), 3.29 - 3.03 (m, 3H, H- 6b, -CH2(linker)), 2.47 (s, 1 H, -OH), 1.49 - 1.35 (m, 4H, -CH2(linker)), 1.23-1.15 (m, 2H, -CH2(linker)), 0.99 (s, 9H, -C(CH3)3).

[0503] 13C NMR (101 MHz, CDCI3) 5 161.72, 156.79, 156.31 , 137.91 , 137.52, 136.75, 135.76, 135.71 , 133.37, 133.25, 129.93, 128.76, 128.72, 128.58, 128.21 , 128.09, 127.94, 127.86, 127.81 , 127.49, 127.31 , 96.86 (C-1 a), 92.84, 77.48, 77.36, 77.16, 76.96, 76.84, 76.49, 71.48, 70.40, 67.93, 67.33, 65.69, 63.30, 50.68, 50.37, 47.16, 46.18, 29.84, 28.93, 28.00, 27.47, 26.96, 23.75, 23.43, 19.34.

[0504] HRMS (ESI): calculated for C5iH59CI3N2O8SiNa [M+Na]+: 985.3004, found: 985.3055.

[0505] 7

[0506] Scheme 3. Synthesis of linker coupled D-quivosamine acceptor 7.

[0507] N-(Benzyl)benzyloxycarbonyl-5-amino-pentanyl 2-trichloroacetamido-3-O- acetyl-4-O-benzyl-p-D-glucopyranoside (S6)

[0508] GAR-P04620W004 Application (final) docx ABK.

[0509] 67

[0510] Anhydrous CH2CI2 (37 mL) was added to the mixture of D-quinovosamine donor 15 (1 .3 g, 2.24 mmol), linker acceptor S3 (0.489 g, 1 .49 mmol) and 4A molecular sieves (2.0 g) and the solution was kept for stirring at room temperature for 0.5 h. Then NIS (0.505 g, 2.24 mmol) and TMSOTf (41 L, 0.224 mmol) were added to the stirring solution at -40 °C and it was stirred for 1 h. After completion of reaction (consumption of both donor and acceptor were monitored by TLC), EtsN was added and 4A molecular sieves were filtered through a celite bed and the reaction mixture was diluted with CH2CI2 (30 mL) and washed with saturated Na2S20s solution. The separated organic layer was dried over anhydrous Na2SO4, concentrated and purified by silica gel column chromatography (3:7 Ethyl acetate: n-Hexane) to give linker coupled D-quinovosamine compound S6 (1.01 g, 91 %) as a white solid.

[0511] 1H NMR (400 MHz, CDCI3) 57.38-7.35 (m, 2H, -ArH), 7.34-7.32 (m, 1 H, -ArH), 7.32- 7.28 (m, 6H, -ArH), 7.28-7.27 (m, 1 H, -ArH), 7.26-7.25 (m, 2H, -ArH), 7.24-7.23 (m, 1 H, -ArH), 7.17 - 7.04 (m, 2H, -ArH), 5.40 - 5.22 (m, 1 H, H-3), 5.18 (d, J = 11.0 Hz, 2H, -CH2Cbz), 4.73 - 4.57 (m, 2H, -CH2Ph), 4.52 - 4.42 (m, 2H, -CH2Ph), 4.37-4.28 (m, 1 H, H-1 / 3), 3.98 (q, J = 9.2 Hz, 1 H, H-2), 3.81 - 3.67 (m, 1 H, -CH(linker)), 3.52 - 3.42 (m, 1 H, H-5),3.29 (t, J = 9.2 Hz, 1 H, H-4), 3.26 - 3.15 (m,

[0512] 3H, -CH2(linker), -CH(linker)), 1.97 (s, 3H, -COCH3), 1.57 - 1.41 (m,

[0513] 4H, -CH2(linker)), 1.30 (d, J = 6.1 Hz, 3H, H-6), 1.26-1.20 (m, 2H, -CH2(linker)).

[0514] 13C NMR (101 MHz, CDCI3) 5 171.45, 162.16, 156.81 , 156.27, 137.97, 137.66, 137.28, 136.83, 128.77, 128.64, 128.53, 128.20, 128.09, 128.06, 127.98, 127.93, 127.38, 127.30, 100.67 (C-1 / 3QuiP), 92.66, 81.75, 77.48, 77.36, 77.16, 76.84, 75.40, 74.46, 71.38, 69.71 , 67.24, 56.12, 50.62, 50.36, 47.21 , 46.26, 29.12, 27.97, 27.43, 23.26, 20.96, 17.89.

[0515] HRMS (ESI): calculated for C37H43Cl3N2O8Na [M+Na]+: 771.1977, found: 771.2029.

[0516] / V-(Benzyl)benzyloxycarbonyl-5-amino-pentanyl 2-trichloroacetamido-4-O- benzyl-j3-D-glucopyranoside (7)

[0517] Hydrazine hydrate (6 mL) was added to the stirring solution of compound S6 (0.93 g, 1.24 mmol) in THF / Methanol (1 / 1 , vlv, 20 mL). After 3 h, the crude was diluted with

[0518] GAR-P04620W004 Application (final) docx -ABK-

[0519] 68 ethyl acetate (50 mL) and washed with brine solution (2x10 mL). The separated organic layer was dried over anhydrous Na2SO4, concentrated and purified by silica gel column chromatography (3:7 Ethyl acetate: n-Hexane) to get deacetylated compound 7 (0.746 g, 85%) as white foam.

[0520] 1H NMR (400 MHz, CDCI3) 5 7.49 - 7.32 (m, 13H, -ArH), 7.26 (d, J = 7.6 Hz, 2H, -ArH), 7.05 (bs, 1 H, -NH), 5.26 (d, J = 11.7 Hz, 2H, -CH2Cbz), 4.93 (d, J = 11.3 Hz, 1 H, -CHPh), 4.83 (dd, J = 11.2, 2.4 Hz, 1 H, -CHPh), 4.74-4.69 (m, 1 H, H-1 / 3), 4.57 (s, 2H, -CH2Ph), 4.16 (t, J = 7.7 Hz, 1 H, H-3), 3.91 (dd, J = 21.8, 9.1 Hz, 1 H, -CH(linker)), 3.65 - 3.42 (m, 3H, H-2, H-5, -CH(linker)), 3.38 - 3.09 (m, 4H, H-4, -CH2(linker), -OH), 1.61 (dt, J = 16.0, 7.9 Hz, 4H, -CH2(linker)), 1.45 (d, J = 6.7 Hz, 3H, H6), 1.41 - 1.24 (m, 2H, -CH2(linker)).

[0521] 13C NMR (100 MHz, CDCI3) 5 162.47, 156.76, 156.25, 138.07, 137.86, 136.72,

[0522] 128.60, 128.58, 128.48, 128.10, 128.05, 127.98, 127.87, 127.35, 99.40 (C-1 / 3),

[0523] 92.60, 84.05, 77.41 , 77.39, 77.30, 77.10, 77.07, 76.78, 76.76, 75.09, 73.21 , 71.37, 69.58, 67.23, 59.26, 50.56, 50.29, 47.13, 46.17, 29.73, 29.07, 27.87, 27.33, 23.29, 18.23.

[0524] HRMS (ESI): calculated for C35H4iCl3N2O7Na [M+Na]+: 729.1871 , found: 729.1728.

[0525] / V-(Benzyl)benzyloxycarbonyl-5-amino-pentanyl 4-azido-3-O-benzyl-2-O- benzoyl-4,6-dideoxy- / ?-D-glucopyranosyl-(1— >4)-2-trichloroacetamido-2-deoxy- 3-0-benzyl-6-0-tertbutyldiphenylsilyl-o-D-galactopyranoside (9)

[0526] Anhydrous CH2CI2(2.63 mL) was added to the mixture of 4-azido-D-viosamine donor 5 (76 mg, 0.16 mmol), 4-OH-D-galactosamine acceptor 8 (100 mg, 0.104 mmol) and 4A molecular sieves (100 mg) and the solution was stirred at room temperature for 0.5 h. Then NIS (35 mg, 0.159 mmol) and TMSOTf (2 L, 0.0104 mmol) were added to the stirring solution at 0 °C and it was allowed to stir for 1 h. After completion of reaction (consumption of both donor and acceptor were monitored by TLC), EtsN was added and 4A molecular sieves were removed by filtering through a celite bed and the reaction mixture was diluted with CH2CI2(10 mL) and washed with saturated Na2S20s solution. The separated organic layer was dried over anhydrous Na2SO4, concentrated and purified by silica gel column chromatography (0.5:0.5:9 Ethyl acetate: CH2CI2: Toluene) to give disaccharide compound 9 (103 mg, 75%) as colorless viscous liquid.

[0527] GAR-P04620W004 Application (final) docx -ABK-

[0528] 69

[0529] 1H NMR (600 MHz, CDCI3) 5 8.10-8.08 (m, 2H, -ArH), 7.67-7.64 (m, 4H,-ArH), 7.51 - 7.48 (m, 1 H, -ArH), 7.44-7.36 (m, 7H, -ArH), 7.35-7.28 (m, 7H, -ArH), 7.26-7.24 (m, 5H, -ArH), 7.24-7.16 (m, 8H, -ArH), 7.14-7.13 (m, 1 H, -ArH) 6.58-6.46 (m, 1 H, -NH) 5.18-5.13 (m, 3H, H-2Vio, -CH2Cbz)), 5.01 (d, J = 12.0 Hz, 1 H, H-1 / 3Vi0), 4.67-4.61 (dd, J = 18.0, 6.0 Hz, 2H, -CH2Ph), 4.57-4.44 (m, 5H, H-1 aGalN, -CH2Ph, -CH2Ph), 4.28 (s, 1 H, H-4GalN), 4.23-4.20 (m, 1 H, H-2GalN), 3.89-3.86 (m, 1 H, H-6aGalN), 3.74- 3.71 (m, 1 H, H-6bGalN), 3.64-3.41 (m, 4H, H-4Vi0, H-3Vi0, H-3GalN, -CH(linker)), 3.19- 3.04 (m, 5H, H-5Vi0, H-5GalN, -CH(linker), -CH2(linker)), 1.48-1.33 (m, 4H, -CH2(linker)), 1.20-1.10 (m, 5H, H-6Vi0, -CH2(I inker)), 1.04 (s, 9H, -C(CH3)3).

[0530] 13C NMR (151 MHz, CDCI3) 5 165.45, 161.07, 156.31 , 137.95, 137.39, 135.71 , 133.77, 132.91 , 130.25, 130.09, 129.86, 129.82, 128.71 , 128.61 , 128.58, 128.45, 128.42, 128.14, 127.97, 127.94, 127.80, 127.58, 127.32, 99.55 (C-1 / 3Vi0, 1 JC-H = 161.0 Hz), 96.45 (C-1 aGalN, 1 JC-H = 168.0 Hz), 92.94, 81.25, 77.64, 77.37, 77.29, 77.16, 76.95, 75.00, 74.56, 71.75, 71.59, 70.73, 69.65, 67.67, 67.32, 63.11 , 51.00, 50.69, 50.37, 47.19, 46.20, 29.85, 28.97, 27.03, 23.64, 19.40, 18.47.

[0531] HRMS (ESI): calculated for C7iH78CI3N5Oi2SiNa [M+Na]+: 1348.4374, found: 1348.4565.

[0532] / V-(Benzyl)benzyloxycarbonyl-5-amino-pentanyl 4-azido-3-O-benzyl-2-O- benzoyl-4,6- dideoxy- / ?-D-glucopyranosyl-(1— >4)-2-trichloroacetamido-2-deoxy- 3-O-benzyl-o-Dgalactopyranoside (10)

[0533] Tetrabutylammoniumfluoride (TBAF, 1 M in THF solution, 2.73 mL) was added to the stirring solution of compound 9 (0.32 g, 0.241 mmol) in THF (7.5 mL) at 0 °C. The reaction mixture was then slowly warm up to room temperature for 10 h. After complete consumption of the starting material (monitored by TLC), the crude was directly concentrated under reduced pressure and purified by silica gel chromatography (100% Ethyl acetate) to get compound 10 (0.218 g, 83%) as a colorless sticky compound.

[0534] 1H NMR (400 MHz, CDCI3) 58.07 (dd, J = 8.3, 1 .3 Hz, 2H), 7.60 - 7.54 (m, 1 H), 7.44 (d, J = 7.9 Hz, 2H), 7.43 - 7.39 (m, 5H), 7.38 - 7.33 (m, 5H), 7.31 -7.23 (m, 10H), 6.45 (dd, J = 65.6, 8.3 Hz, 1 H), 5.32 (t, J = 8.0 Hz, 1 H), 5.22 (d, J = 22.1 Hz, 2H), 4.85 (d, J = 7.9 Hz, 2H), 4.77 - 4.61 (m, 3H), 4.59 - 4.49 (m, 3H), 4.30 (s, 1 H), 4.17

[0535] GAR-P04620W004 Application (final) docx -ABK-

[0536] 70

[0537] - 4.06 (m, 1 H), 3.90 - 3.77 (m, 2H), 3.72-3.62 (m, 3H), 3.65 - 3.49 (m, 1 H), 3.39 - 3.23 (m, 4H), 3.22 - 2.99 (m, 2H), 1.57-1.45 (m, 7H), 1.34 - 1.18 (m, 2H).

[0538] 13C NMR (101 MHz, CDCI3) 5 165.47, 160.80, 156.71 , 156.24, 137.85, 137.54, 137.43, 137.03, 136.67, 132.97, 130.11 , 129.70, 129.10, 128.71 , 128.62, 128.49, 128.41 , 128.38, 128.34, 128.22, 127.99, 127.91 , 127.84, 127.40, 127.24, 101.30 (C-1 / 3Vi0), 96.48 (C-1 aGalN), 92.68, 80.90, 77.48, 77.36, 77.16, 76.84, 76.06, 75.02, 73.92, 72.12, 71.28, 71.00, 69.57, 68.58, 68.06, 67.24, 67.10, 60.37, 51.11 , 50.58, 50.29, 47.13, 46.09, 29.77, 28.95, 28.83, 27.86, 27.27, 23.57, 23.25, 22.23, 18.36.

[0539] HRMS (ESI): calculated for CssHeoC NsO^Na [M+Na]+: 1110.3196 found: 1110.3295.

[0540] / V-(Benzyl)benzyloxycarbonyl-5-amino-pentanyl 4-azido-3-O-benzyl-2-O- benzoyl-4,6-dideoxy- / ?-D-glucopyranosyl-(1— >4)-2-trichloroacetamido-2-deoxy- 3-0-benzyl-6-pentafluorophenyl-o-D-galactopyrano uronaside (11)

[0541] 2,2,6,6-Tetramethylpiperidinyloxyl (TEMPO, 11 mg, 0.068 mmol), (diacetoxyiodo)benzene (BAIB, 0.131 g, 0.408 mmol) were added sequentially to a stirring solution of compound 10 (0.160 g, 0.147 mmol) in CH2CI2 (7.3 mL) and H2O (3.5 mL) at 0 °C. After 1 h, another batch of BAIB (0.131 g, 0.408 mmol) was added followed by addition of excess H2O (2 mL) at 0 °C. The mixture was stirred at room temperature for 48 h. After complete conversion of alcohol to acid via aldehyde formation (monitored by TLC), ethyl acetate (50 mL) was added to it and the crude was washed with sat. NaHCOs solution. The separated organic layer was dried over anhydrous Na2SO4, concentrated and dried under high vacuum to get crude carboxylate compound as yellowish liquid.

[0542] To vacuum dried crude carboxylate compound in anhydrous CH2CI2 (10 mL), pentafluorophenol (PFPOH, 40 mg, 0.218 mmol) and catalytic amount of 4-dimethyl- aminopyridine (DMAP, 8.3 mg, 0.068 mmol) were added sequentially at 0 °C. After that, (3-dimethylamino-propyl)-ethylcarbodiimide hydrochloride (EDOHCI, 91 mg, 0.476 mmol) was added and the reaction mixture was stirred at same temperature for 2 h. After completion of reaction (monitored by TLC), the crude reaction mixture was diluted with CH2CI2 (20 mL) and washed with saturated NaHCOs and brine solution. The separated organic layer was dried over anhydrous Na2SO4, concentrated and

[0543] GAR-P04620W004 Application (final) docx - ABK - 71 purified by silica gel column chromatography (1 :4 Ethyl acetate: n-Hexane) to obtain 6-0 disaccharide ester compound 11 (0.166 g, 89% over two steps) as a white solid.

[0544] 1H NMR (400 MHz, CDCI3) 5 8.18 (dd, J = 8.4, 1.4 Hz, 2H, -ArH), 7.61 -7.57 (m, 1 H, -ArH), 7.50-7.46 (m, 2H, -ArH), 7.42 - 7.39 (m, 4H, -ArH), 7.38 - 7.36 (m, 4H, -ArH), 7.34 - 7.29 (m, 5H, -ArH), 7.28 - 7.20 (m, 7H, -ArH), 6.59 (dd, J = 62.4, 8.5 Hz, 1 H, -NH), 5.29 - 5.14 (m, 4H, H-1 / 3Vi0, H-2Vi0, CH2Cbz), 4.93 - 4.88 (m, 2H, H-1 aGalN, H-5GalN), 4.75 - 4.60 (m, 5H, H-4GalN, -CH2Ph), 4.54 (d, J = 7.1 Hz, 2H, -CH2Ph), 4.42 (d, J = 7.5 Hz, 1 H, H-2GalN), 3.91 - 3.79 (m, 1 H, H-3GalN), 3.73 - 3.60 (m, 2H, H-3Vi0, -CH(linker)), 3.46-3.34 (m, 1 H, -CH(linker)), 3.31 -3.21 (m, 3H, H-4Vi0, -CH2(linker)), 3.16-3.10 (m, 1 H, H-5Vi0), 1.62 - 1.46 (m, 4H, -CH2(linker)), 1.27-1.21 (m, 5H, H6Vi0, -CH2(linker)).

[0545] 13C NMR (101 MHz, CDCI3) 5 165.19, 163.91 , 161.32, 156.79, 156.34, 142.31 , 137.84, 137.16, 133.03, 130.21 , 129.94, 128.84, 128.70, 128.56, 128.53, 128.49, 128.43, 128.01 , 127.88, 127.61 , 99.31 (C-1 / 3Vi0), 97.03 (C-1 aGalN), 92.64, 81.22, 77.48, 77.36, 77.16, 77.03, 76.84, 76.23, 75.10, 74.26, 71.89, 70.85, 70.79, 70.38, 69.15, 68.99, 67.33, 50.36, 47.08, 29.84, 28.83, 27.33, 23.53, 18.37.

[0546] HRMS (ESI): calculated for C61H57CI3F5N5O13 Na [M+Na]+: 1290.2831 found: 1290.2983.

[0547] 5-Amino-pentanyl 4- / V-formamido-4,6-dideoxy- / 3-D-glucopyranosyl-(1 >4)-2- acetamido-2- deoxy-o-D-galactouronamide (12)

[0548] 1. 1 ,3-Propanedithlol, DIPEA MeOH, rt, 2 h

[0549] 18% over five steps

[0550] 1 ,3-Propanedithiol (0.5 mL, 4.9 mmol) was added to the stirring solution of disaccharide 11 (0.13 g, 0.102 mmol) in diisopropylethylamine (DIPEA, 0.17 mL) and methanol (7.5 mL). After 2 h stirring at room temperature, the crude residue was directly concentrated under reduced pressure and co-evaporated with toluene twice. The concentrated residue was dried under high vacuum for next step.

[0551] The crude amine residue was dissolved in anhydrous DMF (9.76 mL). 4-Nitrophenyl- formate (85 mg, 0.51 mmol) was added followed by dropwise addition of DIPEA (0.2 mL, 1.02 mmol). After 2 h and complete consumption of amine (indicated by TLC), the reaction mixture was diluted with ethyl acetate (30 mL) and washed with brine solution three times. The separated organic layer was dried over anhydrous Na2SO4, concentrated to obtain / V-formamido disaccharide compound as sticky solid.

[0552] GAR-P04620W004 Application (final) docx - ABK> 72

[0553] Above prepared compound was dissolved in CH2CI2 (1 mL). After that ammonia solution (7 N in MeOH, 3.5 mL) was added to the solution in dropwise at room temperature. After 2 h and complete consumption of the starting material (indicated by TLC), the crude was directly concentrated under reduced pressure to get amide compound as viscous liquid.

[0554] The obtained amide compound was dissolved in EA / fBuOH / hhO (2 / 1 / 1 , v / v / v, 4 mL). To this solution a suspension of Pd / C (60 mg) was added and stirred under hydrogen atmosphere (1 atm, balloon) for 48 h. The reaction mixture was then filtered out through Celite® 353, concentrated to get desired mono benzoylated disaccharide compound.

[0555] To the crude mono benzoylated compound, 3 mL LiOH (1 N in methanol) was added. The solution was stirred at room temperature for 1 h. After complete consumption of the starting material (monitored by mass-spectrometry), Amberlite IR120H+ was added. The reaction mixture was then filtered out, concentrated and purified by HPLC (Hypercarb Column, 150x10 mm at a flow rate of 3 mL / min, eluted by H2O (with 0.1 % formic acid, Solvent A) and acetonitrile (Solvent B) with a linear gradient from 0% to 30% of solvent B over 30 minutes and lyophilized to get disaccharide 12 (3.52 mg, 18% over five steps) as a white powder.

[0556] 1H NMR (600 MHz, D2O) 5 8.15 (s, 1 H, -NHCHO), 7.97 (s, -NHCHO), 4.98 (d, J = 3.8 Hz, 1 H, H-1 aGalN), 4.89 (d, J = 3.8 Hz, 1 H, H-1 aGalN), 4.58-4.56 (d, J = 6.0 Hz, 1 H, H-1 / 3Vi0), 4.48 - 4.44 (m, 3H, H-1 / 3Vi0, H-5GalN), 4.36 (s, 1 H, H-4GalN), 4.25-4.20 (m, 1 H, H-2GalN), 4.18 (s, 1 H, H-4GalN), 4.00-3.96 (m, 1 H, H-3GalN), 3.68 - 3.61 (m, 1 H, -CH(linker)), 3.59 (t, J = 9.9 Hz, 1 H, H-4Vi0), 3.53 - 3.41 (m, 3H, H-3Vi0, H-5Vi0, -CH(linker)), 3.36 (dt, J = 9.3, 7.3 Hz, 1 H, H-2Vi0), 2.95-2.92 (m, 2H, -CH2(linker)), 2.00 (d, J = 2.9 Hz, 3H, -NHCOCH3), 1.66 - 1.54 (m, 4H, -CH2(linker), -CH2(linker)), 1.42 - 1.35 (m, 2H, -CH2(linker)), 1.22 - 1.15 (m, 3H, H-6Vi0).

[0557] 13C NMR (151 MHz, D2O) 5 174.57, 164.62, 103.87 (C-1 / 3Vi0), 103.15 (C-1 / 3Vi0), 97.10 (C-1 aGalN), 96.95 (C-1 aGalN), 79.07, 78.72, 74.05, 73.20, 73.05, 70.75, 70.67, 69.86, 68.87, 68.23, 68.12, 67.86, 55.50, 55.35, 50.18, 39.25, 27.93, 26.38, 26.21 , 22.20, 21.83, 21.79, 16.87, 16.75.

[0558] HRMS (ESI): calculated for C20H37N4O10 [M+H]+: 493.2503 found: 493.2550.

[0559] 5-Amino-pentanyl 4- / V-formamido-4,6-dideoxy- / 3-D-glucopyranosyl-(1 >4)-2- acetamido-2-deoxy-o-D-galactopyranoside (13)

[0560] GAR-P04620W004 Application (final) docx ABK.

[0561] 73

[0562] 1. NaOMe, MeOH / THF, rt, 2 h

[0563] 48 h, 38% over five steps

[0564] Sodium methoxide (0.108 g, 1.99 mmol) was added to the stirring solution of compound 9 (0.132 g, 0.099 mmol) in MeOH / THF (1 / 1 , v / v, 4 mL) at room temperature. After 1 h, TLC showed complete conversion of the starting material. Then Amberlite IR-120 H+ was added to neutralize the mixture. Then it was filtered out, concentrated to afford debenzoylated disaccharide compound as colorless sticky solid.

[0565] 1 ,3-Propanedithiol (0.4 mL) was added to the stirring solution of disaccharide in DIPEA (0.12 mL) and methanol (5.5 mL). After 2 h stirring at room temperature, the crude residue was directly concentrated under reduced pressure and co-evaporated with toluene twice. The concentrated compound was dried under high vacuum for next step.

[0566] The crude amine residue was dissolved in anhydrous DMF (7.3 mL). 4-Nitrophenyl- formate (62 mg, 0.372 mmol) was added to it followed by dropwise addition of DIPEA (0.13 mL, 0.74 mmol) at room temperature. After 2 h and complete consumption of the amine (indicated by TLC), the reaction mixture was diluted with ethyl acetate (30 mL) and washed with brine solution. The separated organic layer was dried over anhydrous Na2SO4, concentrated to obtain / V-formamido disaccharide compound as a sticky colorless liquid.

[0567] To a stirring solution of above prepared / V-formamido disaccharide in THF (3 mL) was added dropwise solution of 70% HF*Py (0.15 mL) at 0 °C. After 1 h, EtsN was added and crude was directly concentrated under reduced pressure and passed through a small bed of silica gel column chromatography (1 :1 Ethyl acetate: n-Hexane to 100% Ethyl acetate) to get disaccharide diol as colorless sticky liquid. The obtained diol / V-formamido compound was dissolved in EA / / BuOH / H2O (2 / 1 / 1 , v / v / v, 5 mL). To this solution a suspension of Pd / C (90 mg) was added and stirred under hydrogen atmosphere for 48 h. The reaction mixture was then filtered out through Celite® 353, concentrated and purified by HPLC (Hypercarb Column, 150x10 mm) at a flow rate of 3 mL / min, eluted by H2O (with 0.1 % formic acid, Solvent A) and acetonitrile (Solvent B) with a linear gradient from 0% to 30% of solvent B over 30 minutes and lyophilized to get desired compound 13 (18 mg, 38% over five steps) as a white powder.

[0568] GAR-P04620W004 Application (final) docx -ABK-

[0569] 74

[0570] 1H NMR (600 MHz, D2O) <58.21 (s, 1 H, -NHCHO), 4.93 (d, J = 3.8 Hz, 1 H, H-1 aGalN), 4.65 (d, J = 8.0 Hz, 1 H, H-1 / 3Vi0), 4.27 - 4.20 (m, 2H, H-2GalN, H-4GalN), 4.03 - 3.96 (m, 2H, H-3GalN, H-5GalN), 3.84 - 3.76 (m, 2H, H-6aGalN, H-6bGalN), 3.75 - 3.68 (m, 1 H, -CH(linker)), 3.68 - 3.63 (m, 1 H, H-4Vi0), 3.63 - 3.59 (m, 1 H, H-5Vi0), 3.59 - 3.53 (m, 1 H, H-3Vi0), 3.53 - 3.48 (m, 1 H, -CH(linkeij), 3.45 (t, J = 8.0 Hz, 1 H, H-2Vi0), 3.00 (dd, J = 8.4, 6.9 Hz, 2H, -CH2(linker)), 2.05 (s, 3H, -NHCOCH3), 1.72 - 1.61 (m, 4H, -CH2(linker)), 1 .49 - 1 .40 (m, 2H, -CH2(linker)), 1 .30 - 1 .22 (m, 3H, H-6Vi0).

[0571] 13C NMR (151 MHz, D2O) 5 174.63, 167.74, 164.72, 103.63 (C-1 / 3Vi0), 96.97 (C-1 aGalN), 77.95, 77.89, 74.15, 73.99, 73.28, 70.92, 70.46, 70.44, 68.30, 68.27, 67.82, 61.41 , 61.39, 60.20, 55.37, 50.54, 39.35, 27.93, 26.44, 22.25, 21.88, 16.77. HRMS (ESI): calculated for C20H38N3OIO [M+H]+: 480.2551 found: 480.2556.

[0572] Phenyl-3-O-acetyl-4-O-benzyl-2-trichloroacetamido-2,6-dideoxy-1-seleno-a-D- glucopyranoside (15)

[0573] 1. Zn, AcOH, THF rt, 12 h

[0574] 2. TCACI, THF, 0 °C

[0575] 2 h, 87%

[0576] Activated zinc (1.15 g), and AcOH (1 mL) were added sequentially to the stirring solution of compound 14 (1.0 g, 2.17 mmol) in THF (10 mL). After 3 h and complete consumption of starting material (indicated by TLC), the reaction mixture was diluted with ethyl acetate (30 mL). Zinc was removed by filtering through a celite bed. The crude was directly concentrated under reduced pressure, azeotroped with toluene twice and dried under high vacuum for next step without purification.

[0577] The crude amine was dissolved in THF (20 mL) and TCACI (0.48 mL, 4.34 mmol) was added at 0 °C. After 2 h, the reaction mixture was diluted with ethyl acetate (10 mL) and washed with H2O and brine solution. The separated organic layer was dried over anhydrous Na2SO4, concentrated and purified by silica gel column chromatography (1 :4 Ethyl acetate: n-Hexane) to give compound 15 (1.09 g, 87% over two steps) as white foam.

[0578] 1H NMR (600 MHz, CDCI3) 57.56 - 7.53 (m, 2H, -ArH), 7.37 (td, J = 6.9, 1.1 Hz, 2H, -ArH), 7.34 - 7.32 (m, 1 H, -ArH), 7.31 - 7.30 (m, 2H, -ArH), 7.30 - 7.29 (m, 1 H, -ArH), 7.28 - 7.26 (m, 2H, -ArH), 7.26 (d, J = 1.2 Hz, 1 H, -NH), 5.81 (d, J = 6.0 Hz, 1 H, H-1 ), 5.13 (t, J = 12.0 Hz, 1 H, H-3), 4.71 (s, 2H, -CH2Ph), 4.33 - 4.26 (m, 1 H, H-2), 4.21 - 4.14 (m, 1 H, H-5), 3.41 - 3.35 (m, 1 H, H-4), 2.01 (s, 3H, -OCOCH3), 1.38 (d, J = 6.3 Hz, 3H, H-6).

[0579] GAR-P04620W004 Application (final) docx ABK.

[0580] 75

[0581] 13C NMR (151 MHz, CDCI3) 6 171.75, 161.88, 137.61 , 134.31 , 129.49, 128.87, 128.70, 128.28, 128.22, 127.92, 92.10, 87.30 (C-1 ), 81.12, 77.37, 77.35, 77.16, 77.14, 76.95, 76.93, 75.48, 74.03, 71.12, 55.83, 20.95, 17.85.

[0582] HRMS (ESI): calculated for C23H24Cl3NO5SeNa [M+Na]+: 601.9772, found: 601.9790.

[0583] / V-(Benzyl)benzyloxycarbonyl-5-amino-pentanyl 3-O-acetyl-4-O-benzyl-2- trichloroacetamido-2,6-dideoxy-o-D-glucopyranosyl-(1 >2)-4-azido-3-O-benzyl- 4,6-dideoxy-jB-D-glucopyranoside (17)

[0584] Anhydrous CH2CI2 (11.95 mL) was added to the mixture of D-quinosamine donor 15 (0.42 g, 0.72 mmol), linker coupled 4-azido-D-viosamine acceptor 16 (0.28 g, 0.476 mmol) and activated 4A molecular sieves (1 .0 g) and the solution was stirred at room temperature 0.5 h. Then NIS (0.16 g, 0.72 mmol), and TMSOTf (17 L, 0.096 mmol) were added sequentially to the stirring solution at -20 °C and the mixture was stirred at same temperature for 1 h. After completion of reaction (indicated by TLC), EtsN was added and 4A molecular sieves were removed by filtering through a celite pad. The solution was then diluted with CH2CI2 (30 mL) and washed with sat. Na2S2O3 solution. The separated organic layer was dried over anhydrous Na2SO4, concentrated and purified by silica gel column chromatography (1 :4 Ethyl acetate: n-Hexane) to give disaccharide compound 17 (0.46 g, 96%) as white foam.

[0585] 1H NMR (700 MHz, CDCI3) 5 7.39 - 7.35 (m, 5H, -ArH), 7.34 (ddd, J = 7.5, 6.1 , 1.4 Hz, 3H, -ArH), 7.31 - 7.28 (m, 5H, -ArH), 7.27 - 7.24 (m, 6H, -ArH), 7.17 (d, J = 7.2 Hz, 1 H, -ArH), 6.71-6.6 (m, 1 H, -NH), 5.20 - 5.09 (m, 3H, -CH2Cbz, H-3QuiN), 4.99-4.89 (m, 1 H, H-1 / 3QuiN), 4.83 - 4.74 (m, 2H, -CH2Ph), 4.65 - 4.58 (m, 2H, -CH2Ph), 4.56 - 4.44 (m, 2H, -CH2Ph), 4.31 -4.28 (m, 1 H, H-1 / 3Vi0), 3.96-3.98 (m, 1 H, H-2QuiN), 3.83 - 3.76 (m, 1 H, -CH(linker)), 3.63 (q, J = 8.9 Hz, 1 H, H-2Vi0), 3.51 - 3.36 (m, 3H, H-5QuiN, H-3Vi0, -CH(linker)), 3.33-3.26 (m, 2H, H-4QuiN, -CH(linker)), 3.24 - 3.15 (m, 2H, H-5Vi0, -CH(linker)), 3.05 (t, J = 9.7 Hz, 1 H, H-4Vi0), 1.94 (s, 3H, -OCOCH3), 1.61 - 1.51 (m, 4H, -CH2(linker)), 1.32-1.28 (m, 8H, H-6QuiN, H- 6Vi0, -CH2(linker)).

[0586] 13C NMR (151 MHz, CDCI3) 5 170.90, 162.13, 156.40, 138.09, 137.78, 137.03, 128.69, 128.67, 128.59, 128.17, 128.03, 127.97, 127.42, 101.74 (C-1 / 3QuiN), 99.54 ((C-1 / 3Vi0), 92.53, 82.96, 81.57, 79.95, 77.37, 77.25, 77.16, 77.08, 76.95, 75.15,

[0587] GAR-P04620W004 Application (final) docx - ABK - 76

[0588] 75.09, 74.25, 71.65, 70.58, 69.92, 69.71 , 68.04, 67.38, 57.37, 50.61 , 50.34, 47.30, 46.21 , 29.84, 29.44, 27.94, 27.52, 23.50, 20.90, 18.57, 18.17.

[0589] HRMS (ESI): calculated for CsoHssC NsOnNa [M+Na]+: 1032.3090, found: 1032.3191.

[0590] 5-Amino-pentanyl 2-acetamido-2,6-dideoxy-o-D-glucopyranosyl-(1 >2)-4- / V- formamido-4,6-dideoxy- / 3-D-glucopyranoside (18)

[0591] I . NaOMe, MeOH, THF, rt, 2 h

[0592] 48 h 50% over four stens

[0593] Sodium methoxide (4.2 mg, 0.07 mmol) was added to the stirring solution of compound 17 (18 mg, 0.018 mmol) in MeOH / THF (1 / 1 , v / v, 1 mL) at room temperature. After 1 h, TLC showed complete conversion of the starting material. Then Amberlite IR-120 H+ was added to neutralize the mixture. Then it was filtered out, concentrated to afford deacetylated disaccharide compound as colorless foam.

[0594] 1 ,3-Propanedithiol (87 juL) was added to the stirring solution of above formed disaccharide in DIPEA (27 juL) and methanol (1.5 mL). After 2 h stirring at room temperature, the crude residue was directly concentrated under reduced pressure and co-evaporated with toluene twice. The concentrated compound was then dried under high vacuum for the next step.

[0595] The crude amine residue was dissolved in anhydrous DMF (1.7 mL). 4-Nitrophenyl- formate (15 mg, 0.09 mmol) was added to it followed by dropwise addition of DIPEA (0.03 mL, 0.18 mmol). After 2 h and complete consumption of the amine (indicated by TLC), the reaction mixture was diluted with ethyl acetate (20 mL) and washed with brine solution. The separated organic layer was dried over anhydrous Na2SO4, concentrated to obtain / V-formamido disaccharide compound as a sticky white solid. The obtained amide compound was dissolved in EA / fBuOH / FhO (2 / 1 / 1 , v / v / v, 5 mL). To this solution a suspension of Pd / C (50 mg) was added and stirred under hydrogen atmosphere (1 atm, balloon) for 48 h. the reaction mixture was then filtered out through Celite® 353, concentrated and purified by HPLC (Hypercarb Column, 150x10 mm) at a flow rate of 3 mL / min, eluted by H2O (with 0.1 % formic acid, Solvent A) and acetonitrile (Solvent B) with a linear gradient from 0% to 30% of solvent B over 30 minutes and lyophilized to get desired disaccharide 18 (4.05 mg, 50% over four steps) as a white solid.

[0596] GAR-P04620W004 Application (final) docx - ABK - 77

[0597] 1H NMR (400 MHz, D2O) 5 8.14-7.94 (m, -1 H, -NHCHO), 4.66 (d, J = 8.4 Hz, 1 H, H-1 / 3QuiN), 4.41 (d, J = 7.9 Hz, 1 H, H-1 / 3Vi0), 3.86-3.80 (m, 1 H, -CH(linker)), 3.68 - 3.56 (m, 2H, H-2Vi0, -CH(linker)), 3.56 - 3.45 (m, 3H, H-3QuiN, H-4QuiN, H-5QuiN), 3.45 - 3.29 (m, 3H, H-2QuiN, H-3Vi0, H-5Vi0), 3.14 (t, J = 9.2 Hz, 1 H, H-4Vi0), 2.94 (t, J = 7.6 Hz, 2H, -CH2(linker)), 1.96 (s, 3H, -NHCOCH3), 1.67 - 1.55 (m, 4H, -CH2(linker)), 1.44 - 1.34 (m, 2H, -CH2(linker)), 1.26 (d, J = 6.2 Hz, 3H, H-6Vi0), 1.17 (dd, J = 6.1 Hz, 3H, H 6QuiN).

[0598] 13C NMR (151 MHz, D2O) 5 174.80, 169.65, 164.70, 101.81 (C-1 / 3QuiN), 101.20 (C-1 / 3Vi0), 82.01 , 75.05, 73.30, 73.02, 71.80, 70.40, 70.00, 60.42, 56.20, 55.52, 39.27, 28.36, 26.46, 22.19, 22.09, 16.88, 16.62.

[0599] HRMS (ESI): calculated for C20H38N3O9 [M+H]+: 464.2603, found: 464.2615.

[0600] / V-(Benzyl)benzyloxycarbonyl-5-amino-pentanyl 3-O-benzyl-2-trichloro- acetamido-o-Dgalactopyranosyl-(1 >3)-4-O-benzyl-2-trichloroacetamido-2,6- dideoxy-jB-D-glucopyranoside (19)

[0601] Anhydrous CH2CI2(13 mL) was added to the mixture of D-galactosamine donor 6 (0.54 g, 0.78 mmol), D-quinosamine acceptor 7 (0.365 g, 0.51 mmol) and molecular sieves (1.5 g) and this solution was stirred at room temperature for 0.5 h. Then NIS (0.174 g, 0.77 mmol) and TMSOTf (9 juL, 0.051 mmol) were added to the stirring solution at -30 °C and it was allowed to stir for 1 h. After completion of the reaction (consumption of both donor and acceptor were monitored by TLC), Et3N was added and 4A molecular sieves were removed by filtering through a celite bed and the reaction mixture was diluted with CH2CI2(20 mL) and washed with saturated Na2S2O3solution. The separated organic layer was dried over anhydrous Na2SO4, concentrated and purified by silica gel column chromatography (1 :4 Ethyl acetate: n-Hexane) to give disaccharide compound (0.494 g, 77%) as colorless viscous liquid.1H NMR (700 MHz, CDCI3) 5 7.36 (s, 1 H, -ArH), 7.33 (d, J = 8.2 Hz, 4H, -ArH), 7.30 (d, J = 7.2 Hz, 6H, -ArH), 7.25 (dd, J = 11.9, 5.9 Hz, 7H, -ArH), 7.14 (dd, J = 23.3, 8.3 Hz, 2H, -ArH), 6.94 - 6.76 (m, 1 H, -NH), 5.60 (s, 1 H, H-1 aGalN), 5.17 (d, J = 22.8 Hz, 2H, -CH2Cbz), 4.69 - 4.67 (m, 2H, H-2GalN, H-6aGalN, 4.58 - 4.52 (m, 4H, H-1 / 3QuiN, H-6bGalN, -CH2Ph), 4.51 -4.43 (m, 3H, H-4GalN, -CH2Ph), 4.15 - 4.06 (m, 3H, H-3QuiN, -CH2Ph), 3.81 - 3.63 (m, 4H, -CH(linker), H-2QuiN, H-5GalN, H-3GalN), 3.53-3.51

[0602] GAR-P04620W004 Application (final) docx -ABK>

[0603] 78

[0604] (m, 1 H, H-5QuiN), 3.42 - 3.27 (m, 1 H, -CH(linker), 3.27 - 3.13 (m, 3H, -CH2(linker), H-4QuiN), 1.56 - 1.45 (m, 4H, -CH2(linker)), 1.35 - 1.27 (m, 5H, H-6QuiN, -CH2(linker)), 1.04 (s, 18H, -C(CH3)3).

[0605] 13C NMR (176 MHz, CDCI3) 5 161.94, 161.77, 156.83, 156.36, 137.93, 137.90, 137.01 , 136.68, 128.85, 128.71 , 128.66, 128.60, 128.28, 128.08, 127.99, 127.92, 127.86, 127.48, 127.34, 99.59 (C-1 / 3QuiN), 96.96 (C-1 aGalN), 92.76, 92.59, 84.23, 84.04, 77.34, 77.16, 76.98, 75.22, 75.04, 74.50, 74.45, 71.33, 70.29, 69.84, 69.40, 68.33, 67.34, 67.29, 56.96, 56.88, 50.62, 50.40, 49.86, 47.20, 46.19, 29.84, 29.34, 29.07, 27.73, 27.43, 23.61 , 23.31 , 20.86, 18.46.

[0606] HRMS (ESI): calculated for C58H73CI6N3Oi2SiNa [M+Na]+: 1264.2987, found: 1264.2646.

[0607] To a stirring solution of protected disaccharide (0.68 g, 0.55 mmol) in THF (5.6 mL) was added dropwise solution of HF*Py (70% in THF, 0.1 mL) at 0 °C. After 1 h, Et3N was added and the crude was directly concentrated under reduced pressure and purified by silica gel column chromatography (1 :1 Ethyl acetate: n-Hexane to 100% Ethyl acetate) to get disaccharide diol 19 (0.501 g, 83%) as white foam.

[0608] 1H NMR (700 MHz, CDCI3) 57.97-7.90 (m, 1 H, -NH), 7.39 - 7.35 (m, 2H, -ArH), 7.33 - 7.29 (m, 10H, -ArH), 7.28 - 7.24 (m, 4H, -ArH), 7.23 (d, J = 6.8 Hz, 2H, -ArH), 7.17 (dd, J = 14.8, 7.3 Hz, 2H, -ArH), 7.11 - 6.99 (m, 1 H, -NH), 5.54 (s, 1 H, H-1 aGalN), 5.16 (d, J = 34.3 Hz, 2H, -CH2Cbz), 4.60 (d, J = 14.0 Hz, 1 H, -CHPh), 4.57 - 4.41 (m, 7H, -CHPh, -CH2Ph, H-2GalN, H-1 / 3QuiN), 4.09-4.03 (m, 1 H, H-3QuiN), 3.99 - 3.92 (m, 4H, H-2QuiN, H-4GalN, H-6aGalN, H-5GalN), 3.82 - 3.74 (m, 1 H, -CH(linker)), 3.71 -3.67 (m, 2H, H-3GalN, H-6bGalN), 3.48 - 3.46 (m, 1 H, H-5QuiN), 3.40-3.37 (m, 1 H, -CH(linker)), 3.33 - 3.23 (m, 2H, -CH(linker), H-4QuiN), 3.18-3.14 (m, 1 H, -CH(linker)), 1.57-1.45 (m, 4H, -CH2(linker)), 1.31 - 1.26 (m, 5H, H-6QuiN, -CH2(linker)).

[0609] 13C NMR (176 MHz, CDCI3) 5 162.89, 162.45, 162.10, 156.88, 156.41 , 137.79,

[0610] 137.09, 136.91 , 136.72, 136.60, 134.91 , 129.13, 128.79, 128.73, 128.66, 128.60,

[0611] 128.55, 128.36, 128.32, 128.19, 128.16, 128.10, 128.06, 127.93, 127.86, 127.78,

[0612] 127.44, 127.31 , 125.39, 100.09 (C-1 / 3QuiN, 1 JC-H = 161.0 Hz), 96.47 (C-1 aGalN, 1 JC-H =

[0613] 175.0 Hz), 92.73, 92.59, 84.84, 77.34, 77.16, 76.98, 75.56, 75.09, 74.64, 71.71 , 71.09, 70.56, 69.32, 67.35, 67.32, 66.54, 62.99, 56.80, 50.51 , 50.47, 50.29, 47.18, 46.10, 29.34, 29.17, 27.90, 27.32, 23.19, 18.06.

[0614] HRMS (ESI): calculated for C5oH57CI6N3Oi2Na [M+Na]+: 1124.1965, found: 1124.1958.

[0615] / V-(Benzyl)benzyloxycarbonyl-5-amino-pentanyl 3-O-benzyl-2-trichloro- acetamido-6-pentafluorophenyl-o-D-galactopyranosyl uronate-(1 >3)-4-O- benzyl-2-trichloroacetamido-2,6-dideoxy- / 3-D-glucopyranoside (20)

[0616] GAR-P04620W004 Application (final) docx ABK.

[0617] 79

[0618] TEMPO (2.2 mg, 0.014 mmol), BAIB (101 mg, 0.314 mmol) were added sequentially to a stirring solution of diol 19 (77 mg, 0.069 mmol) in CH2CI2 (4.6 mL) and H2O (2.3 mL) at 0 °C. The mixture was stirred at same temperature for 5 h. After complete conversion of alcohol to acid (monitored by TLC), ethyl acetate (20 mL) was added to it and crude was washed with sat. NaHCOs solution. Separated organic layer was dried over anhydrous Na2SO4, concentrated and dried under high vacuum to get crude carboxylate compound as yellowish liquid.

[0619] To vacuum dried crude carboxylate compound in anhydrous CH2CI2 (2 mL), pentafluorophenol (20 mg, 0.11 mmol) and catalytic amounts of DMAP (4.2 mg, 0.035 mmol) were added sequentially at 0 °C. After 5 minutes, EDOHCI (47 mg, 0.24 mmol) was added to the reaction mixture. The mixture was stirred at same temperature for 3 h. After completion of the reaction (monitored by TLC), the crude reaction mixture was diluted with CH2CI2 (20 mL) and washed with saturated NaHCOs and brine solution. The separated organic layer was dried over anhydrous Na2SO4, concentrated and purified by silica gel column chromatography (1 :4 Ethyl acetate: n-Hexane) to obtain 6-0 ester compound 20 (27 mg, 30% over two steps) as a white solid.

[0620] 1H NMR (400 MHz, CDCI3) 57.36 (d, J = 2.3 Hz, 3H), 7.32 (td, J = 6.4, 2.4 Hz, 13H), 7.27 (d, J = 2.1 Hz, 2H), 7.18 - 7.12 (m, 1 H), 7.09 - 7.01 (m, 1 H), 5.90 (d, J = 5.4 Hz, 1 H), 5.18 (d, J = 4.2 Hz, 2H), 4.90 (d, J = 12.1 Hz, 1 H), 4.72 (dd, J = 10.8, 6.8 Hz, 2H), 4.64 (d, J = 10.5 Hz, 1 H), 4.55 (d, J = 10.5 Hz, 2H), 4.48 (q, J = 4.8 Hz, 3H), 4.38 - 4.16 (m, 2H), 4.01 - 3.76 (m, 3H), 3.45 - 3.35 (m, 2H), 3.34 - 3.14 (m, 4H), 1 .58 - 1 .40 (m, 7H), 1 .37 (d, J = 6.1 Hz, 3H).

[0621] 13C NMR (101 MHz, CDCI3) 5 170.95, 162.84, 162.15, 156.90, 156.50, 139.27, 137.83, 136.93, 136.68, 136.34, 128.97, 128.84, 128.70, 128.60, 128.20, 128.00, 127.90, 127.50, 100.37-100.12 (C-1 / 3QuiN), 97.78 (C-1 aGalN), 92.35, 91.97, 84.90, 78.68, 77.48, 77.36, 77.26, 77.16, 77.03, 76.84, 75.52, 74.28, 72.73, 71.00, 69.74, 69.44, 67.44, 56.26, 55.17, 50.48, 47.25, 31.56, 30.30, 29.84, 29.80, 29.50, 28.80, 27.14, 23.20, 22.84, 17.97, 14.28.

[0622] HRMS (ESI): calculated for CseHs^leFsNsO Na [M+Na]+: 1304.1600, found: 1304.1756.

[0623] GAR-P04620W004 Application (final) docx ABK.

[0624] 80

[0625] 5-Amino-pentanyl 2-acetamido-o-D-galactopyranosyl uronamide-(1 >3)-2- acetamido-2,6-dideoxy- / 3-D-glucopyranoside (21 )

[0626] Ammonia solution (7N in methanol, 2.4 mL) was added dropwise to the stirred solution of compound 20 (20 mg, 0.016 mmol) in CH2CI2 (0.5 mL) at room temperature. After 1 h and complete consumption of the starting material, the crude was directly concentrated under reduced pressure to get amide compound as viscous liquid.

[0627] The obtained amide compound was dissolved in EA / fBuOH / hhO (2 / 2 / 1 , v / v / v, 5 mL). To this solution, a suspension of Pd / C (30 mg) was added and stirred under hydrogen atmosphere (1 atm, balloon) for 48 h. The reaction mixture was then filtered through Celite® 353, concentrated, purified by HPLC (Hypercarb Column, 150x10 mm at a flow rate of 3 mL / min, eluted by H2O (with 0.1 % formic acid, Solvent A) and acetonitrile (Solvent B) with a linear gradient from 0% to 30% of solvent B over 30 minutes and lyophilized to get disaccharide compound 21 (2.8 mg, 36% over two steps) as a white solid.

[0628] 1H NMR (600 MHz, D2O) <55.35 (d, J = 3.9 Hz, 1 H, H-1 aGalN), 4.48 (d, J = 8.4 Hz, 1 H, H-1 / 3QuiN), 4.27 (s, 2H, H-4GalN, H-5GalN), 4.23 (dd, J = 6.0 Hz, 1 H, H-2GalN), 3.93 (dd, J = 11.2, 3.5 Hz, 1 H, H-3GalN), 3.87 (dt, J = 10.1 , 6.1 Hz, 1 H, -CH(linker)), 3.73 (t, J = 9.0 Hz, 1 H, H-2QuiN), 3.63 (d, J = 9.7 Hz, 1 H, H-3QuiN), 3.58 (dt, J = 10.0, 6.3 Hz, 1 H, -CH(linker)), 3.49 - 3.43 (m, 1 H, H-5QuiN), 3.43 - 3.37 (m, 1 H, H-4QuiN), 3.02 - 2.95 (m, 2H, -CH2(linker)), 2.06 (s, 3H, -NHCOCH3), 1.98 (s, 3H, -NHCOCH3), 1.67 (p, J = 7.6 Hz, 2H, -CH2(linker)), 1.61 - 1.54 (m, 2H, -CH2(linker)), 1.38 (dtd, J = 14.6, 7.0, 4.2 Hz, 2H, -CH2(linker)), 1.31 (d, J = 6.1 Hz, 3H, H-6QuiN).

[0629] 13C NMR (151 MHz, D2O) 5 174.47, 174.31 , 173.70, 101.00 (C-1 / 3QuiN), 98.63 (C-1 aGalN), 80.24, 75.97, 71.68, 71.20, 70.12, 68.67, 67.00, 54.59, 49.23, 39.20, 28.08, 26.34, 22.07, 21.98, 21.88, 16.40.

[0630] HRMS (ESI): calculated for C21H39N4O10[M+H]+: 507.2660, found: 507.2665.

[0631] 5-Amino-pentanyl 2-acetamido-o-D-galactopyranosyl-(1 >3)-2-acetamido-2,6- dideoxy-jB-Dglucopyranoside (22)

[0632] GAR-P04620W004 Application (final) docx " ABK

[0633] 81

[0634] To a solution of compound 19 (7.7 mg, 0.007 mmol) in EA / / BUOH / H2O (2 / 1 / 1 , v / v / \z, 4 mL) was added Pd / C (20 mg) at room temperature. After stirring under hydrogen atmosphere (1 atm, balloon) for 48 h, the reaction mixture was filtered through Celite® 353, concentrated and purified by HPLC (Hypercarb Column, 150x10 mm at a flow rate of 3 mL / min, eluted by H2O (with 0.1 % formic acid, Solvent A) and acetonitrile (Solvent B) with a linear gradient from 0% to 30% of solvent B over 30 minutes and lyophilized to obtain disaccharide compound 22 (3.2 mg, 92%) as a white solid.

[0635] 1H NMR (600 MHz, D2O) <55.40 (d, J = 3.9 Hz, 1 H, H-1 aGalN), 4.49 (d, J = 8.5 Hz, 1 H, H-1 / 3QuiN), 4.15 (dd, J = 11.1 , 3.9 Hz, 1 H, H-2GalN), 3.96 (d, J = 3.7 Hz, 1 H, H-4GalN), 3.86-3.82 (m, 2H, -CH(linker), H-6aGalN), 3.79 - 3.68 (m, 4H, H-3GalN, H-5GalN, H-2QuiN, -CH(linker)), 3.64 - 3.54 (m, 2H, H-3QuiN, H-6bGalN), 3.47 - 3.41 (m, 1 H, H-5QuiN), 3.37 (t, J = 12.0 Hz, 1 H, H-4QuiN), 2.95 (t, J = 7.7 Hz, 2H, -CH2(linker)), 2.02 (s, 6H, -NHCOCH3), 1.64 (p, J = 7.6 Hz, 2H, -CH(linker)), 1.60 - 1.53 (m, 2H, -CH(linker)), 1.40 - 1.32 (m, 2H, -CH2(linker), 1.27 (d, J = 6.1 Hz, 3H, H-6QuiN).

[0636] 13C NMR (151 MHz, D2O) 5 174.45, 174.28, 100.79 (C-1 aGalN), 97.19 (C-1 / 3QuiN), 77.78, 76.34, 71.76, 70.86, 70.13, 68.16, 67.49, 60.56, 54.40, 49.59, 39.30, 28.11 , 26.40, 22.24, 22.12, 21.94, 16.41.

[0637] HRMS (ESI): calculated for C2I H4ON3OIO [M+H]+: 494.2707, found: 494.2721 .

[0638] / V-(Benzyl)benzyloxycarbonyl-5-amino-pentanyl 3-O-benzyl-2-trichloro- acetamido-6-0-tertbutyldiphenylsilyl-o-D-galactopyranosyl-(1 >3)-4-O-benzyl-2- trichloroacetamido-2,6-dideoxy- / 3-D-glucopyranoside (23)

[0639] Imidazole (68 mg, 0.996 mmol) and TBDPSCI (0.23 mL, 0.905 mmol) were added sequentially to the stirring solution of disaccharide diol 19 (500 mg, 0.453 mmol) in CH3CN (9 mL) at 0 °C. After 2 h and complete consumption of the starting material, the crude reaction mixture was diluted with EtOAc (20 mL) and washed with brine

[0640] GAR-P04620W004 Application (final) docx ABK.

[0641] 82 solution. The separated organic layer was dried over anhydrous Na2SO4, concentrated and purified by silica gel column chromatography (3:7 Ethyl acetate: n-Hexane) to afford 4-OH disaccharide acceptor 23 (541 mg, 89%) as a white sticky solid.

[0642] 1H NMR (400 MHz, CDCI3) 57.78 - 7.66 (m, 5H), 7.48 - 7.30 (m, 24H), 7.20 (dd, J = 5.1 , 3.1 Hz, 1 H), 7.09 - 6.98 (m, 1 H), 6.95-6.75 (m, 1 H), 5.63 (d, J = 3.9 Hz, 1 H, H-1 aGalN), 5.25 - 5.12 (m, 2H), 4.66 - 4.58 (m, 4H), 4.53 (dd, J = 9.7, 4.0 Hz, 3H, H-1 / 3QuiN), 4.35 (q, J = 8.0 Hz, 1 H), 4.10 - 4.01 (m, 3H), 4.01 - 3.91 (m, 2H), 3.88 (dd, J = 10.3, 4.5 Hz, 1 H), 3.84 - 3.73 (m, 1 H), 3.72 - 3.64 (m, 1 H), 3.48 - 3.34 (m, 2H), 3.29 (t, J = 8.6 Hz, 2H), 3.25 - 3.15 (m, 1 H), 2.53 (s, 1 H), 1.55 - 1. 50 (m, 4H), 1.37 (d, J = 6.2 Hz, 3H), 1.33-1.30 (m, 2H), 1.11 (s, 9H).

[0643] 13C NMR (101 MHz, CDCI3) 5 162.04, 161.92, 156.80, 156.29, 137.92, 137.30, 136.97, 136.76, 135.76, 135.33, 134.91 , 133.05, 132.89, 130.02, 129.95, 129.73, 128.79, 128.66, 128.56, 128.33, 128.28, 128.05, 127.97, 127.92, 127.90, 127.81 , 127.44, 127.32, 100.22 (C-1 / 3QuiN), 95.95 (C-1 aGalN), 92.70, 92.59, 85.01 , 77.48, 77.36, 77.16, 76.84, 74.45, 74.22, 71.86, 71.33, 70.87, 69.54, 67.27, 66.03, 63.86, 56.73, 50.60, 50.38, 47.16, 46.19, 29.81 , 29.25, 27.97, 27.42, 27.24, 26.66, 23.29, 19.38, 18.02.

[0644] HRMS (ESI): calculated for CeeHysCleNsO^SiNa [M+Na]+: 1362.3143, found: 1362.2823.

[0645] / V-(Benzyl)benzyloxycarbonyl-5-amino-pentanyl 3-O-benzyl-2-trichloro- acetamido-4,6-Osilylidene-o-D-galactopyranosyl-(1 >4)-3-O-benzyl-2-trichloro- acetamido-6-O-tertbutyldiphenylsilyl-a-D-galactopyranosyl-(1 >3)-4-O-benzyl-2- trichloroacetamido-2,6-dideoxy- / 3-D-glucopyranoside (24)

[0646] Anhydrous CH2CI2 (13 mL) was added to the mixture of D-galactosamine donor 6 (0.593 g, 0.855 mmol), 4-OH-disaccharide acceptor 23 (0.574 g, 0.428 mmol) and molecular sieves (1.5 g) and this solution was stirred at room temperature for 0.5 h. Then NIS (0.192 g, 0.855 mmol) and TMSOTf (15 L, 0.085 mmol) were added to the stirring solution at -30 °C and it was stirred for 2 h. After completion of the reaction (monitored by TLC), EtsN was added and 4A molecular sieves were removed by

[0647] GAR-P04620W004 Application (final) docx -ABK>

[0648] 83 filtering through a celite bed and the reaction mixture was diluted with CH2CI2 (20 mL) and washed with saturated Na2S2O3 solution. The separated organic layer was dried over anhydrous Na2SO4, concentrated and purified by silica gel column chromatography (1 :4 Ethyl acetate: n-Hexane) to give protected trisaccharide 24 (0.57 g, 71 %) as colorless viscous liquid.

[0649] 1H NMR (400 MHz, CDCI3) 57.54 (dd, J = 23.0, 7.6 Hz, 4H), 7.31 (t, J = 7.3 Hz, 7H), 7.27 - 7.21 (m, 10H), 7.21 - 7.14 (m, 11 H), 7.10 (d, J = 7.7 Hz, 4H), 6.99 (t, J = 11.9 Hz, 1 H), 6.60 (d, J = 9.7 Hz, 2H), 5.23 (s, 1 H, H-1 aGalN), 5.16 (d, J = 3.3 Hz, 1 H, H-1 ’aGalN), 5.08 (d, J = 16.1 Hz, 2H), 4.63 - 4.52 (m, 3H), 4.46 (q, J = 5.4 Hz, 4H), 4.43 - 4.35 (m, 4H), 4.32-4.27 (m, 2H, H-1 / 3QuiN), 4.03 (s, 1 H), 3.84 (t, J = 8.8 Hz,

[0650] 1 H), 3.71 (t, J = 11.6 Hz, 4H), 3.59 (dd, J = 18.9, 12.0 Hz, 3H), 3.32 (d, J = 7.1 Hz,

[0651] 2H), 3.09 (d, J = 8.9 Hz, 4H), 1 .40 (dd, J = 14.9, 7.5 Hz, 4H), 1 .17 (d, J = 5.6 Hz, 5H),

[0652] 0.98 (d, J = 13.7 Hz, 18H), 0.87 (s, 9H).

[0653] 13C NMR (101 MHz, CDCI3) 5 162.25, 161.95, 161.49, 156.78, 156.29, 138.10,

[0654] 137.97, 137.89, 136.97, 136.77, 135.64, 135.60, 133.46, 132.30, 130.45, 130.17,

[0655] 129.15, 128.85, 128.67, 128.56, 128.50, 128.47, 128.34, 128.23, 128.07, 128.03,

[0656] 127.92, 127.87, 127.64, 127.44, 127.30, 126.94, 125.41 , 99.39 (C-1 / 3QuiP), 97.28

[0657] (C-1 ’aGalN), 96.54 (C-1 aGalN), 92.58, 83.86, 77.48, 77.36, 77.16, 77.01 , 76.84, 76.02,

[0658] 75.62, 74.37, 72.05, 71.93, 71.08, 70.70, 69.83, 69.51 , 68.91 , 67.96, 67.28, 66.96,

[0659] 61.62, 57.12, 51.53, 50.59, 50.32, 49.72, 47.13, 46.18, 29.81 , 29.27, 27.66, 27.44, 27.13, 23.39, 23.29, 21.59, 20.75, 19.36, 18.15.

[0660] HRMS (ESI): calculated for C89Hio7Cl9N4Oi7Si2Na [M+Na]+: 1897.4259, found: 1897.3906.

[0661] / V-(Benzyl)benzyloxycarbonyl-5-amino-pentanyl 3-O-benzyl-2-trichloro- acetamido-o-Dgalactopyranosyl-(1 >4)-3-0-benzyl-2-trichloroacetamido-o-D- galactopyranosyl-(1— >3)-4-O-benzyl-2-trichloroacetamido-2,6-dideoxy- / ?-D- glucopyranoside (25)

[0662] GAR-P04620W004 Application (final) docx -ABK-

[0663] 84

[0664] To a stirring solution of protected trisaccharide 24 (0.68 g, 0.363 mmol) in THF (6.7 mL) was added dropwise solution of HF*Py (70% in THF, 0.07 mL) at 0 °C. After 5 h, EtsN was added and the crude was directly concentrated under reduced pressure and purified by silica gel column chromatography (100% ethyl acetate to 5:95 Methanol: Dichloromethane) to get trisaccharide triol 25 (0.364 g, 67%) as colorless liquid.

[0665] 1H NMR (600 MHz, CDCI3) 5 7.39 - 7.28 (m, 15H), 7.26 (td, J = 8.1 , 4.4 Hz, 8H), 7.22 - 7.14 (m, 2H), 7.07 - 6.92 (m, 2H), 5.43 (d, J = 4.0 Hz, 1 H, H-1 aGalN), 5.16 (d, J = 25.2 Hz, 2H), 5.08 (d, J = 3.7 Hz, 1 H, H-1’aGalN), 4.71 - 4.64 (m, 2H), 4.64 - 4.56 (m, 3H), 4.56 - 4.50 (m, 2H, H-1 / 3QuiN), 4.50 - 4.43 (m, 4H), 4.26 (s, 1 H), 4.17 - 4.08 (m, 3H), 4.08 - 3.99 (m, 1 H), 3.89 (t, J = 8.9 Hz, 1 H), 3.83 - 3.73 (m, 3H), 3.71 (dd, J = 10.9, 2.5 Hz, 1 H), 3.62 (dd, J = 10.8, 5.3 Hz, 1 H), 3.58 - 3.47 (m, 2H), 3.44 - 3.31 (m, 2H), 3.28 - 3.15 (m, 3H), 1.52-1.45 (m, 4H), 1.32-1.25 (m, 5H).

[0666] 13C NMR (151 MHz, CDCI3) 5 162.22, 162.13, 156.44, 137.78, 137.14, 137.07, 137.00, 136.59, 134.52, 128.77, 128.75, 128.72, 128.67, 128.57, 128.13, 128.10, 128.07, 127.85, 127.54, 127.40, 99.88 (C-1 / 3QuiN), 97.58 (C-1’aGalN), 96.72 (C-1 aGalN),

[0667] 92.70, 92.51 , 92.47, 84.72, 84.37, 77.37, 77.26, 77.16, 76.95, 75.62, 75.49, 74.31 ,

[0668] 74.10, 71.92, 71.78, 71.53, 71.15, 70.94, 69.68, 69.39, 67.37, 67.25, 62.79, 61.15,

[0669] 60.52, 56.69, 51.22, 50.67, 50.30, 47.18, 46.02, 29.78, 29.30, 29.14, 27.82, 27.36,

[0670] 23.25, 21.16, 18.16, 14.29.

[0671] HRMS (ESI): calculated for CesHysC N^iyNa [M+Na]+: 1519.2059, found: 1519.2161.

[0672] 5-Amino-pentanyl 2-acetamido-o-D-galactopyranosyl-(1 >4)-2-acetamido-o-D- galactopyranosyl-(1 >3)-2-acetamido-2,6-dideoxy- / 3-D-glucopyranoside (26)

[0673] To a solution of trisaccharide triol 25 (10.8 mg, 0.0072 mmol) in EA / tBuOH / H2O (2 / 1 / 1 , v / v / v, 4 mL), Pd / C (20 mg) was added at room temperature and the reaction was stirred under hydrogen atmosphere (1 atm, balloon) for 48 h. Then crude reaction mixture was filtered through Celite® 353, concentrated, purified by HPLC

[0674] GAR-P04620W004 Application (final) docx -ABK-

[0675] 85

[0676] (Hypercarb Column, 150x10 mm at a flow rate of 3 mL / min, eluted by H2O (with 0.1 % formic acid, Solvent A) and acetonitrile (Solvent B) with a linear gradient from 0% to 30% of solvent B over 30 minutes and lyophilized to afford trisaccharide 26 (4.5 mg, 90%) as a white solid.

[0677] 1H NMR (400 MHz, D2O) <55.43 (d, J = 3.8 Hz, 1 H, H-1 aGalN), 4.93 (d, J = 3.9 Hz, 1 H, H-1 ’aGalN), 4.48 (d, J = 8.6 Hz, 1 H, H-1 / 3QuiN), 4.33 (t, J = 6.7 Hz, 1 H), 4.23 (dd, J = 11 .4, 3.9 Hz, 1 H), 4.20 - 4.14 (m, 1 H), 4.00 (d, J = 9.3 Hz, 3H), 3.89 - 3.78 (m, 3H), 3.75 - 3.61 (m, 6H), 3.61 - 3.51 (m, 1 H), 3.46 - 3.33 (m, 2H), 2.99 - 2.91 (m, 2H), 2.05 (s, 3H), 2.01 (d, J = 3.4 Hz, 6H), 1.63 (p, J = 7.6 Hz, 2H), 1.59 - 1.51 (m, 2H), 1.41 - 1 .29 (m, 2H), 1 .26 (d, J = 6.0 Hz, 3H).

[0678] 13C NMR (151 MHz, D2O) 5 174.48, 174.40, 174.24, 100.72 (C-1 / 3QuiN), 98.24 (C-1 aGalN), 97.14 (C-1 ’aGalN), 77.84, 76.41 , 76.25, 71.68, 71.54, 70.56, 70.09, 68.05, 66.99, 66.80, 60.34, 59.68, 54.33, 50.06, 49.68, 39.21 , 28.06, 26.33, 22.15, 22.07, 21.84, 21.79, 16.33.

[0679] HRMS (ESI): calculated for C29H53N4Oi5 [M+H]+: 697.3501 , found: 697.3515.

[0680] / V-(Benzyl)benzyloxycarbonyl-5-amino-pentanyl 3-O-benzyl-2-trichloro- acetamido-6-O-tertbutyldiphenylsilyl-a-D-galactopyranosyl-(1 >4)-3-O-benzyl-2- trichloroacetamido-6-O-tert-butyldiphenylsilyl-a-D-galactopyranosyl-(1 >3)-4-O- benzyl-2-trichloroacetamido-2,6-dideoxy-p-D-glucopyranoside (4)

[0681] To the stirring solution of trisaccharide triol 25 (200 mg, 0.13 mmol) in CH3CN (4.8 mL), imidazole (39 mg, 0.58 mmol) and TBDPSCI (0.13 mL, 0.53 mmol) were added sequentially at 0°C. After 6 h and complete consumption of the starting material (indicated by TLC), the crude reaction mixture was diluted with EtOAc (20 mL) and washed with brine solution. The separated organic layer was dried over anhydrous Na2SO4, concentrated and purified by silica gel column chromatography (3:7 Ethyl acetate: n-Hexane) to afford 4-OH trisaccharide acceptor 4 (234 mg, 89%) as white sticky liquid.

[0682] 1H NMR (600 MHz, CDCI3) 57.58 (dt, J = 8.2, 1 .5 Hz, 1 H), 7.56 - 7.53 (m, 4H), 7.51 (dd, J = 8.0, 1.4 Hz, 2H), 7.46 (d, J = 7.1 Hz, 2H), 7.35 - 7.31 (m, 3H), 7.30 (s, 2H),

[0683] GAR-P04620W004 Application (final) docx - ABK - 86

[0684] 7.28 - 7.23 (m, 13H), 7.23 - 7.20 (m, 7H), 7.18 (t, J = 1.5 Hz, 2H), 7.16 - 7.12 (m, 4H), 7.10 - 7.06 (m, 2H), 7.02 - 6.99 (m, 3H), 6.90 - 6.85 (m, 3H), 6.66 - 6.45 (m, 2H), 5.31 (d, J = 3.9 Hz, 1 H, H-1 aGalN), 5.08 (d, J = 22.8 Hz, 2H), 4.92 (s, 1 H, H-1 ’aGalN), 4.61 (d, J = 11.7 Hz, 1 H), 4.51 - 4.44 (m, 2H), 4.44 - 4.37 (m, 6H), 4.36 -

[0685] 4.28 (m, 1 H), 4.28 - 4.18 (m, 3H, H-1 / 3QuiN), 4.15 - 4.07 (m, 2H), 3.86 - 3.76 (m, 2H), 3.74 - 3.65 (m, 4H), 3.60 - 3.50 (m, 3H), 3.41 - 3.34 (m, 1 H), 3.31 - 3.21 (m, 2H), 3.16 (dd, J = 17.9, 8.9 Hz, 2H), 3.08 (s, 2H), 1.45 - 1.34 (m, 4H), 1.18-1.10 (m, 5H), 1.00 (s, 9H), 0.93 (s, 9H).

[0686] 13C NMR (151 MHz, CDCI3) 5 162.17, 161.93, 161.40, 156.32, 137.95, 137.73, 136.87, 135.97, 135.78, 135.68, 135.62, 134.93, 133.27, 132.90, 132.81 ,129.17, 128.84, 128.81 , 128.69, 128.63, 128.59, 128.55, 128.33, 128.09, 127.98, 127.96, 127.94, 127.92, 127.82, 127.77, 127.35, 125.43, 99.64 (C-1 / 3QuiN), 97.24 (C-1 ’aGalN), 96.10 (C-1 aGalN), 92.69, 92.61 , 84.13, 77.37, 77.16, 76.95, 75.26, 74.99, 74.39, 72.31 , 71.91 , 71.58, 69.52, 69.04, 67.31 , 64.34, 62.16, 56.99, 51.47, 50.65, 50.32, 47.20, 46.24, 29.83, 29.31 , 28.02, 27.30, 26.92, 26.69, 23.33, 21.60, 19.39, 19.26, 18.14.

[0687] HRMS (ESI): calculated for C97Hi09Cl9N4Oi7Si2Na [M+Na]+: 1995.4415, found: 1995.4016.

[0688] / V-(Benzyl)benzyloxycarbonyl-5-amino-pentanyl 4-azido-3-O-benzyl-2-O- benzoyl-4,6-dideoxy- / ?-D-glucopyranosyl-(1— >2)-3-O-benzyl-2-trichloro- acetamido-6-O-tertbutyldiphenylsilyl-a-D-galactopyranosyl-(1 >4)-3-O-benzyl-2- trichloroacetamido-6-O-tertbutyldiphenylsilyl-a-D-galactopyranosyl-(1 >3)-4-O- benzyl-2-trichloroacetamido-2,6-dideoxy- / 3-D-glucopyranoside (3)

[0689] Anhydrous CH2CI2 (1.1 mL) was added to the mixture of 4-azido-D-viosamine donor 5 (33 mg, 0.067 mmol), 4-OH-trisaccharide acceptor 4 (90 mg, 0.046 mmol) and molecular sieves (100 mg) and this solution was stirred at room temperature for 0.5 h. Then NIS (15 mg, 0.068 mmol) and TMSOTf (1 .7 L, 0.009 mmol) were added to the stirring solution at -30 °C and it was allowed to warm up to -10 °C for 2 h. After completion of reaction (monitored by TLC), EtsN was added and 4A molecular sieves

[0690] GAR-P04620W004 Application (final) docx - ABK> 87 were removed by filtering through a celite bed and the reaction mixture was diluted with CH2CI2 (10 mL) and washed with saturated Na2S2O3 solution. The separated organic layer was dried over anhydrous Na2SO4, concentrated and purified by silica gel column chromatography (0.5:0.5:9 Ethyl acetate: Dichloromethane: Toluene) to give protected tetrasaccharide compound 3 (55 mg, 52%) as colorless viscous liquid. 1 H NMR (700 MHz, CDCI3) 5 8.16 (d, J = 8.3 Hz, 2H), 7.63 (d, J = 7.0 Hz, 2H), 7.53 (dd, J = 15.5, 7.3 Hz, 4H), 7.46 (d, J = 7.5 Hz, 2H), 7.39 - 7.30 (m, 17H), 7.26 - 7.20 (m, 13H), 7.18 (d, J = 4.7 Hz, 8H), 7.15 (d, J = 7.3 Hz, 3H), 7.04 (d, J = 7.3 Hz, 2H), 6.68 - 6.50 (m, 2H), 5.37 (d, J = 3.9 Hz, 1 H, H-1 aGalN), 5.30 (d, J = 8.0 Hz, 1 H, H- 1 / 3Vio), 5.20 - 5.14 (m, 2H), 5.14 (s, 1 H), 4.69 - 4.62 (m, 2H), 4.62 - 4.57 (m, 3H, H- 1 ’aGalN), 4.50 - 4.42 (m, 2H), 4.42 - 4.36 (m, 3H), 4.36 - 4.25 (m, 3H), 4.16 (s, 2H), 4.02 (d, J = 12.6 Hz, 1 H, H-1 / 3QuiN), 3.92 - 3.84 (m, 3H), 3.80 (t, J = 6.7 Hz, 1 H), 3.68 (dd, J = 10.4, 7.0 Hz, 2H), 3.61 - 3.50 (m, 4H), 3.50 - 3.44 (m, 1 H), 3.34 - 3.23 (m, 1 H), 3.20 (q, J = 7.8 Hz, 1 H), 3.12 (t, J = 9.7 Hz, 2H), 3.06 (t, J = 8.4 Hz, 1 H), 2.85 (dd, J = 9.9, 6.1 Hz, 1 H), 1.49 - 1.36 (m, 4H), 1.21 (s, 2H), 1.15 - 1.10 (m, 6H), 1.06 (s, 9H), 0.90 (s, 9H).

[0691] 13C NMR (176 MHz, CDCI3) 5 165.51 , 162.03, 161.62, 161.42, 156.79, 156.28,

[0692] 137.96, 137.66, 137.38, 136.95, 135.84, 135.74, 135.49, 135.47, 133.39, 133.30,

[0693] 133.26, 132.99, 132.41 , 130.23, 128.82, 128.79, 128.68, 128.65, 128.54, 128.50,

[0694] 128.46, 128.40, 128.21 , 128.17, 128.04, 127.96, 127.94, 127.71 , 127.68, 127.36,

[0695] 99.63 (C-1 / 3QuiN, 1 JC-H = 154.0 Hz), 98.13 (C-1 / 3Vi0, 1 JC-H = 168.0 Hz), 96.61 (C-1 ’aGalN, 1 JC-H = 168.0 Hz), 96.14 (C-1 aGalN, 1 JC-H = 175.0 Hz), 92.60, 92.51 , 83.71 ,

[0696] 81.43, 77.34, 77.26, 77.16, 77.06, 76.98, 75.24, 74.69, 73.02, 72.19, 72.03, 71.68,

[0697] 71.01 , 70.67, 69.50, 68.28, 67.83, 67.28, 66.67, 62.75, 61.94, 56.64, 51.39, 50.62,

[0698] 50.31 , 47.16, 46.23, 29.85, 29.29, 27.98, 27.49, 27.37, 27.18, 27.15, 23.30, 19.44,

[0699] 19.28, 18.44, 18.10.

[0700] HRMS (ESI): calculated for CnyH^sC NyO^Na [M+Na]+: 2360.5791 , found: 2360.6353.

[0701] GAR-P04620W004 Application (final) docx -ABK>

[0702] 88

[0703] 5-Amino-pentanyl 4-acetamido-4,6-dideoxy- / ?-D-glucopyranosyl-(1— >2)-2- acetamido-o-D-galactopyranosyl-(1 >4)-2-acetamido-o-D-galactopyranosyl-

[0704] (1 — >3)-2-acetamido-2,6-dideoxy- / ?-D-glucopyranoside (27)

[0705] Activated zinc dust (0.1 g), acetic acid (0.2 mL) and acetic anhydride (1.0 mL) were added sequentially to the stirring solution of protected tetrasaccharide 3 (70 mg, 0.029 mmol) in THF (3 mL). The mixture was stirred for 48 h at room temperature. After completion of reaction (monitored by mass spectrometry analysis), the reaction mixture was diluted with ethyl acetate and zinc was filtered through celite pad, then the liquor was directly concentrated under reduced pressure. Toluene azeotrope was performed to remove the remaining acetic acid and kept under high vacuum for the next step without purification. Rfproduct = 0.5 (100% Ethyl acetate) To a stirring solution of crude tetrasaccharide in THF (3 mL), was added dropwise solution of HF*Py (70% in THF, 0.1 mL) at 0 °C. After 6 h and complete conversion of starting material (monitored by TLC, Rfproduct = 0.1 (100% Ethyl acetate)), EtsN was added and the crude was directly concentrated under reduced pressure to get tetrasaccharide diol. Sodium methoxide (22 mg, 0.41 mmol) was added to the stirring solution of the above prepared tetrasaccharide diol in CH2Cl2 / MeOH (1 / 1 , v / v, 2 mL) at room temperature. After 2 h, TLC showed complete conversion of the starting material. Then Amberlite IR-120 H+ was added to neutralize the mixture. Then it was filtered out, concentrated and passed through a small bed of silica gel column chromatography (5:95 to 1 :9 Methanol: Dichloromethane) to afford the debenzoylated tetrasaccharide triol compound as a colorless sticky solid (Rfproduct = 0.5, 5:95 Methanol: Dichloromethane)). To the crude tetrasaccharide triol compound in EA / fBuOH / H2O (2 / 1 / 1 , v / v / v, 5 mL), was added Pd / C (30 mg) at room temperature and the reaction was stirred under hydrogen atmosphere (1 atm, balloon) for 72 h. The reaction mixture was then filtered through Celite® 353, concentrated, purified by HPLC (Hypercarb Column, 150x10 mm at a flow rate of 3 mL / min, eluted by H2O (with 0.1 % formic acid, Solvent A) and acetonitrile (Solvent B) with a linear gradient from 0% to 30% of solvent B over 30 minutes and lyophilized to obtain tetrasaccharide 27 (9.5 mg, 36% over four steps) as a white solid.

[0706] 1H NMR (700 MHz, D2O) 5 5.42 (d, J = 4.0 Hz, 1 H, H-1 aGalN), 4.92 (d, J = 3.9 Hz, 1 H, H-1’aGalN), 4.60 (d, J = 7.9 Hz, 1 H, H-1 / 3Vio), 4.47 (d, J = 8.6 Hz, 1 H, H-7 / 3QuiN),

[0707] GAR-P04620W004 Application (final) docx - ABK - 89

[0708] 4.36 (t, J = 6.4 Hz, 1 H, H-3QuiN), 4.26 (dd, J = 11 .2, 3.8 Hz, 1 H, H-2’GalN), 4.23 - 4.18 (m, 2H, H-4GalN, H-2GalN), 4.09 (dd, J = 11 .2, 3.1 Hz, 1 H, H-3’GalN), 4.00 (d, J = 3.2 Hz, 1 H, H-4’GalN), 3.89 - 3.81 (m, 4H, H-3GalN, H-5’GalN, -CH(linker)), 3.73 - 3.68 (m, 3H, H- 2QuiN, H-6’aGalN, H-6’bGalN), 3.65 (tt, J = 11.4, 5.4 Hz, 3H, H-5GalN, H-6aGalN, H-6bGalN), 3.62 - 3.58 (m, 1 H, H-4QuiN), 3.57 - 3.50 (m, 3H, H-4Vi0, H-5Vi0, -CH(linker)), 3.46 (t, J = 9.4 Hz, 1 H, H-3Vi0), 3.43 - 3.38 (m, 2H, H-2Vi0, H-5QuiN), 3.36 (t, J = 9.1 Hz, 1 H), 2.94 (t, J = 7.7 Hz, 2H), 2.04 (s, 3H, -NHCOCH3), 2.01 (s, 3H, -NHCOCH3), 1.99 (s, 3H, -NHCOCH3), 1.99 (s, 3H, -NHCOCH3), 1.62 (p, J = 7.7 Hz, 2H, -CH2(linker)), 1.56 - 1.51 (m, 2H, -CH2(linker)), 1.34 (tt, J = 7.9, 3.8 Hz, 2H, -CH2(linker)), 1.25 (d, J = 6.1 Hz, 3H, H-6QuiP), 1.16 (d, J = 5.9 Hz, 3H, H-6Vi0).

[0709] 13C NMR (176 MHz, D2O) 5 174.53, 174.47, 174.23, 170.90, 103.66 (C-1 / 3Vi0), 100.72 (C-1 / 3QuiN), 98.27 (C- 1 ’aGalN), 97.11 (C-1 aGalN), 77.83, 77.60, 76.26, 74.12, 73.41 , 71.68, 71.45, 71.13, 70.09, 70.01 , 67.50, 66.67, 60.33, 59.57, 56.46, 54.33, 50.56, 49.59, 39.21 , 28.06, 26.33, 22.14, 22.07, 22.02, 21.83, 21.77, 16.63, 16.32.

[0710] HRMS (ESI): calculated for C37H66N5O19 [M+H]+: 884.4346, found: 884.4346.

[0711] / V-(Benzyl)benzyloxycarbonyl-5-amino-pentanyl 4-azido-3-O-benzyl-2-O- benzoyl-4,6-dideoxy- / ?-D-glucopyranosyl-(1— >2)-3-O-benzyl-2-trichloro- acetamido-o-D-galactopyranosyl-(1 >4)-3-0-benzyl-2-trichloroacetamido-o-D- galactopyranosyl-(1— >3)-4-O-benzyl-2-trichloroacetamido-2,6-dideoxy- / ?-D- glucopyranoside (28)

[0712] To a stirring solution of protected tetrasaccharide 3 (35 mg, 0.15 mmol) in THF (2 mL) was added dropwise solution of HF*Py (70% in THF, 0.1 mL) at 0 °C. After 12 h, EtsN was added and the crude was directly concentrated under reduced pressure and purified by silica gel column chromatography (1 :1 Ethyl acetate: n- Hexane to 100% Ethyl acetate) to get tetrasaccharide diol 28 (17 mg, 60%) as colorless sticky liquid.

[0713] 1H NMR (600 MHz, CDCI3) 5 8.02 - 7.95 (m, 2H), 7.52 - 7.48 (m, 1 H), 7.38 - 7.34 (m, 4H), 7.34 - 7.31 (m, 4H), 7.31 - 7.29 (m, 4H), 7.29 - 7.26 (m, 8H), 7.24 (td, J = 8.1 , 1.4 Hz, 4H), 7.16 (dd, J = 5.0, 1.9 Hz, 3H), 7.14 - 7.12 (m, 2H), 6.81 (d, J =

[0714] GAR-P04620W004 Application (final) docx -ABK-

[0715] 90

[0716] 9.0 Hz, 1 H), 6.48 (s, 1 H), 5.37 (s, 1 H, H-1 aGalN), 5.22 - 5.10 (m, 3H), 4.87 (d, J = 3.7 Hz, 1 H, H-1 ’aGalN), 4.78 (d, J = 8.3 Hz, 1 H, H-1 / 3Vi0), 4.72 - 4.61 (m, 2H), 4.55 (ddd, J = 21 .5, 11 .2, 6.0 Hz, 4H), 4.49-4.42 (m, 3H, H-1 / 3QuiN), 4.43 - 4.35 (m, 2H), 4.34 (dd, J = 8.1 , 2.9 Hz, 1 H), 4.27 - 4.18 (m, 2H), 4.16 - 4.04 (m, 3H), 3.98 (s, 1 H), 3.86 - 3.77 (m, 2H), 3.72 (s, 1 H), 3.66 - 3.59 (m, 2H), 3.57 (t, J = 9.1 Hz, 2H), 3.45 - 3.35 (m, 2H), 3.32 (d, J = 7.5 Hz, 1 H), 3.25 - 3.12 (m, 5H), 2.72 (t, J = 7.0 Hz, 1 H), 1 .54 - 1 .40 (m, 4H), 1 .35 (d, J = 5.7 Hz, 3H), 1 .28 - 1 .23 (m, 5H).

[0717] 13C NMR (151 MHz, CDCI3) 5 165.66, 162.10, 161.12, 156.49, 137.91 , 137.42,

[0718] 137.14, 137.12, 136.93, 133.09, 130.24, 129.77, 128.91 , 128.85, 128.79, 128.72,

[0719] 128.62, 128.52, 128.47, 128.42, 128.37, 128.33, 128.31 , 128.29, 128.10, 128.06,

[0720] 128.03, 127.92, 127.63, 127.50, 127.38, 101.17 (C-1 / 3Vi0, 1 JC-H = 168.0 Hz), 99.99 (C-1 / 3QuiN, 1 JC-H = 161.0 Hz), 97.19 (C-1 ’aGalN, 1 JC-H = 175.0 Hz), 96.85 (C-1 aGalN,

[0721] 1 JC-H = 175.0 Hz), 92.78, 92.55, 83.97, 81.25, 77.37, 77.29, 77.16, 77.08, 76.95,

[0722] 75.67, 75.26, 74.75, 73.99, 72.41 , 71.93, 71.61 , 71.14, 70.75, 70.21 , 69.40, 67.46,

[0723] 67.42, 61.20, 60.61 , 56.48, 51.25, 50.38, 47.24, 46.07, 29.85, 29.22, 27.90, 27.44,

[0724] 27.20, 23.32, 18.40, 18.29.

[0725] HRMS (ESI): calculated for C85H92Cl9N7O2iNa [M+Na]+: 1884.3435, found: 1884.3804.

[0726] / V-(Benzyl)benzyloxycarbonyl-5-amino-pentanyl 2-azido-3-O-benzyl-4,6-O- silylidene-o-Dgalactopyranosyl-(1 >3)-4-O-benzyl-2-trichloroacetamido-2,6- dideoxy-jB-D-glucopyranoside (31)

[0727] Anhydrous CH2CI2 (21 mL) was added to the mixture of D-galactosamine donor 30 (0.73 g, 1.27 mmol), D-quinosamine acceptor ? (0.600 g, 0.847 mmol) and molecular sieves (2.0 g) and this solution was kept stirring at room temperature for 0.5 h. Then NIS (0.286 g, 1.27 mmol) and TMSOTf (16 L, 0.085 mmol) were added to the stirring solution at -30 °C and it was stirred for another 2 h. After completion of reaction (consumption of both donor and acceptor were monitored by TLC), EtsN was added and 4A molecular sieves were filtered through a celite bed and the reaction mixture was diluted with CH2CI2 (30 mL) and washed with saturated Na2S20s solution. The separated organic layer was dried over anhydrous Na2SC>4,

[0728] GAR-P04620W004 Application (final) docx - ABK - 91 concentrated and purified by silica gel column chromatography (1 :4 Ethyl acetate: n-Hexane) to give protected disaccharide 31 (0.751 g, 79%) as white foam.

[0729] 1H NMR (400 MHz, CDCI3) 5 7.43 - 7.39 (m, 2H, -ArH), 7.38 - 7.35 (m, 3H, -ArH), 7.33 (d, J = 2.9 Hz, 5H, -ArH), 7.32 - 7.29 (m, 5H, -ArH), 7.28 (t, J = 1.7 Hz, 2H, -ArH), 7.26 (d, J = 1.7 Hz, 1 H, -ArH), 7.15 (dd, J = 14.7, 7.1 Hz, 2H, -ArH), 5.55 (s, 1 H, H-1 aGalN), 5.18 (d, J = 11.0 Hz, 2H, -CH2Cbz), 4.94 (d, J = 10.6 Hz, 1 H, -CHPh), 4.74 - 4.62 (m, 4H, - CH2Ph, -CHPh, H-1 / 3QuiN), 4.52 - 4.41 (m, 3H, H-5GalN3, -C / - / 2Ph), 4.42-4.15 (m, 1 H, H-3QuiN), 4.12 (d, J = 2.8 Hz, 2H, -CH2(linker)), 3.89 - 3.77 (m, 3H, H-2GalN3, H-4GalN3, H-6aGalN3), 3.73 - 3.62 (m, 2H, H-6bGalN3, H-2QuiN), 3.56 - 3.47 (m, 1 H, H-5QuiN), 3.38 (q, J = 9.5 Hz, 2H, H-4QuiN, H-3GalN3), 3.20 (dt, J = 30.0, 7.6 Hz, 2H, -CH2(linker)), 1.58 - 1.47 (m, 4H, -CH2(linker)), 1.41 (d, J = 6.2 Hz, 3H, H-6QuiN), 1.25-1.22 (m, 2H, -CH2(linker)), 1.04 (s, 9H, -C(CH3)3), 0.98 (s, 9H, -C(CH3)3).

[0730] 13C NMR (101 MHz, CDCI3) 5 161.60, 156.75, 156.24, 137.85, 137.68, 137.58, 136.89, 136.66, 128.60, 128.57, 128.50, 128.06, 127.99, 127.96, 127.86, 127.63, 127.36, 127.25, 99.40 (C-1 / 3QuiN), 97.76 (C-1 aGalN), 92.55, 84.87, 84.68, 77.41 , 77.30, 77.09, 76.78, 75.91 , 75.46, 74.29, 71.37, 70.65, 69.78, 69.52, 67.70, 67.37, 67.23, 58.08, 57.52, 50.28, 47.12, 46.12, 31.98, 29.75, 27.63, 27.29, 23.48, 23.33, 23.20, 22.75, 20.73, 18.30.

[0731] HRMS (ESI): calculated for C56H72CI3N5OiiSiNa [M+Na]+: 1146.3955, found: 1146.4083.

[0732] / V-(Benzyl)benzyloxycarbonyl-5-amino-pentanyl 2-azido-3-O-benzyl-a-D- galactopyranosyl- (1 >3)-4-O-benzyl-2-trichloroacetamido-2,6-dideoxy- / 3-D- glucopyranoside (32)

[0733] To a stirring solution of protected disaccharide 31 (0.552 g, 0.496 mmol) in THF (4.9 mL) was added dropwise solution of HF*Py (70% in THF, 0.11 mL) at 0 °C. After 1 h, Et3N was added and crude was directly concentrated under reduced pressure and purified by silica gel column chromatography (1 :1 Ethyl acetate: n-Hexane to 100% Ethyl acetate) to get disaccharide diol 32 (0.425 g, 88%) as white foam.

[0734] 1H NMR (400 MHz, CDCI3) 5 7.89 - 7.46 (m, 1 H, -NH), 7.41 - 7.25 (m, 19H, -ArH), 7.22 - 7.14 (m, 1 H, -ArH), 5.45 (d, J = 3.7 Hz, 1 H, H-1 aGalN3), 5.18 (d, J = 16.7 Hz,

[0735] GAR-P04620W004 Application (final) docx - ABK - 92

[0736] 2H, -CH2Cbz), 4.95 (d, J = 10.7 Hz, 1 H, -CHPh), 4.72 - 4.60 (m, 4H, H- 1 / 3QuiN, -CH2Ph, -CHPh), 4.53-4.43 (m, 2H, -CH2Ph), 4.22 - 4.14 (m, 1 H, H-3QuiN), 3.98 (s, 2H, H-4GalN3, H-5GalN3), 3.88 (dd, J = 10.5, 3.0 Hz, 2H, H-3GalN3, H-6aGalN3), 3.84 - 3.70 (m, 4H, H-2GalN3, H-6bGalN3, H- 2QuiN, -CH(linker)), 3.54 (t, J = 7.6 Hz, 1 H, H-5QuiN), 3.36 (q, J = 9.5 Hz, 2H, -CH(linker), H-4QuiN), 3.30 - 3.13 (m, 2H, -CH2(linker)), 2.88 (bs, 1 H, -OH), 1.55 (s, 4H, -CH2(linker)), 1.39 (d, J = 6.2 Hz, 3H, H-6QuiN), 1.32 - 1 .25 (m, 2H, -CH2(linker)).

[0737] 13C NMR (101 MHz, CDCI3) 5 162.01 , 156.93, 156.38, 137.74, 137.69, 137.03, 136.78, 136.55, 128.72, 128.60, 128.53, 128.34, 128.15, 128.02, 127.84, 127.76, 127.38, 99.66 (C-1 / 3QuiN), 97.62 (C-1 aGalN3), 92.73, 84.24, 77.49, 77.37, 77.17, 76.85, 76.07, 74.56, 72.00, 71.08, 70.17, 69.42, 68.00, 67.31 , 67.26, 62.93, 60.49, 59.24, 57.64, 50.40, 50.19, 47.15, 45.95, 29.73, 29.13, 27.75, 27.35, 25.62, 23.28, 23.08, 21.11 , 18.17.

[0738] HRMS (ESI): calculated for C^HseC NsOnNa [M+Na]+: 1006.2934, found: 1006.2846.

[0739] / V-(Benzyl)benzyloxycarbonyl-5-amino-pentanyl 2-azido-3-O-benzyl-6-O- tertbutyldiphenylsilyl-o-D-galactopyranosyl-(1 >3)-4-O-benzyl-2- trichloroacetamido-2,6-dideoxy- / 3-D-glucopyranoside (33)

[0740] To the stirring solution of disaccharide diol 32 (0.301 g, 0.306 mmol) in CH3CN (3.0 mL), imidazole (41.5 mg, 0.61 mmol) and TBDPSCI (0.17 mL, 0.672 mmol) were added sequentially at 0 °C. After 3 h and complete consumption of the starting material (indicated by TLC), the crude reaction mixture was diluted with EtOAc (20 mL) and washed with brine solution. The separated organic layer was dried over anhydrous Na2SO4, concentrated and purified by silica gel column chromatography (3:7 Ethyl acetate: n-Hexane) to afford 4-OH disaccharide acceptor 33 (0.321 g, 86%) as white foam.

[0741] 1H NMR (400 MHz, CDCI3) 57.69 (dd, J = 6.6, 1 .5 Hz, 4H, -ArH), 7.48 - 7.43 (m, 2H, -ArH), 7.43 - 7.29 (m, 23H, -ArH), 7.19 (d, J = 7.6 Hz, 1 H, -ArH), 6.91 (dd, J = 57.1 , 7.4 Hz, 1 H, -NH), 5.53 (d, J = 3.3 Hz, 1 H, H-1 aGalN3), 5.20 (d, J = 13.9 Hz, 2H, - CH2Cbz), 4.95 (d, J = 10.7 Hz, 1 H, -CHPh), 4.78 - 4.65 (m, 3H, -CH2Ph, -CHPh), 4.60-4.55 (m, 1 H, H- 1 / 3QuiN), 4.51 (d, J = 6.8 Hz, 2H, -CH2Ph), 4.12 (d, J = 8.7 Hz, 1 H, H-3QuiN), 4.06 (s, 1 H, H-4GalN3), 3.96 (s, 1 H, H-5GalN3), 3.88 (tdd, J = 7.4, 4.1 , 2.5 Hz, 3H, H-2QuiN, H-3GalN3, H-6aGalN3), 3.79 (ddd, J = 10.5, 3.8, 1.4 Hz,

[0742] GAR-P04620W004 Application (final) docx ABK.

[0743] 93

[0744] 3H, H-2GalN3, H-6bGalN3, -CH(linker)), 3.52 - 3.42 (m, 1 H, H-5QuiN), 3.38 (t, J = 8.7 Hz, 2H, H-4QuiN, -CH(linker)), 3.22 (d, J = 29.7 Hz, 2H, -CH2(linker)), 2.66 (d, J = 11.6 Hz, 1 H, -OH), 1.62 - 1.47 (m, 4H, -CH2(linker)), 1.43 (d, J = 6.2 Hz, 3H, H- 6QuiN), 1.31 (d, J = 7.6 Hz, 2H, -CH2(linker)), 1.10 (s, 9H, -C(CH3)3).

[0745] 13C NMR (101 MHz, CDCI3) 5 161.74, 156.80, 137.98, 137.68, 135.85, 135.79,

[0746] 132.94, 132.85, 130.02, 130.00, 128.77, 128.66, 128.58, 128.32, 128.16, 128.05,

[0747] 127.94, 127.90, 127.74, 127.41 , 99.77 (C-1 / 3QuiN), 97.38 (C-1 aGalN3), 92.56, 84.65, 77.48, 77.36, 77.16, 76.84, 76.03, 74.40, 72.01 , 71.40, 70.34, 69.63, 67.25, 66.86, 64.10, 59.11 , 57.52, 50.61 , 47.19, 46.24, 29.26, 27.17, 23.35, 19.29, 18.21.

[0748] HRMS (ESI): calculated for Ce^ysC NsOnSi [M+H]+: 1222.4293, found: 1222.4196.

[0749] / V-(Benzyl)benzyloxycarbonyl-5-amino-pentanyl2-azido-3-O-benzyl-4,6-O- silylidene-o-Dgalactopyranosyl-( 1 >4)-2-azido-3-O-benzyl-6-O-tert- butyldiphenylsilyl-o-Dgalactopyranosyl-( 1 >3)-4-O-benzyl-2- trichloroacetamido-2,6-dideoxy- / 3-D-glucopyranoside (34)

[0750] Anhydrous CH2CI2 (14 mL) was added to the mixture of D-galactosamine donor 30 (0.479 g, 0.833 mmol), disaccharide acceptor 33 (0.68 g, 0.556 mmol) and molecular sieves (1 g) and this solution was kept stirring at room temperature for 0.5 h. Then NIS (0.187 g, 0.833 mmol) and TMSOTf (20 L, 0.112 mmol) were added to the stirring solution at -30 °C and it was stirred for another 2 h. After completion of reaction (consumption of both donor and acceptor were monitored by TLC), EtsN was added and 4A molecular sieves were filtered through a celite bed and the reaction mixture was diluted with CH2CI2 (20 mL) and washed with saturated Na2S20s solution. The separated organic layer was dried over anhydrous Na2SO4, concentrated and purified by silica gel column chromatography (1 :4 Ethyl acetate: n- Hexane) to give protected trisaccharide 34 (647 mg, 71 %) as a colorless sticky solid. 1H NMR (400 MHz, CDCI3) 57.55 (tt, J = 5.0, 2.5 Hz, 4H), 7.36 - 7.29 (m, 6H), 7.28 - 7.23 (m, 9H), 7.22 - 7.16 (m, 11 H), 7.15 - 7.12 (m, 3H), 7.10 - 7.03 (m, 2H), 6.74- 6.56 (m, 1 H), 5.27 (d, J = 3.4 Hz, 1 H, H-1 aGalN3), 5.06 (d, J = 12.1 Hz, 2H), 4.91 (d, J = 2.9 Hz, 1 H, H-1’aGalN3), 4.75 (d, J = 10.8 Hz, 1 H), 4.62 (d, J = 11.2 Hz, 1 H), 4.50 (d, J = 10.9 Hz, 3H), 4.45 (d, J = 10.8 Hz, 2H, H-1 / 3QuiN), 4.41 - 4.32 (m, 3H),

[0751] GAR-P04620W004 Application (final) docx ABK.

[0752] 94

[0753] 4.16 (s, 1 H), 4.03 (t, J = 8.9 Hz, 1 H), 3.95 - 3.86 (m, 2H), 3.85 - 3.75 (m, 2H), 3.75 - 3.66 (m, 4H), 3.63 (d, J = 3.4 Hz, 1 H), 3.61 - 3.53 (m, 2H), 3.50 (dd, J = 10.6, 3.5 Hz, 1 H), 3.45 (dd, J = 7.2, 3.8 Hz, 1 H), 3.41 - 3.33 (m, 1 H), 3.28 - 3.18 (m, 1 H), 3.18 - 3.08 (m, 2H), 3.04 (t, J = 7.3 Hz, 1 H), 1.41 (t, J = 7.8 Hz, 4H), 1.24 (d, J = 6.2 Hz, 3H), 1.16 (d, J = 6.7 Hz, 2H), 0.97 (s, 9H), 0.89 (d, J = 2.0 Hz, 18H).

[0754] 13C NMR (101 MHz, CDCI3) 5 161.61 , 156.81 , 156.26, 138.01 , 137.98, 137.78, 137.72, 137.04, 135.70, 135.65, 132.89, 132.84, 130.30, 130.20, 129.17, 128.73, 128.67, 128.60, 128.56, 128.36, 128.13, 128.09, 128.05, 128.02, 127.99, 127.96, 127.47, 127.33, 125.43, 99.53 (C-1 / 3QuiN), 98.54 (C- 1 ’aGalN3), 97.49 (C-1 aGalN3), 92.56, 83.71 , 77.48, 77.36, 77.16, 76.84, 75.50, 74.73, 71.80, 71.15, 70.28, 69.50, 67.59, 67.27, 67.12, 62.20, 60.31 , 58.05, 57.71 , 50.61 , 50.30, 47.18, 46.25, 29.84, 29.35, 27.71 , 27.41 , 27.19, 23.44, 21.61 , 20.76, 19.33, 18.21.

[0755] HRMS (ESI): calculated for CssH sCIsNsO^Na [M+Na]+: 1661.6196, found: 1661.6432.

[0756] / V-(Benzyl)benzyloxycarbonyl-5-amino-pentanyl 2-azido-3-O-benzyl-a-D- galactopyranosyl- (1 >4)-2-azido-3-0-benzyl-o-D-galactopyranosyl-(1 >3)-4-O- benzyl-2-trichloroacetamido- 2,6-dideoxy- / 3-D-glucopyranoside (35)

[0757] To a stirring solution of protected trisaccharide 34 (0.475 g, 0.289 mmol) in THF (10 mL) was added dropwise solution of HF*Py (70% in THF, 0.5 mL) at 0 °C. After 5 h, EtsN was added and the crude was directly concentrated under reduced pressure and purified by silica gel column chromatography (100% ethyl acetate to 5:95 Methanol: CH2CI2) to get trisaccharide triol 35 (0.321 g, 88%) as white foam.

[0758] 1H NMR (700 MHz, CDCI3) 5 7.38 - 7.35 (m, 8H), 7.35 - 7.29 (m, 11 H), 7.29 - 7.23 (m, 5H), 7.16 (d, J = 6.5 Hz, 1 H), 5.41 (s, 1 H, H-1 aGalN3), 5.17 (d, J = 24.0 Hz, 2H), 4.95-4.92 (m, 2H, H-1 ’aGalN3), 4.74 (d, J = 11.7 Hz, 2H, H-1 / 3QuiN), 4.69 (s, 2H), 4.63 (dd, J = 16.9, 11.1 Hz, 2H), 4.53 - 4.42 (m, 2H), 4.22 - 4.11 (m, 3H), 4.04 (q, J = 6.2 Hz, 2H), 3.92 (td, J = 12.0, 3.2 Hz, 2H), 3.87 (dd, J = 10.7, 2.9 Hz, 1 H), 3.83 (q, J = 3.8 Hz, 1 H), 3.72 (td, J = 10.3, 3.7 Hz,

[0759] GAR-P04620W004 Application (final) docx ABK.

[0760] 95

[0761] 4H), 3.59 - 3.51 (m, 3H), 3.42 - 3.32 (m, 2H), 3.28 - 3.17 (m, 2H), 1.56 - 1.45 (m, 4H), 1 .37 (d, J = 6.2 Hz, 3H), 1 .33 - 1 .29 (m, 2H).

[0762] 13C NMR (176 MHz, CDCI3) 5 162.02, 157.11 , 156.50, 137.86, 137.77, 137.10,

[0763] 136.99, 136.62, 134.91 , 134.53, 134.51 , 128.80, 128.75, 128.68, 128.62, 128.59,

[0764] 128.46, 128.27, 128.24, 128.21 , 128.10, 128.00, 127.95, 127.92, 127.89, 127.86,

[0765] 127.84, 127.81 , 127.70, 127.45, 127.31 , 125.40, 99.43 (C-1 / 3QuiN), 99.02 (C- 1 ’aGalN3), 97.88 (C-1 aGalN3), 92.80, 84.02, 83.80, 77.76, 77.34, 77.16, 76.98, 75.84, 75.52, 74.50, 74.42, 73.49, 72.17, 71.80, 71.78, 71.71 , 71.00, 69.68, 69.54, 67.51 , 67.41 , 62.87, 61.34, 60.09, 59.35, 57.91 , 57.80, 50.39, 50.24, 47.23, 45.85, 32.03, 31.78, 29.80, 29.14, 27.70, 27.40, 26.08, 23.38, 23.03, 18.24.

[0766] HRMS (ESI): calculated for CeiHyiC NsOisNa [M+Na]+: 1283.3996, found: 1283.3840.

[0767] / V-(Benzyl)benzyloxycarbonyl-5-amino-pentanyl 2-azido-3-O-benzyl-6-

[0768] Opentafluorophenyl-o-D-galactopyranosyl uronate-(1 >4)-2-azido-3-O-benzyl-6-

[0769] Opentafluorophenyl-o-D-galactopyranosyl uronate-(1 >3)-4-O-benzyl-2- trichloroacetamido-2,6-dideoxy- / 3-D-glucopyranoside (36)

[0770] TEMPO (64 mg, 0.408 mmol) and NaHCOs (214 mg, 2.55 mmol) were added sequentially to a stirring solution of trisaccharide triol 35 (321 mg, 0.255 mmol) in EA / fBuOH / H2O (1 / 1 / 1 , vlvlv, 5.25 mL) at 0 °C. After 10 minutes, BAIB (658 mg, 2.04 mmol) were added at same temperature. After addition of all reagents, the reaction mixture was warmed up to 4 °C and allowed to stir at the same temperature for 16 h. After complete conversion of alcohol to acids (monitored by TLC), the reaction mixture was diluted with ethyl acetate (20 mL) and then quenched by addition of saturated aqueous Na2S2O3 (2 mL) and aqueous NaH2PO4 (0.5 mL). The organic layer was washed with brine solution and aqueous layer was extracted with ethyl acetate (10 mL) three times. The separated organic layer was dried over anhydrous Na2SO4, concentrated and dried under high vacuum to get crude carboxylate compound as colorless liquid. To the vacuum dried crude carboxylate compound in anhydrous CH2CI2(6 mL), pentafluoro phenol (469 mg, 2.55 mmol) and catalytic amounts of DMAP (6.2 mg, 0.051 mmol) were added sequentially at 0 °C. After that,

[0771] GAR-P04620W004 Application (final) docx -ABK>

[0772] 96

[0773] EDOHCI (459 mg, 2.39 mmol) was added to the reaction mixture at same temperature. After 2 h and completion of reaction (monitored by TLC), the crude reaction mixture was diluted with CH2CI2 (20 mL) and washed with brine solution two times. The separated organic layer was dried over anhydrous Na2SO4, concentrated and purified by silica gel column chromatography (1 :4 Ethyl acetate: n-Hexane) to obtain trisaccharide diester 36 (214 mg, 70% over two steps) as a white solid.

[0774] 1H NMR (600 MHz, CDCI3) 5 7.46 - 7.40 (m, 5H), 7.39 (d, J = 7.0 Hz, 3H), 7.36 - 7.31 (m, 9H), 7.29 (d, J = 1.3 Hz, 7H), 7.22 - 7.15 (m, 1 H), 5.69 (d, J = 3.6 Hz, 1 H, H-1 aGalN3), 5.36 - 5.28 (m, 2H, H-1’aGalN3), 5.23 - 5.12 (m, 2H), 4.90 - 4.77 (m, 3H), 4.77 - 4.65 (m, 4H), 4.65 - 4.55 (m, 2H, H-1 / 3QuiN), 4.55 - 4.43 (m, 3H), 4.08 (t, J = 8.4 Hz, 1 H), 4.02 (dd, J = 10.4, 3.2 Hz, 1 H), 3.98 - 3.91 (m, 1 H), 3.91 - 3.80 (m, 2H), 3.77 (d, J = 7.9 Hz, 1 H), 3.69 - 3.58 (m, 2H), 3.45 - 3.16 (m, 4H), 1 .63 (d, J = 4.7 Hz, 3H), 1.57 - 1 .47 (m, 4H), 1 .36 (d, J = 6.4 Hz, 3H).

[0775] 13C NMR (151 MHz, CDCI3) 5 164.69, 163.80, 161.90, 156.36, 141.99, 138.90, 137.84, 137.34, 136.76, 135.89, 129.08, 128.92, 128.88, 128.69, 128.67, 128.61 , 128.53, 128.16, 128.11 , 128.00, 127.94, 127.86, 127.80, 127.75, 127.45, 127.29,

[0776] 124.37, 100.05 (C-1’aGalN3), 99.41 (C-1 / 3QuiN), 98.03 (C-1 aGalN3), 92.33, 83.23,

[0777] 77.37, 77.30, 77.16, 77.08, 76.95, 75.89, 73.95, 72.60, 72.50, 72.11 , 71.01 , 70.89, 70.51 , 69.19, 67.32, 67.08, 58.84, 58.70, 50.62, 50.37, 47.13, 46.21 , 32.04, 29.81 , 29.48, 29.19, 29.04, 27.91 , 27.28, 23.15, 22.81 , 18.37, 14.25.

[0778] HRMS (ESI): calculated for CysHesCHFioNsOiyNa [M+Na]+: 1643.3266, found: 1643.3289.

[0779] 5-Amino-pentanyl 2-acetamido-o-D-galactopyranosyl uronamide-(1 >4)-2- acetamido-o-D-galactopyranosyl uronamide-(1 >3)-2-acetamido-2,6-dideoxy- / 3- D-glucopyranoside (37)

[0780] Ammonia solution (7N in methanol, 3.1 mL) was added dropwise to a stirred solution of compound 36 (32 mg, 0.0197 mmol) in CH2CI2 (0.6 mL) at room temperature. After 2 h and complete consumption of the starting material (monitored by mass spectrometry analysis), the crude was directly concentrated under reduced pressure

[0781] GAR-P04620W004 Application (final) docx - ABK> 97 and the compound was purified by silica gel column chromatography (5:95 Methanol: Dichloromethane) to get trisaccharide diamide compound (17 mg, 68%) as colorless foam.

[0782] 1H NMR (600 MHz, CDCI3) 57.39 - 7.34 (m, 8H), 7.34 - 7.28 (m, 15H,), 7.18 (s, 2H), 6.74 - 6.67 (m, 1 H), 6.45 (s, 1 H), 5.52 (d, J = 3.7 Hz, 1 H, H-1aGalN3), 5.37 - 5.29 (m, 2H, H-1’aGalN3), 5.16 (s, 2H), 4.80 - 4.74 (m, 2H), 4.74 - 4.69 (m, 3H), 4.66 (dd, J = 13.6, 11.0 Hz, 3H, H-1 / 3QuiN), 4.60 - 4.53 (m, 2H), 4.49 (s, 2H), 4.40 (s, 1 H), 4.17 (s, 1 H), 3.86 (ddd, J = 29.3, 10.7, 2.9 Hz, 2H), 3.79 - 3.66 (m, 3H), 3.63 (dd, J = 10.5, 3.7 Hz, 1 H), 3.55 (dd, J = 10.8, 3.7 Hz, 1 H), 3.41 (t, J = 6.9 Hz, 1 H), 3.36 - 3.16 (m, 3H), 2.32 (s, 1 H), 1 .33 (d, J = 6.5 Hz, 3H), 1 .24 - 1 .21 (m, 2H).

[0783] 13C NMR (151 MHz, CDCI3) 5 171.04, 170.14, 162.23, 156.88, 138.01 , 137.34,

[0784] 136.97, 136.33, 134.95, 129.99, 129.80, 128.86, 128.83, 128.79, 128.70, 128.63,

[0785] 128.47, 128.30, 128.26, 128.11 , 128.00, 127.97, 127.91 , 127.87, 127.45, 127.36,

[0786] 122.22, 98.97 (C-1’aGalN3, 1JC-H = 168.0 Hz), 98.87 (C-1 aGalN3, 1JC-H = 175.0 Hz, C-1 / 3QuiN, 1JC-H = 168.0 Hz), 92.49, 83.05, 74.83, 73.93, 72.42, 71.83, 71.59, 71.48, 69.66, 67.33, 66.52, 58.93, 58.52, 56.28, 50.41 , 47.28, 46.21 , 32.08, 29.85, 29.51 , 29.06, 27.46, 26.70, 23.59, 23.33, 22.84, 18.71 , 14.27.

[0787] MALDI-QToF-MS: calculated for C61H69CI3N10O15K [M+K]+: 1327.7263, found: 1327.612.

[0788] Activated zinc dust (30 mg), acetic acid (0.2 mL) and acetic anhydride (0.5 mL) were added sequentially to a stirring solution of the diamide compound (12 mg, 0.009 mmol) in THF (2 mL). The mixture was stirred for 20 h at room temperature. After completion of reaction (monitored my MALDI-ToF MS analysis), the reaction mixture was diluted with ethyl acetate and zinc was removed by filtering through a celite pad, then the liquor was directly concentrated under reduced pressure. Toluene azeotrope was performed to remove the remaining acetic acid and the solute was passed through silica gel column chromatography (100% Ethyl acetate to 10% Methanol:CH2Cl2) to get triacetamido trisaccharide diamide compound as viscous liquid. The obtained crude triacetamido diamide trisaccharide compound was dissolved in EA / fBuOH / H2O (2 / 1 / 1 , v / v / v, 2 mL). To this solution, a suspension of Pd / C (30 mg) was added and stirred under hydrogen atmosphere (1 atm, balloon) for 48 h. The reaction mixture was then filtered through Celite® 353, concentrated and purified by HPLC (Hypercarb Column, 150x10 mm at a flow rate of 3 mL / min, eluted by H2O (with 0.1 % formic acid, Solvent A) and acetonitrile (Solvent B) with a linear gradient from 0% to 30% of solvent B over 30 minutes and lyophilized to afford trisaccharide diamide 37 (4.2 mg, 63% over two steps) as a white powder.

[0789] 1H NMR (600 MHz, D2O) 5 5.42 (d, J = 4.0 Hz, 1 H, H-1 aGalN), 5.04 (d, J = 4.0 Hz, 1 H, H-1’aGalN), 4.89 (d, J = 1.5 Hz, 1 H, H-5’GalN), 4.50 (d, J = 8.4 Hz, 1 H, H-

[0790] GAR-P04620W004 Application (final) docx -ABK-

[0791] 98

[0792] 5GalN), 4.46 - 4.41 (m, 1 H, H-1 / 3Quip), 4.31 - 4.24 (m, 3H, H-2GalN, H-4GalN, H- 4’GalN), 4.19 (dd, J = 11 .1 , 3.8 Hz, 1 H, H-2’GalN), 4.08 - 4.03 (m, 2H, H-3’GalN, H- 3GalN), 3.87 (dt, J = 10.2, 6.0 Hz, 1 H, -CH(linker)), 3.72 (d, J = 9.4 Hz, 1 H, H- 2QuiN), 3.64 (t, J = 9.3 Hz, 1 H, H-3QuiN), 3.59 - 3.54 (m, 1 H, -CH(linker)), 3.47 (dd, J = 9.7, 6.2 Hz, 1 H, H-5QuiN), 3.41 (d, J = 8.5 Hz, 1 H, H-4QuiN), 3.00 - 2.95 (m, 2H, -CH2(linker)), 2.06 (d, J = 5.1 Hz, 6H, -NHCOCH3), 1.95 (s, 3H, -NHCOCH3), 1.67 (p, J = 7.7 Hz, 2H, -CH2(linker)), 1.62 - 1.54 (m, 2H, -CH2(linker)), 1.42 - 1.35 (m, 2H, -CH2(linker)), 1.31 (d, J = 6.2 Hz, 3H, H-6QuiN).

[0793] 13C NMR (176 MHz, D2O) 5 174.60, 174.34, 174.16, 174.13, 172.98, 100.91 (C- 1 / 3QuiN), 98.24 (C- 1 aGalN), 97.72 (C-1 ’aGalN), 79.78, 76.15, 75.16, 71.73, 71.22, 70.28, 70.15, 68.66, 66.85, 66.20, 54.59, 49.23, 49.06, 39.22, 28.10, 26.36, 22.10, 22.04, 21.93, 21.87, 16.39.

[0794] HRMS (ESI): calculated for C29H51N6O15 [M+H]+: 723.3406 found: 723.3408.

[0795] 4-Methyl phenyl 3-O-benzyl-2-O-benzoyl-4- / V-(9-fluorenylmethyloxycarbonyl)- 4,6-dideoxy-1 -thio-jB-D-glucopyranoside (38)

[0796] Acetic acid (0.6 mL) and activated zinc dust (600 mg) were added sequentially to the stirring solution of compound 5 (0.56 g, 1.14 mmol) in THF (6 mL) at room temperature. The reaction was kept stirring at same temperature for 9 h. After completion of reaction (indicated by TLC), zinc dust was removed by filtering through a celite bed and the reaction mixture was washed with EtOAc. Solvents were removed under reduced pressure and purified by silica gel column chromatography (1 :1 Ethyl acetate: n-Hexane) to afford 4-amino compound (0.376 mg, 71 %) as white foam.

[0797] 1H NMR (400 MHz, CDCI3) 5 8.30 (d, J = 6.9 Hz, 2H, -ArH), 7.83 - 7.76 (m, 1 H, - ArH), 7.71 - 7.63 (m, 2H, -ArH), 7.54 (d, J = 8.2 Hz, 2H, -ArH), 7.46 - 7.34 (m, 5H, - ArH), 7.27 (d, J = 8.2 Hz, 2H, -ArH), 5.49 (t, J = 9.5 Hz, 1 H, H-2), 4.94 (d, J = 9.9 Hz, 1 H, H-1 ), 4.87 (d, J = 11.1 Hz, 1 H, -CHPh), 4.72 (d, J = 11.1 Hz, 1 H, -CHPh), 3.74 (t, J = 9.3 Hz, 1 H, H-3), 3.55 (dq, J = 9.3, 6.1 Hz, 1 H, H-5), 2.93 (t, J = 9.5 Hz, 1 H, H-4), 2.51 (s, 3H, -CH3(STol)), 1 .55 (d, J = 6.1 Hz, 3H, H-6).

[0798] 13C NMR (101 MHz, CDCI3) 5 165.44, 138.12, 137.74, 133.38, 133.14, 130.06, 129.97, 129.68, 128.62, 128.60, 128.25, 128.09, 86.89 (C-1 / 3), 84.49, 77.48, 77.16, 76.84, 74.63, 73.33, 57.96, 21.27, 18.42.

[0799] GAR-P04620W004 Application (final) docx -ABK-

[0800] 99

[0801] Then amine compound (0.526 mg, 1.14 mmol) was dissolved in anhydrous THF (5 mL) and 9-fluorenylmethoxycarbonylchloride (FmocCI, 0.89 g, 3.43 mmol) was added to the solution at 0 °C. The reaction was kept stirring at same temperature for 3 h. After completion of reaction, the crude was diluted in EtOAc (20 mL) and washed with aq. NaHCOs solution. The separated organic layer was dried over anhydrous Na2SO4, concentrated and purified by silica gel column chromatography (3:7 Ethyl acetate: n-Hexane) to afford compound 38 (0.67 g, 86%) as white foam.

[0802] 1H NMR (400 MHz, CDCI3) 58.09 (t, J = 8.6 Hz, 2H, -ArH), 7.76 (dd, J = 7.5, 3.4 Hz, 2H, -ArH), 7.58 (q, J = 6.6 Hz, 4H, -ArH), 7.47 (t, J = 7.8 Hz, 1 H, -ArH), 7.42 - 7.35 (m, 3H, - ArH), 7.33 - 7.24 (m, 3H, -ArH), 7.23 - 7.20 (m, 1 H, -ArH), 7.13 - 7.06 (m, 5H, -ArH), 7.02 - 6.94 (m, 1 H, -ArH), 5.26 (t, J = 9.4 Hz, 1 H, H-2), 4.94 (d, J = 9.8 Hz, 1 H, H-1 ), 4.76 (d, J = 10.0 Hz, 1 H, -CHPh), 4.53 - 4.41 (m, 3H, -CHPh, - CH2Fmoc), 4.18 (q, J = 6.0 Hz, 1 H, -CH Fmoc), 4.13 - 3.98 (m, 1 H, H-3), 3.86 - 3.72 (m, 1 H, H-4), 3.28 (q, J = 9.8 Hz, 1 H, H-5), 2.38 (d, J = 37.9 Hz, 3H, -CH3(STol)), 1.29 (d, J = 7.1 , 3H, H-6).

[0803] 13C NMR (101 MHz, CDCI3) 5 165.25, 155.81 , 143.76, 141.43, 138.19, 137.46, 133.89, 133.36, 133.14, 129.96, 129.66, 128.55, 128.36, 128.25, 127.85, 127.18, 124.95, 120.12, 86.43 (C-1 / 3), 79.41 , 77.48, 77.36, 77.16, 76.84, 74.78, 73.62, 73.02, 66.48, 58.47, 47.35, 21.26, 18.25.

[0804] HRMS (ESI): calculated for C42H39NO6SNa [M+Na]+: 708.2390, found: 708.2197.

[0805] / V-(Benzyl)benzyloxycarbonyl-5-amino-pentanyl 3-O-benzyl-2-O-benzoyl-4- / V-(9- fluorenylmethyloxycarbonyl)-4,6-dideoxy- / ?-D-glucopyranosyl-(1— >2)-2-azido-3- O-benzyl-6-O-pentafluorophenyl-a-D-galactopyranosyl uronate-(1 >4)-2-azido- 3-O-benzyl-6-O-pentafluorophenyl-a-D-galactopyranosyl uronate-(1 >3)-4-O- benzyl-2-trichloroacetamido-2,6-dideoxy- / 3-D-glucopyranoside (39)

[0806] Anhydrous CH2CI2 (2 mL) was added to the mixture of D-viosamine donor 38 (65 mg, 0.095 mmol), trisaccharide acceptor 36 (50 mg, 0.031 mmol) and molecular sieves (100 mg) and this solution was kept stirring at room temperature for 0.5 h. Then NIS

[0807] GAR-P04620W004 Application (final) docx - ABK> 100

[0808] (17 mg, 0.077 mmol) and TMSOTf (2.8 L, 0.015 mmol) were added to the stirring solution at -60 °C and it was allowed to warm up to -40 °C for 2 h. After completion of reaction (monitored by TLC), pyridine was added and 4A molecular sieves was filtered through a celite bed and the reaction mixture was diluted with CH2CI2 (10 mL) and washed with saturated Na2S2O3 solution. The separated organic layer was dried over anhydrous Na2SO4, concentrated and purified by silica gel column chromatography (2:3 Ethyl acetate: n-Hexane) to give protected tetrasaccharide diester 39 (33 mg, 49%) as a colorless sticky solid.

[0809] 1H NMR (700 MHz, CDCI3) 57.90 (d, J = 7.6 Hz, 2H), 7.76 (dd, J = 7.7, 4.1 Hz, 2H), 7.57 (d, J = 7.4 Hz, 2H), 7.54 - 7.47 (m, 1 H), 7.41 - 7.38 (m, 4H), 7.38 - 7.33 (m, 10H), 7.31 - 7.27 (m, 11 H), 7.25 - 7.20 (m, 4H), 7.18 - 7.07 (m, 5H), 7.07 - 6.95 (m, 3H), 5.59 (s, 1 H, H-1 aGalN3), 5.22 - 5.12 (m, 4H, H-1’aGalN3), 4.88 (d, J = 8.2 Hz, 1 H, H-1 / 3Vio), 4.82 - 4.72 (m, 2H), 4.72 - 4.55 (m, 8H, H-1 / 3QuiN), 4.51 - 4.36 (m, 8H), 4.19 (t, J = 6.6 Hz, 1 H), 4.01 (s, 1 H), 3.88 - 3.69 (m, 5H), 3.64 - 3.52 (m, 4H), 3.50 - 3.31 (m, 2H), 3.31 - 3.22 (m, 1 H), 3.17 (dt, J = 19.7, 9.8 Hz, 3H), 1.70 - 1.62 (m, 2H), 1.52 - 1 .42 (m, 4H), 1.31 (d, J = 6.5 Hz, 3H), 0.99 (d, J = 6.2 Hz, 3H).

[0810] 13C NMR (176 MHz, CDCI3) 5 171.40, 165.10, 163.75, 161.85, 156.87, 156.34,

[0811] 155.74, 143.83, 141.47, 140.24, 138.70, 137.91 , 137.38, 136.02, 133.19, 129.82,

[0812] 128.93, 128.87, 128.80, 128.77, 128.68, 128.63, 128.57, 128.55, 128.41 , 128.36,

[0813] 128.24, 128.17, 127.96, 127.89, 127.82, 127.21 , 125.03, 125.00, 121.82, 120.17,

[0814] 100.32 (C-1 / 3Vio), 99.72 (C-1 / 3QuiN), 99.34 (C- 1 aGalN3), 98.04 (C-1’aGalN3), 92.36, 83.05, 77.74, 77.34, 77.16, 76.98, 74.28, 74.07, 73.96, 73.29, 72.74, 71.86,

[0815] 71.79, 71.45, 70.99, 70.90, 70.25, 69.20, 67.37, 67.33, 66.55, 60.58, 59.20, 58.96,

[0816] 58.34, 50.64, 50.38, 47.40, 47.12, 46.22, 32.07, 31.73, 29.84, 29.05, 27.95, 27.32,

[0817] 23.23, 23.15, 22.80, 21.21 , 18.44, 17.77.

[0818] HRMS (ESI): calculated for Cio8H96Cl3FioN9023Na [M+Na]+: 2204.5417, found: 2204.5584.

[0819] GAR-P04620W004 Application (final) docx 5-Amino-pentanyl 4- / V-formamido-4,6-dideoxy- / 3-D-glucopyranosyl-(1 >4)-2- acetamido-2-deoxy-o-D-galactopyranosyl uronamide-(1 >4)-2-acetamido-o-D- galactopyranosyluronamide-(1— >3)-2-acetamido-2,6-dideoxy- / ?-D- glucopyranoside (2)

[0820] Protected tetrasaccharide diester 39 (40 mg, 0.0183 mmol) was dissolved in CH2CI2 (0.6 mL). After that, ammonia solution (7 / V in methanol, 2.8 mL) was added to the solution at room temperature. After 1 h and complete consumption of the starting material (monitored by TLC), the crude was directly concentrated under reduced pressure and the compound was purified by silica gel column chromatography (3:2 Ethyl acetate: n-Hexane) to get tetrasaccharide diamide compound (24 mg, 69%) as a colorless sticky solid.

[0821] 1H NMR (700 MHz, CDCI3) 57.78 (d, J = 7.7 Hz, 2H), 7.64 (d, J = 8.4 Hz, 2H), 7.48 - 7.38 (m, 3H), 7.27 (s, 2H), 7.23 (dt, J = 7.4, 4.1 Hz, 6H), 7.18 (q, J = 5.8 Hz, 16H), 7.14 (t, J = 2.9 Hz, 8H), 7.04 (d, J = 8.1 Hz, 1 H), 6.97 (dt, J = 15.0, 7.3 Hz, 2H), 6.92 (d, J = 7.7 Hz, 2H), 6.48 (s, 1 H, -NH), 6.25 (s, 1 H, -NH), 5.38 - 5.30 (m, 2H, -NH, H- 1aGalN3), 5.08 - 5.00 (m, 3H), 4.94 (s, 1 H„ H-1’aGalN3), 4.64 (dd, J = 18.7, 9.4 Hz, 2H, H-1 / 3Vio), 4.58 (d, J = 11.8 Hz, 2H), 4.53 - 4.43 (m, 6H, H-1 / 3QuiN), 4.39 - 4.31 (m, 8H), 4.28 - 4.21 (m, 1 H), 4.16 (d, J = 28.9 Hz, 1 H), 4.08 - 4.00 (m, 2H), 3.65 -

[0822] GAR-P04620W004 Application (final) docx - ABK> 102

[0823] 3.58 (m, 3H), 3.54 - 3.47 (m, 2H), 3.42 (d, J = 11.1 Hz, 1 H), 3.34 - 3.25 (m, 2H), 3.22 (p, J = 8.6 Hz, 2H), 3.13 (dq, J = 17.1 , 9.1 Hz, 2H), 3.04 (t, J = 8.1 Hz, 1 H), 1.40 - 1.30 (m, 4H), 1.18 (d, J = 6.8 Hz, 5H), 1.11 (d, J = 6.6 Hz, 3H).

[0824] 13C NMR (176 MHz, CDCI3) 5 170.63, 169.88, 165.43, 162.05, 156.75, 156.23,

[0825] 155.73, 143.80, 143.74, 141.37, 137.87, 137.56, 137.17, 136.92, 129.74, 128.70,

[0826] 128.67, 128.63, 128.61 , 128.57, 128.56, 128.53, 128.49, 128.47, 128.37, 128.28,

[0827] 128.21 , 128.13, 128.04, 127.99, 127.97, 127.88, 127.83, 127.76, 127.31 , 127.22,

[0828] 127.11 , 124.92, 120.04, 100.27 (C-1 / 3Vio, 1JC-H = 168.0 Hz), 98.74 (C-1 aGalN3,

[0829] 1JC-H = 175.0 Hz), 98.46 (C-1 ’aGalN3, 1JC-H = 175.0 Hz, C-1 / 3QuiN, 1JC-H = 161.0 Hz), 92.34, 82.82, 77.94, 77.23, 77.05, 76.86, 75.70, 74.45, 73.75, 73.05, 72.03,

[0830] 71.73, 71.34, 71.09, 70.52, 69.55, 69.38, 67.19, 66.41 , 58.92, 58.11 , 56.26, 50.49, 50.24, 47.32, 47.12, 46.09, 44.04, 31.96, 29.73, 29.69, 29.39, 29.12, 28.90, 27.86, 27.31 , 23.41 , 23.17, 22.73, 18.55, 17.77.

[0831] HRMS (ESI): calculated for C96H101CI3N11O21 [M+H]+: 1848.6234, found: 1848.6322.

[0832] Activated zinc dust (30 mg), acetic acid (0.1 mL) and acetic anhydride (0.25 mL) were added sequentially to the stirring solution of tetrasaccharide diamide (11 mg, 0.006 mmol) in THF (1 mL). The mixture was stirred for 36 h at room temperature. After completion of reaction (monitored by MALDI-ToF analysis), the reaction mixture was diluted with ethyl acetate and zinc was filtered out through celite pad, then the liquor was directly concentrated under reduced pressure. Toluene azeotrope was performed to remove the remaining acetic acid and kept under high vacuum for the next step.

[0833] MALDI-QToF-MS: calculated for CiooHm N7023Na [M+Na]+: 1802.0038, found: 1801.3690.

[0834] Sodium methoxide (11 mg, 0.20 mmol) was added to the stirring solution of so formed crude tetrasaccharide diamide in methanol / CH2Cl2 (2 / 1 , v / v, 1 mL). After 1 h, Amberlite IR120H+ was added to the solution and the reaction mixture was filtered out, concentrated to obtain 4-amino- 2-OH tetrasaccharide diamide compound as brown sticky liquid. The crude compound was dissolved in anhydrous DMF (1 mL). 4- Nitrophenylformate (5 mg, 0.034 mmol) was added to it followed by dropwise addition of DIPEA (12 juL, 0.07 mmol). After 2 h and consumption of the amine (indicated by TLC), the reaction mixture was directly concentrated to obtain / V-formamido tetrasaccharide compound as colorless sticky liquid. The obtained / V-formamido tetrasaccharide compound was dissolved in EA / fBuOH / H2O (2 / 1 / 1 , v / v / v, 2 mL). To this solution, a suspension of Pd / C (20 mg) was added and stirred under hydrogen atmosphere (1 atm, balloon) for 48 h. The reaction mixture was then filtered through Celite® 353, concentrated, purified by HPLC (Hypercarb Column, 150x10 mm at a flow rate of 3 mL / min, eluted by H2O (with 0.1 % formic acid, Solvent A) and acetonitrile (Solvent B) with a linear gradient from 0% to 30% of solvent B over 30

[0835] GAR-P04620W004 Application (final) docx -ABK-

[0836] 103 minutes and lyophilized to obtain tetrasaccharide 2 (0.9 mg, 16% over four steps) as a white solid. Notably a minor amount (3%) of 4-amino tetrasaccharide compound was obtained during final purification which indicated possible incompletion of 4-N- formido formation in previous step.

[0837] 1H NMR (700 MHz, D2O) <58.18 (s, 1 H, -NHCHO), 8.00 (s, -NHCHO), 5.38 (d, J = 3.8 Hz, 1 H, H-1 aGalN), 5.00 (d, J = 3.8 Hz, 1 H, H- 1’aGalN), 4.86 (d, J = 1.7 Hz, 1 H), 4.47 (d, J = 7.5 Hz, 1 H), 4.42 - 4.40 (m, 2H, H-1 / 3Vio, H-1 / 3 QuiN), 4.27 (d, J = 3.0 Hz, 1 H), 4.24 (dd, J = 11.4, 3.9 Hz, 1 H), 4.21 (s, 1 H), 4.16-4.14 (m, 1 H), 4.05 - 4.00 (m, 1 H), 3.88 - 3.84 (m, 2H), 3.69-3.63 (m, 1 H), 3.62- 3.58 (m, 3H), 3.54-3.50 (m, 2H), 3.45 - 3.42 (m, 1 H), 3.37 (t, J = 8.7 Hz, 1 H), 3.32 - 3.27 (m, 2H), 3.13-3.08 (m, 2H), 3.01 (t, J = 7.0 Hz, 1 H), 2.95 (t, J = 7.0 Hz, 1 H), 2.85 (solvent peak), 2.67 (solvent peak), 2.03 (s, 3H, - NHCOCH3), 2.02 (s, 3H, -NHCOCH3), 1.92 (s, 3H, - NHCOCH3), 1 .74 - 1 .70 (m, 1 H), 1 .68 (d, J = 7.6 Hz, 1 H), 1 .65 - 1 .62 (m, 3H), 1 .57- 1.53 (m, 1 H), 1.45-1.40 (m, 2H), 1.37-1.36 (m, 1 H), 1.27- 1.25 (m, 3H), 1.20 (d, J = 5.8 Hz, 3H).

[0838] 13C NMR (176 MHz, D2O) 5 174.60, 174.35, 174.14, 172.97, 170.99, 167.70, 164.69, 101.96 (C-1 / 3Vio, 1JC-H = 154 Hz), 101.94 (C-1 / 3QuiN, 1JC-H = 154 Hz), 98.24 (C- 1 aGalN, 1JC-H = 175 Hz), 97.73 (C-1’aGalN, 1JC-H = 182 Hz), 76.15, 75.16, 73.55, 73.37, 73.31 , 71.72, 71.22, 70.74, 70.28, 70.15, 69.99, 69.94, 68.66, 66.85, 66.20, 60.27, 57.61 , 55.44, 54.57, 49.23, 48.89, 42.50, 39.22, 32.54, 28.15, 28.13, 28.10, 26.35, 25.04, 23.60, 22.10, 22.08, 22.04, 21.93, 21.87, 16.70, 16.62, 16.40.

[0839] HRMS (ESI): calculated for C36H62N7O19 [M+H]+: 896.4095, found: 896.4089.

[0840] 5-Amino-pentanyl 2-acetamido-jB-D-glucopyranoside (40)

[0841] To a solution of compound 7 (12 mg, 0.0169 mmol) in EtOAc / fBuOH / H2O (2 / 1 / 1 , v / v / v, 4 mL), was added Pd / C (30 mg) at room temperature. The reaction mixture then was stirred under hydrogen atmosphere (1 atm, balloon) for 48 h. After completion of reaction, the crude mixture was then filtered through Celite® 353, concentrated, purified by HPLC (Hypercarb Column, 150x10 mm at a flow rate of 3 mL / min, eluted by H2O (with 0.1 % formic acid, Solvent A) and acetonitrile (Solvent B) with a linear gradient from 0% to 30% of solvent B over 30 minutes and lyophilized to get linker D-quinovosamine 40 (2.51 mg, 96%) as a white powder.

[0842] 1H NMR (700 MHz, D2O) 5 4.43 (d, J = 8.5 Hz, 1 H, H-1 ), 3.86 - 3.78 (m, 1 H, -CH(linker)), 3.65 - 3.59 (m, 1 H, H-2), 3.57 - 3.49 (m, 1 H, -CH(linker)), 3.47 -

[0843] GAR-P04620W004 Application (final) docx -ABK-

[0844] 104

[0845] 3.38 (m, 2H, H-3, H-5), 3.19 - 3.08 (m, 1 H, H-4), 2.93 (t, J = 6.5 Hz, 2H,- CH2(linker)), 1.98 (s, 3H, -COCH3), 1.65 - 1.50 (m, 4H, -CH2(linker)), 1.34 (dt, J = 8.1 , 4.2 Hz, 2H, -CH2(linker)), 1.26 (d, J = 3.5 Hz, 3H, H-6).

[0846] 13C NMR (176 MHz, D2O) 5 174.37, 100.97 (C-1 ), 75.05, 73.43, 71.81 , 70.00, 55.75, 39.22, 28.03, 26.30, 22.04, 16.56.

[0847] HRMS (ESI): calculated for C13H27N2O5 [M+H]+: 291.1915, found: 291.1941.

[0848] 5-Amino-pentanyl 2-acetamido-o-D-galactopyranoside (41)

[0849] To a stirred solution of diol compound S5 (80 mg, 0.111 mmol) in EA / fBuOH / H2O / (2 / 1 / 1 , v / v / v, 6 mL), was added Pd / C (130 mg) at room temperature. The reaction mixture was then allowed to stir under hydrogen atmosphere (1 atm, balloon) for 24 h. After completion of the reaction, the crude mixture was then filtered through Celite® 353, concentrated, purified by HPLC (Hypercarb Column, 150x10 mm at a flow rate of 3 mL / min, eluted by H2O (with 0.1 % formic acid, Solvent A) and acetonitrile (Solvent B) with a linear gradient from 0% to 30% of solvent B over 30 minutes and lyophilized to afford D-galactosamine derivative 41 (32 mg, 95%) as colorless sticky liquid.

[0850] 1H NMR (600 MHz, D2O) 54.79 (d, J = 3.8 Hz, 1 H, H-1 ), 4.03 (dd, J = 11.1 , 3.8 Hz, 1 H, H-2), 3.87 - 3.78 (m, 3H, H-3, H-4, H-5), 3.68 - 3.57 (m, 3H, H-6a, H-6b, - CH(linker)), 3.38 (dt, J = 10.1 , 6.3 Hz, 1 H, -CH(linker)), 2.88 (dd, J = 8.4, 7.0 Hz, 2H, -CH2(linker)), 1.93 (s, 3H, - NHCOCH3), 1.61 - 1.48 (m, 4H, -CH2(linker)), 1.37 - 1.28 (m, 2H, -CH2(linker)).

[0851] 13C NMR (151 MHz, D2O) 5 174.46, 96.79 (C-1 ), 70.84, 68.46, 67.62, 67.59, 61.24, 49.96, 39.28, 27.89, 26.39, 22.23, 21.84.

[0852] HRMS (ESI): calculated for C13H27N2O6 [M+H]+: 307.1864, found: 307.1884.

[0853] GAR-P04620W004 Application (final) docx

[0854] Scheme 4. Synthesis of D-galacto uronamide derivative 42.

[0855] / V-(Benzyl)benzyloxycarbonyl-5-amino-pentanyl 2-trichloroacetamido-4-O- benzyl-6-Opentafluorophenyl-o-D-galactopyranoside uronate (S8)

[0856] 1. TEMPO BAIB

[0857] TEMPO (11 mg, 0.068 mmol), BAIB (275 mg, 0.85 mmol) and three drops of acetic acid were added sequentially to a stirring solution of known D-galactosamine diol S73 (207 mg, 0.34 mmol) in CH2CI2 / / BuOH / H2O (4 / 4 / 1 , vlvlv, 2.25 mL) at 0 °C. The reaction mixture was allowed to stir at the same temperature for 2 h. After complete conversion of the alcohol to acid (monitored by TLC), the reaction mixture was quenched with addition of saturated aqueous Na2S20s (1 mL) and aqueous NaH2PO4 (0.5 mL). The organic layer was diluted with ethyl acetate (20 mL) and washed with brine solution. The aqueous layer was again extracted with 10 mL ethyl acetate three times. The separated organic layer was dried over anhydrous Na2SC>4, concentrated and dried under high vacuum to get crude carboxylate compound as brownish liquid. To vacuum dried crude carboxylate compound in anhydrous CH2CI2(25 mL), pentafluoro phenol (100 mg, 0.547 mmol) and catalytic amounts of DMAP (21 mg, 0.17 mmol) were added. After that, EDOHCI (229 mg, 1.19 mmol) was added to the reaction mixture. The mixture was stirred at same temperature for 2 h. After completion of the reaction (monitored by TLC), the crude reaction mixture was diluted with CH2CI2(30 mL) and washed with brine solution two times. The separated

[0858] GAR-P04620W004 Application (final) docx - ABK - 106 organic layer was dried over anhydrous Na2SO4, concentrated and purified by silica gel column chromatography (1:4 Ethyl acetate: n-Hexane) to obtain 6-0 ester compound S8 (126 mg, 47% over two steps) as white foam.

[0859] 1H NMR (400 MHz, CDCI3) 5 7.33 - 7.27 (m, 6H, -ArH), 7.25 - 7.17 (m, 8H, -ArH), 7.09 (d, J = 7.3 Hz, 1 H, -ArH), 5.09 (d, J = 16.0 Hz, 2H, -CH2Cbz), 4.95 (dd, J = 12.7, 3.6 Hz, 1 H, H-1 a), 4.71 - 4.60 (m, 3H, H-5, -CH2Ph), 4.49 - 4.38 (m, 3H, H- 4, -CH2Ph), 3.99 - 3.89 (m, 1 H, H-3), 3.64 (td, J = 11 .6, 4.7 Hz, 2H, H-2, -CH(linker)), 3.41 (dt, J = 28.7, 8.0 Hz, 1 H, -CH(linker)), 3.15 (dt, J = 24.1 , 7.3 Hz, 2H, - CH2(linker)), 2.54 (s, 1 H, -OH), 1.62 - 1.37 (m, 6H, -CH2(linker)).

[0860] 13C NMR (101 MHz, CDCI3) 5 164.50, 156.28, 137.86, 136.75, 128.83, 128.59, 128.54, 128.10, 127.99, 127.86, 127.35, 127.21 , 98.39 (C-1 a), 77.40, 77.28, 77.08, 76.76, 75.10, 72.47, 69.94, 69.31 , 67.33, 67.23, 58.36, 50.53, 50.26, 47.04, 46.06, 29.74, 28.99, 27.85, 27.42, 23.27.

[0861] HRMS (ESI): calculated for C^H^FsN^eNa [M+Na]+: 807.2424, found: 807.2418.

[0862] 5-Amino-pentanyl 2-acetamido-o-D-galactopyranoside uronamide (42) .tNH2C 24 h, 52% over three steps „!L

[0863] S85 42 5

[0864] Ammonia solution (7N in methanol, 20 mL) was added dropwise to the stirred solution of compound S8 (100 mg, 0.127 mmol) in CH2CI2(4 mL). After 1 h and complete consumption of the starting material (indicated by TLC), the crude was directly concentrated under reduced pressure to get 6-amido compound as viscous liquid. Activated zinc dust (100 mg), acetic anhydride (0.5 mL) and acetic acid (0.1 mL) were added sequentially to the stirring solution of 6-amido compound (78.4 mg, 0.127 mmol) in THF (3 mL). The mixture was stirred overnight at room temperature. After completion of reaction (indicated by TLC), the reaction mixture was diluted with ethyl acetate and zinc was filtered out through celite pad, then the liquor was directly concentrated under reduced pressure. Toluene azeotrope was performed to remove the remaining acetic acid and kept under high vacuum for the next step. The obtained amide compound (80 mg, 0.127 mmol) was dissolved in EA / fBuOH / H2O (2 / 1 / 1 , vlvlv, 7.5 mL1.5 mL). To this solution, Pd / C (150 mg) was added and stirred under hydrogen atmosphere (1 atm, balloon) for 24 h. The reaction mixture was then filtered through Celite® 353, concentrated, purified by HPLC (Hypercarb Column, 150x10 mm at a flow rate of 3 mL / min, eluted by H2O (with 0.1%

[0865] GAR-P04620W004 Application (final) docx -ABK-

[0866] 107 formic acid, Solvent A) and acetonitrile (Solvent B) with a linear gradient from 0% to 30% of solvent B over 30 minutes and lyophilized to obtain D-galactose uronamide 42 (21 mg, 52% over three steps) as sticky colorless liquid.

[0867] 1H NMR (600 MHz, D2O) <55.01 (d, J = 3.8 Hz, 1 H, H-1 a), 4.40 (d, J = 1.7 Hz, 1 H, H- 5), 4.29 (d, J = 1.6 Hz, 1 H, H-4), 4.17 (dd, J = 11.1 , 3.8 Hz, 1 H, H-2), 3.98 (dd, J = 11 .1 , 3.2 Hz, 1 H, H-3), 3.71 (dt, J = 10.2, 6.6 Hz, 1 H, -CH(linker)), 3.53 (dt, J = 10.2, 6.4 Hz, 1 H, -CH(linker)), 3.01 - 2.94 (m, 2H, -CH2(linker)), 2.04 (s, 3H, -NHCOCH3), 1 .72 - 1 .59 (m, 4H, -CH2(linker)), 1 .48 - 1 .35 (m, 2H, -CH2(linker)).

[0868] 13C NMR (151 MHz, D2O) 5 174.05, 97.05 (C-1 ), 70.67, 68.77, 68.22, 67.34, 49.61 , 39.32, 27.97, 26.45, 22.25, 21.88.

[0869] HRMS (ESI): calculated for Ci3H26N3O6 [M+H]+: 320.1816, found: 320.1835.

[0870] Scheme 5. Synthesis of 4-N-formamido-D-quinovosamine derivative 43.

[0871] / V-(Benzyl)benzyloxycarbonyl-5-amino-pentanyl 4- / V-formamido-3-O-benzyl-4,6- dideoxy-jB-D-glucopyranoside (S9) ,

[0872] Activated zinc dust (106 mg) and acetic acid (0.1 mL) were added sequentially to the stirring solution of compound 16 (80 mg, 0.136 mmol) in THF (1 mL) at room temperature. The reaction was stirred at same temperature for 9 h. After completion of reaction (indicated by TLC), Zn dust was removed by filtering through a celite bed and the reaction mixture was washed with EtOAc. Solvents were removed under reduced pressure and dried under high vacuum for 0.5 h. The crude amine residue was dissolved in anhydrous DMF (2.3 mL). 4-Nitrophenylformate (114 mg, 0.68 mmol) was added to it followed by dropwise addition of DIPEA (0.24 mL, 1.36 mmol). After 2 h and complete consumption of the amine (indicated by TLC), the

[0873] GAR-P04620W004 Application (final) docx -ABK-

[0874] 108 reaction mixture was diluted with ethyl acetate (30 mL) and washed with brine solution. The separated organic layer was dried over anhydrous Na2SO4, concentrated and purified by silica gel column chromatography (5:95 Methanol: Dichloromethane) to obtain / V-formamido compound S9 (46 mg, 58% over two steps) as a sticky white solid.

[0875] 1H NMR (600 MHz, CDCI3) 58.10 - 7.97 (m, 1 H), 7.38 - 7.20 (m, 14H), 7.16 (d, J = 7.7 Hz, 1 H), 5.17 (d, J =24.0 Hz, 2H) 4.89 (q, J = 10.0 Hz, 1 H), 4.66 (dd, J = 11.3, 3.5 Hz, 1 H), 4.53 - 4.40 (m, 2H), 4.20-4.14 (m, 1 H, H-1 ), 3.89 - 3.77 (m, 1 H), 3.57 (dq, J = 16.8, 7.8 Hz, 2H), 3.51 - 3.37 (m, 2H), 3.32 - 3.16 (m, 3H), 3.10 - 2.94 (m, 1 H), 1 .64 - 1 .46 (m, 4H), 1.37 - 1 .28 (m, 2H), 1 .23 (d, J = 5.9 Hz, 3H).

[0876] 13C NMR (151 MHz, CDCI3) 5 165.61 , 163.27, 161.57, 156.93, 156.46, 138.49, 128.66, 128.60, 128.55, 128.45, 128.36, 128.06, 127.89, 127.29, 126.20, 115.76, 102.83-102.74 (C-1 ), 81.35, 79.95, 77.37, 77.16, 76.95, 75.25, 75.15, 74.84, 73.36, 70.71 , 70.47, 69.96, 69.74, 67.36, 59.59, 55.37, 50.56, 50.33, 47.12, 46.20, 32.01 , 30.40, 29.78, 29.29, 29.17, 27.90, 27.37, 23.40, 23.25, 22.78, 18.12, 18.08.

[0877] HRMS (ESI): calculated for Cs^^OyNa [M+Na]+: 613.2884, found: 613.2903.

[0878] 5-Amino-pentanyl 4- / V-formamido-4,6-dideoxy-jB-D-glucopyranoside (43)

[0879] The formamido compound S9 (45 mg, 0.076 mmol) was dissolved in THF / MeOH / H2O (1 / 2 / 2, v / v / v, 5 mL) and two drops of AcOH was added to it. To this solution, a suspension of Pd(OH)2 (90 mg) was added and stirred under hydrogen atmosphere (1 atm, balloon) for 48 h. The reaction mixture was then filtered through Celite® 353, concentrated, purified by HPLC (Hypercarb Column, 150x10 mm at a flow rate of 3 mL / min, eluted by H2O (with 0.1 % formic acid, Solvent A) and acetonitrile (Solvent B) with a linear gradient from 0% to 30% of solvent B over 30 minutes and lyophilized to obtain linker coupled / V-formamido monosaccharide 43 (17 mg, 80%) as a colorless sticky solid.

[0880] 1H NMR (600 MHz, D2O) <57.97 (s, 1 H, -NHCHO), 4.40 (d, J = 8.1 Hz, 1 H, H-1 ), 3.86 (dt, J = 10.0, 6.6 Hz, 1 H, -CH(linker)), 3.65 - 3.54 (m, 3H, H-4, H-5, -CH(linker)), 3.46 (m, J = 31 .1 , 9.5 Hz, 1 H, H-3), 3.26 (td, J = 9.4, 8.0 Hz, 1 H, H-2), 2.96 (t, J = 7.6 Hz, 2H, -CH2(linker)), 1 .67 - 1 .58 (m, 4H, -CH2(linker)), 1 .44 - 1 .36 (m, 2H, -CH2(linker)), 1.24 - 1.12 (m, 3H, H-6).

[0881] 13C NMR (151 MHz, D2O) 5 167.68, 164.67, 101.94 (C-1 ), 73.52, 73.28, 70.72, 70.26, 70.02, 55.42, 39.25, 28.13, 26.35, 22.03, 16.67.

[0882] GAR-P04620W004 Application (final) docx - ABK> 109

[0883] HRMS (ESI): calculated for C12H25N2O5 [M+H]+: 277.1577, found: 277.1783.

[0884] Example B: Glycan microarray binding studies

[0885] Material and Methods

[0886] The sera were investigated and collected at the National Reference Laboratory for Tularemia for diagnostic and screening purposes.

[0887] The glycans were dissolved at 0.1 mM in 50 mM sodium phosphate buffer pH 8.5 and printed in 64 identical fields to NHS activated hydrogel glass slides (TRIDIA™ Activated Slides, Surmodics) using a non-contact sciFLEXARRAYER S3 microarray spotter (Scienion, Berlin, Germany). After incubation overnight in a humidified box, the remaining NHS groups of the slides were quenched with ethanolamine. The slides were blocked with 1 % (w / v) bovine serum albumin (BSA) in phosphate buffered saline (PBS) and a 64 well incubation gasket (FlexWell Grid, Grace Bio Labs) was attached. The slides were incubated with pig, horse, dog, rabbit, cat or cheetah serum diluted 1 :100 in 1 % BSA-PBS for 1 h at 37° C. After three washes with PBS containing 0.1 % (v / v) Tween-20 (PBS-T) the slides were incubated with goat anti-pig IgG (H+L) FITC conjugate (Invitrogen, Cat. PA1 -84850), rabbit anti-horse IgG (whole molecule) - Fluorescein isothiocyanate (Sigma-Aldrich, Cat. F7759), rabbit anti-dog IgG (whole molecule) - Fluorescein isothiocyanate (Sigma-Aldrich, Cat. F4012), goat anti-rabbit IgG (H+L) Alexa Fluor® 647 AffiniPure™ (Jackson ImmunoResearch, Cat. 111-605-003) or goat anti-cat IgG (whole molecule) - Fluorescein isothiocyanate (Sigma-Aldrich, Cat. F4262) diluted 1 :400 for 1 h at 37°C. The slides were washed twice with PBS-T. After removing the gasket, the slides were washed once with PBS and once with water. The dried slides were scanned with an InnoScan 1100 Fluorescence Scanner (Innopsys). Intensities were evaluated with Mapix (Innopsys). The statistical analysis was performed with the software GraphPad Prism 9.3.1 (GraphPad Software, Inc.).

[0888] The synthetic glycans 2, 12, 13, 18, 21, 22, 26, 27, 37, and 40-43 were immobilized in triplicates on glass slides to detect antibodies in serum samples derived from tularemia positive and negative animals (Figures 7 and Figures 8A-6D). The sera of tularemia positive pigs showed significantly higher IgG antibody binding to the monosaccharide 43, the disaccharides 12, 13, 18, 21 and trisaccharide 37 as well as tetrasaccharides 2 and 27 compared to tularemia negative pigs (Figure 7). Significant higher IgG antibody binding to monosaccharide 42, disaccharides 12, 13 and 18, trisaccharide 26 and tetrasaccharide 2 were observed in sera of tularemia positive horses. Monosaccharide 43, disaccharides 21, 13 and 18 as well as trisaccharide 26 were recognized by antibodies in sera of tularemia positive cats and cheetahs. Tularemia positive dogs

[0889] GAR-P04620W004 Application (final) docx - ABK> 110 showed IgG antibody binding to the monosaccharide 43, the disaccharides 13, 12, 18 and tetrasaccharide 2, whereas the sera of tularemia negative rabbits showed IgG antibody binding of monosaccharides 40, 41 and 42 (Figure 8). These experiments identified disaccharides 13 and 18 as leads for the development of diagnostic tools and therapeutics.

[0890] Example C: Synthesis and characterization of conjugates

[0891] General procedure synthesis

[0892] For further immunization studies, glycan 13 and 18 were conjugated to CRM197 to generate semi-synthetic glycoconjugate vaccine candidates.

[0893] The saccharide (13: 0.657 mg; 18: 0.635 mg) was dissolved in 200 pL DMSO, 25 pL pyridine and 10 pL triethylamine were added. 6.5 equivalents of (4-nitrophenyl)- adipate linker in DMSO were added to the saccharide solution. After stirring for 5 hours, the reaction mixture was frozen in liquid nitrogen and then lyophilized to obtain a crude white solid. The residue was washed with chloroform (5x 100 pL) and DCM (3x 1 pL) to remove the excess of bis(4-nitrophenyl) adipate. TLC was used to check that all excess linker was washed off and that no glycan had dissolved. 350 pL of water was added to a 10k Amicon filter and centrifuged at 10000 rpm for 8 minutes to wet the filter. Then CRMigywas transferred to the Amicon 10k filter (180 pL, 1 mg) and the tube was washed with 300 pL of water and also added to the Amicon filter. After centrifugation at 10000 rpm for 8 minutes, the CRMw vial was washed with 350 pL water and transferred to the filter. After centrifugation, the CRMw vial was washed with 350 pL of 0.1 M phosphate buffer pH 8. The filter was removed after centrifugation, inverted into a clean vial and centrifuged at 1000 rpm for 2 min, yielding a colorless filtrate containing CRM197. The filtrate (~70 pL) was transferred to the vial containing the sugar-PNP ester, the tube was washed with phosphate buffer pH 8 (2 x 30 pL) and added to the reaction solution. The reaction was stirred slowly for 24 hours. The solution was transferred to an Amicon 10K filter and the reaction vial was washed with 300 pL of the reaction buffer. The solution was washed three times with 400 pL of water. The solution was then washed with 400 pL of PBS. Finally, the filter was placed upside down in a clean vial and centrifuged at 1 ,000 rpm for 2 minutes. The filtrate was diluted with 350 pL PBS and stored at -20°C.

[0894] GAR-P04620W004 Application (final) docx -ABK>

[0895] 111

[0896] Scheme 6: Preparation of Glycoconjugates. Coupling of 13 and 18 to the carrier protein CRM197 resulted in the glycoconjugate I3-CRM197 and I8-CRM197 respectively.

[0897] Characterization of glycoconjugates13-CRMi97and I8-CRM197

[0898] Mass spectra were recorded using an Autoflex Speed MALDI-TOF system (Bruker Daltonics; Bremen, Germany). Samples were spotted onto MTP 384 ground steel target plates (Bruker Daltonics) using the dried droplet technique with 2,5- dihydroxyacetophenone (DHAP) as matrix. The mass spectrometer was operated in linear positive mode. Mass spectra were acquired over an m / z range of 30,000 to 210,000 and the data analyzed using the FlexAnalysis software supplied with the instrument.

[0899] Conjugation was checked by MALDI-TOF-MS (Figure 9). The results showed that glycan 13 and 18 were successfully conjugated to CRM197. The average loading was 7 units of glycan 13 and 5 units of glycan 18 per protein monomer. ABK.

[0900] 112

[0901] Example D: Mice immunization and generation of polyclonal sera

[0902] In order to test the ability of 13 and 18 to induce a natural immune response, mice were immunized subcutaneously on day 0 with 13-CRM197 or 18-CRM197. They were boosted on days 14 and 28. Blood samples were collected every two weeks and a final bleeding and spleen extraction took place on day 31. The sera were stored at -20°C for further testing on glycan arrays or bacterial ELISA.

[0903] Immunization with the glycoconjugate vaccines lead to the development of glycan specific antibodies in sera of mice.

[0904] The immunizations were conducted by BioGenes GmbH. 8 weeks old C57BL / 6NRj mice (Janvier, Le Genest-Saint_lsle, France) were housed in groups of five animals in individually ventilated cages (Tecniplast, Hohenpeiftenberg, Germany) under specific pathogen-free conditions. Housing and experiments were in accordance with institutional guidelines and with the regulations of the Federation of European Laboratory Animal Science Associations (FELASA).

[0905] Mice were immunized subcutaneously (s.c.) with 1 pg of glycoconjugate per injection. The glycoconjugates, together with Alum adjuvant, were diluted in sterile PBS to a final volume of 100 pL per dose. The animals were immunized on day 0 (primary immunization) and boosted on days 14 and 28. Blood (max. 80pL) samples were collected every two weeks. After coagulation at room temperature, serum was separated by centrifugation at 2,000 g for 10 min. The sera and saliva were frozen at -20°C until further usage.

[0906] Scheme 7. Immunization Schedule. Two groups of five C57 / BL / 6NRj mice were immunized with either I3-CRM197 or I8-CRM197. The primary immunization was followed by two boosts with 14 days interval. Blood was collected every two weeks and the final bleeding and spleen extraction.

[0907] GAR-P04620W004 Application (final) docx -ABK>

[0908] 113

[0909] Hybridoma Generation

[0910] The spleens were taken out of the mice and mashed with 5 mL serum-free RPMI w / o additions. The supernatant was collected in a 50 mL Falcon and filled up with serum- free RPMI w / o additions. The tube was centrifuged at 300 g for 10 min at RT and the pellet was washed with 50 mL serum-free RPMI w / o additions and resuspended in 15 mL serum-free RPMI w / o additions. X63-Ag8 myeloma cells were washed two times in 50 mL serum-free RPMI w / o additions and then transferred to the spleen cells. After centrifugation the pellet was gently disrupted by tapping the bottom of the tube and placed in a 37°C water bath and kept in there during the fusion. 1.5 mL prewarmed 50% PEG 1500 were gradually added to the pellet over a period of 1 min, while continually stirring the cells gently with the pipette tip. The cells were stirred for 1 min and while gently swirling the tube, pre-warmed serum-free RPMI w / o additions medium was slowly added: 1 ml over 60 s, 3 ml over 60 s and 16 ml over 120 s. The cells were immediately centrifuged at 300 g for 10 min in an uncooled centrifuge and incubated for 5 min at RT. The supernatant was removed and the cells gently resuspended in 200 mL selection medium (RPMI 500mL, 2 mM L-Glutamine, 0.05 mg / mL Gentamycin, 1 % Penicillin / Streptomycin, 10% FCS, 1 % Non-Essential Amino Acids, 1xHAT (Hypoxanthin / Aminopterin / Thymidin), 1x BM- Condimed H1 supplement). 200 pL / well of cells were plated onto 96-well flat-bottom plates and incubated at 37°C and 5% CO2

[0911] Binding to synthetic glycans was checked via Glycan microarray analysis after 10 days. Subclonings were performed until the clones were monoclonal. The cells were expanded and slowly adapted to ISF-1 w / o FCS. The supernatant containing the antibody was harvested and sterile filtered 10 days after the last splitting, when the cells were about 100% dead. The antibodies were purified using a protein A / G column.

[0912] Glycan Microarray Experiments (sera and hybridoma)

[0913] The glycans were dissolved at 0.1 mM in 50 mM sodium phosphate buffer pH 8.5 and printed in 64 identical fields to NHS activated hydrogel glass slides (TRIDIA™ Activated Slides, Surmodics) using a non-contact sciFLEXARRAYER S3 microarray spotter (Scienion, Berlin, Germany). After incubation overnight in a humidified box, the remaining NHS groups of the slides were quenched with ethanolamine. The slides were blocked with 1 % (w / v) bovine serum albumin (BSA) in phosphate buffered saline (PBS) and a 64 well incubation gasket (FlexWell Grid, Grace Bio Labs) was attached. The slides were incubated with serum of the immunized mice diluted 1 : 100 and 10 ng / mL, 10Ong / mL, 1000 ng / mL and 10000 ng / mL of monoclonal antibody in 1 % BSA-PBS for 1 h at 37° C. After three washes with PBS containing 0.1 % (v / v) Tween-20 (PBS-T) the slides were incubated with Alexa Fluor® 488

[0914] GAR-P04620W004 Application (final) docx - ABK> 114

[0915] AffiniPure Goat Anti-Mouse IgG, Fey fragment specific, Jackson ImmunoResearch diluted 1 :400 for 1 h at 37°C. The slides were washed twice with PBS-T. After removing the gasket, the slides were washed once with PBS and once with water. The dried slides were scanned with an InnoScan 1100 Fluorescence Scanner (Innopsys). Intensities were evaluated with Mapix (Innopsys). The statistical analysis was performed with the software GraphPad Prism 9.3.1 (GraphPad Software, Inc.).

[0916] ELISA

[0917] Bacteria were cultured overnight. Bacteria were grown to an OD of 0.7 and centrifuged at 3000 g during 5 min. Supernatant was discarded. Bacteria were washed three times with PBS and were afterwards diluted in 10 ml of carbonate bicarbonate coating buffer. High-binding flat bottom ELISA plates (Corning) were coated with 100 ul of diluted bacteria and were incubated at 4 °C overnight. ELISA plates were washed 3 times with PBST. 50 ul of 100pg / mL of monoclonal antibodies in triplicates were pipetted into corresponding wells and incubated at RT for 2 hours. Plates were washed 3 times with PBST.

[0918] Per well 50 ul of goat- anti mouse IgG HRP antibody (Dianova) was added at a dilution of 1 :10000 and incubated for 1 hour. Plates were washed 3 times with PBST. 100 ul of substrate TMB was added to each well. After 10 min the reaction was stopped by adding H2SO4. The absorbance was read at 450 nm in a CLARIOstar Plus plate reader (BMG Labtech).

[0919] Example E: Semisynthetic Glycoconjuqate Vaccine Lead against Francisella tularensis Strain 15 O-Antigen induce functional antibodies and enables the formation of monoclonal antibodies

[0920] Methods

[0921] Glycoconjugate immunizations and hybridoma generation

[0922] The mouse experiments were conducted by BioGenes GmbH. Each five mice (C57BL / 6NRj; 6-8 weeks old) were immunized subcutaneously with 13-CRM197 or 18-CRM197 (1 pg of synthetic glycan per dose). The generation of monoclonal antibodies was done by the hybridoma technique. Myleoma cells (X63-Ag8) were fused with mouse spleen cells using polyethylene glycol and antibody producing clones were subcloned and selected by glycan microarrays using the culture supernatant. Purification of the monoclonal antibodies from the supernatant was done by Protein A / G columns (Thermo Scientific, Pierce™). The Isotyping was carried out with Mouse Isotyping Kits (Biorad). Specific name of the mAbs are: 13 (5383BF8D1 C2C5), 18_1 (5403CE9C1 B2A3), 18_2 (5403CE9G1 D3B5) and 18_3 (5403CE9G1 C1 B6).

[0923] GAR-P04620W004 Application (final) docx -ABK>

[0924] Bacterial ELISA

[0925] The species Francisella tularensis novicida (F048), mediasiatica (18T22166) and holarctica live vaccine strains (FSC155) and holarctica (19T0445) from the Friedrich Loeffler institute were used for testing. The bacteria were grown on CHA plate at 37°C and 5% CO2. High-binding 96-well polystyrene microtiter plates (Corning, USA) were coated overnight at 4°C with 100 pL of each subspecies with an ODeoo= 1.0 in coating buffer (150 mM carbonate-bicarbonate buffer, pH 9.7). After washing three times with PBS-Tween (0.1 % (v / v) Tween in PBS) the plates were incubated with the mAbs (0.1 ng / pL- 0.5 mg / mL in 1 % (w / v) BSA-PBS) in triplicates. After an incubation at RT for 2 h the plates were washed three times with PBS-Tween and were incubated with HRP-conjugated goat anti-mouse IgG secondary antibody (Sigma- Aldrich) (1 :10000 in 1 % BSA-PBS) and again incubated for 2 h at RT. After washing the plates three times with PBS-Tween, HRP substrate 3,3’,5,5’-tetramethylbenzidine (BD Biosciences, United States) was added and the reaction was stopped by 2% H2SO4. The absorbance was measured at 450 nm with an ELISA plate reader instrument (Thermo Scientific SkyHigh Microplate Spectrophotometer).

[0926] Formulated Glycoconjugate Vaccine enables the production of Strain 15 O- antigen capsular polysaccharide antibodies

[0927] The formulated glycoconjugate vaccines successfully induced the production of antibodies targeting the F. tularensis Strain 15 O-antigen capsular polysaccharide. In the immunization study, groups of five C57BL / 6NRj mice (6-8 weeks old) were vaccinated with the synthetic conjugates I3-CRM197 or I8-CRM197. The resulting sera demonstrated clear antibody responses specific to the respective synthetic glycans, confirming that these conjugates effectively elicited an immune response. Subsequent analyses, including glycan microarray profiling, verified the progressive increase in antibody levels against each target glycan throughout the immunization period (see Figure 10), and these immune sera were then used for the generation of monoclonal antibodies.

[0928] Vaccination with the I3-CRM197 conjugate elicited a robust immune response characterized by strong production of both IgM and IgG antibodies (Figure 11), indicating effective activation of both primary and class-switched humoral immune pathways.

[0929] The IgG antibodies generated following immunization with I3-CRM197 showed strong binding not only to the specific target glycan 13 but also to several structurally related glycans, indicating recognition of shared or overlapping epitopes. Similarly,

[0930] GAR-P04620W004 Application (final) docx - ABK> 116 vaccination with 18-CRM197 induced a robust immune response, with high levels of both IgM and IgG antibodies, and the IgG antibodies exhibited specific and pronounced binding to the corresponding glycan 18 (Figure 12).

[0931] Monoclonal antibodies exhibit specific binding to the synthetic glycans and to different Francisella tularensis subspecies. The monoclonal antibodies (mAbs) generated from mice immunized with I3-CRM197 and I8-CRM197 are intended for use in developing a diagnostic kit and a passive immunization strategy for the detection and prevention of F. tularensis infections. From the I3-CRM197 immunization, one lgG2b (K light chain) monoclonal antibody (mAb13) was obtained, while immunization with I8-CRM197 yielded three lgG1 (K light chain) monoclonal antibodies (mAb18_1— 3). These antibodies demonstrated specific binding to their respective synthetic glycans on glycan microarrays, confirming their antigen specificity (Figure 13).

[0932] To confirm the ability of the monoclonal antibodies to recognize Francisella tularensis bacteria, ELISA were performed. The monoclonal antibody mAb13, derived from the I3-CRM197 immunization, exhibited strong and specific binding to multiple F. tularensis subspecies, demonstrating its broad reactivity and potential diagnostic applicability (Figure 14).

[0933] Deposited Biological Material

[0934] Hybridoma cell line producing the monoclonal antibodies mAb 13 of the invention has been deposited under the provisions of the Budapest Treaty with the Leibniz Institute DSMZ-German Collection of Microorganisms and Cell Cultures, Inhoffenstrafte 7 B, 38124 Braunschweig, Germany by the Max Planck Institute of Colloids and Interfaces, Am Muhlenberg 1 , 14476 Potsdam, Germany. The deposit with the DSMZ was made on October 16, 2025. The DSMZ Accession Number is: DSM ACC3386

[0935] The deposited hybridoma is viable and produces monoclonal antibodies specific for the Francisella tularensis O-antigen capsular polysaccharide as described in Example E and Figures 10-14 of this application. Specifically: The hybridoma mAb 13 (lgG2b, K light chain) secretes an antibody showing binding to synthetic glycan 13 and to several F. tularensis subspecies.

[0936] The hybridoma can be maintained by standard mammalian cell-culture methods and the secreted antibodies can be purified from culture supernatant using protein A / G affinity chromatography.

[0937] GAR-P04620W004 Application (final) docx

Claims

-ABK>117Claims1 . A saccharide of general formula (I)H-Ux+1-Ux-T-O-L-NH2(I) wherein x is an integer selected from 1 , 2, 3, and 4;- [Ux+3- Ux+2- Ux+i- Ux]n- with n being an integer selected from 1 , 2 and 3;R1represents -CH2OH or -CONH2;L represents a linker; or a pharmaceutically acceptable salt thereof.

2. The saccharide according to claim 1 , wherein x represents 1 or 2, or a pharmaceutically acceptable salt thereof.

3. The saccharide according to claim 1 or 2, wherein -T- represents a bond, -Ux+3- or —Ux+3— Ux+2— , or a pharmaceutically acceptable salt thereof.

4. The saccharide according to any one of the claims 1 to 3, wherein -L- represents -La-, -La-Le-, -La-Lb-Le-, or -La-Ld-Le- ;-La- represents -(CH2)o-, -(CH2-CH2-O)o-C2H4-, or -(CH2-CH2-O)o-CH2;GAR-P04620W004 Application (final) docx-ABK>118-Lb- represents -O-, -NH-CO-NH-, -NH-CO-CH2-NH-, -NH-CO-; -Ld- represents -(CH2)q- -(CH(OH))q- -(CF2)q- -(CH2-CH2-O)q-C2H4- or -(CH2-CH2-O)q-CH2- ;-Le- represents -(CH2)PI- — (CF2)PI— , -C2H4-(O-CH2-CH2)PI- -CH2-(O-CH2-CH2)PI- or -(CH2)pi-O-(CH2)p2- ; and o, q, p1 and P2 are independently of each other an integer selected from 1 , 2, 3, 4, 5, and 6.

5. The saccharide according to any one of the claims 1 to 3, wherein -L- represents - (CH2)O- and o is an integer selected from 2, 3, 4, 5, 6, 7, and 8.

6. The saccharide according to claim 1 selected from5-amino-pentanyl 4- / V-formamido-4,6-dideoxy- / 3-D-glucopyranosyl-(1 — >4)-2- acetamido-2- deoxy-a-D-galactouronamide;5-amino-pentanyl 4- / V-formamido-4,6-dideoxy- / 3-D-glucopyranosyl-(1 — >4)-2- acetamido-2-deoxy-a-D-galactopyranoside;5-amino-pentanyl 2-acetamido-2,6-dideoxy-o-D-glucopyranosyl-(1^2)-4- / \ / - formamido-4,6-dideoxy- / 3-D-glucopyranoside;5-amino-pentanyl 2-acetamido-a-D-galactopyranosyl uronamide-(1 -^3)-2- acetamido-2,6-dideoxy-[3-D-glucopyranoside5-am ino-pentanyl 2-acetam ido-a-D-galactopyranosyl-( 1 -^3)-2-acetam ido-2,6-dideoxy- / 3-D-glucopyranoside;5-amino-pentanyl 2-acetamido-o-D-galactopyranosyl-(1 ^4)-2-acetamido-o- D-galactopyranosyl-(1 ^3)-2-acetamido-2,6-dideoxy- / 3-D-glucopyranoside 5-amino-pentanyl 4-acetamido-4,6-dideoxy- / 3-D-glucopyranosyl-(1 ^2)-2- acetamido-o-D-galactopyranosyl-(1 ^4)-2-acetamido-o-D-galactopyranosyl- (1 ^3)-2-acetamido-2,6-dideoxy- / 3-D-glucopyranoside;5-amino-pentanyl 2-acetamido-a-D-galactopyranosyl uronamide-(1 -^4)-2- acetamido-a-D-galactopyranosyl uronamide-(1 ^3)-2-acetamido-2,6- dideoxy- / 3-D-glucopyranoside; and 5-amino-pentanyl 4- / V-formamido-4,6-dideoxy- / 3-D-glucopyranosyl-(1 — >4)-2- acetam ido-2-deoxy-a-D-galactopyranosyl uronam ide-( 1 -^4)-2-acetam ido-a- D-galactopyranosyluronamide-(1 ^3)-2-acetamido-2,6-dideoxy- / 3-D- glucopyranoside.

7. A conjugate comprising a saccharide of general formula (I) according to any of the claims 1 to 6 covalently linked to an immunogenic carrier through the nitrogen atom of the -O-L-NH2group, wherein the immunogenic carrier is a carrier protein or a glycosphingolipid.GAR-P04620W004 Application (final) docx-ABK>1198. The conjugate according to claim 7 of general formula (VI)[H-Ux+i-Ux-T-O-L-NH-W]m-IM (VI) wherein m is comprised between about 2 and about 18;— W— is selected from:a represents an integer from 1 to 10; b represents an integer from 1 to 4;IM represents an immunogenic carrier, andUx, Ux+i, T, x, n and L have the meanings as defined in any one of the claims 1 to 5.

9. The conjugate according to claim 7 of general formula (VII)[H-Ux+i-Ux-T-O-L-NH-W]m-CRMi97 (VII) wherein m is comprised between about 2 and about 18;— W— is selected from:a represents an integer from 1 to 10; b represents an integer from 1 to 4; andUx, Ux+i, T, x, n and L have the meanings as defined in any one of the claims 1 to 5.GAR-P04620W004 Application (final) docx-ABK>12010. The conjugate according to claim 8 or 9, wherein-L- represents -La-, -La-Le-, -La-Lb-Le-, or -La-Ld-Le- ; -La- represents -(CH2)0- -(CH^CH^O)O-C2H4- or -(CH^CH^O)o-CH2; -Lb- represents -O-, -NH-CO-NH-, -NH-CO-CH^NH- -NH-CO-; -Ld- represents -(CH2)q- -(CH(OH))q- -(CF2)q- -(CH^CH^O)q-C2H4- or -(CH^CH^O)q-CH^ ;-Le- represents -(CH2)PI- — (CF2)PI— , -C2H4-(O-CH2-CH2)PI--CH2-(O-CH2-CH2)PI- or -(CH2)pi-O-(CH2)p2- ; and o, q, p1 and P2 are independently of each other an integer selected from 1 , 2, 3, 4, 5, and 6.11 . The conjugate according to claim 8 or 9, wherein -L- represents -(CH2)O- and o is an integer selected from 2, 3, 4, 5, 6, 7, and 8.

12. The conjugate according to claim 7, wherein the glycosphingolipid is (2S,3S,4R)- 1-(a-D-galactopyranosyl)-2-hexacosanoylaminooctadecane-3,4-diol.13 . The conjugate according to claim 9 wherein x represents an integer selected from 1 or 2,-T- represents a bond,R1represents -CH2OH, and L, Ux, and Ux+i have the meanings as defined in claims 1 to 5.

14. The conjugate according to claim 9 of general formula (Vlll-a), (Vlll-b), (Vlll-c), (IX-d), or (X-a)GAR-P04620W004 Application (final) docx-ABK>wherein L,R1, m and W have the meanings as defined in claim 9 to 13.

15. A pharmaceutical composition comprising at least one saccharide according to any one of the claims 1 to 6 and / or at least one conjugate according any one ofGAR-P04620W004 Application (final) docx- ABK - 122 the claims 7 to 14 as an active ingredient together with at least one pharmaceutically acceptable adjuvant and / or excipient.

16. The saccharide according to any one of the claims 1 to 6 for use in prevention and / or treatment of a Francisella tularensis infection in an animal susceptible to a Francisella tularensis infection.

17. The conjugate according to any one of the claims 7 to 14 for use in prevention and / or treatment of a Francisella tularensis infection in an animal susceptible to a Francisella tularensis infection.

18. The pharmaceutical composition according to claim 15 for use in prevention and / or treatment of a Francisella tularensis infection in an animal susceptible to a Francisella tularensis infection.

19. A monoclonal antibody or a fragment thereof having specificity for a saccharide of general formula (I) according to any one of the claims 1 to 5, wherein x represents an integer selected from 1 or 2, -T- represents a bond, R1represents -CH2OH, and L, Ux, and Ux+i have the meanings as defined in claims 1 to 5.

20. The monoclonal antibody or fragment thereof according to claim 19 having specificity for a saccharide selected from5-amino-pentanyl 4- / V-formamido-4,6-dideoxy- 3-D-glucopyranosyl-(1 — >4)-2- acetam ido-2-deoxy-a-D-galactopyranoside; and 5-amino-pentanyl 2-acetamido-2,6-dideoxy-a-D-glucopyranosyl-(1— >2)-4- / V- formamido-4,6-dideoxy- / 3-D-glucopyranoside.

21. A diagnostic kit for conducting an immunological assay for detection of antibodies against Francisella tularensis comprising at least one saccharide according to any one of the claims 1 to 6 on a solid support.

22. A diagnostic kit for detection of Francisella tularensis bacteria in a specimen comprising a monoclonal antibody according to claim 19 or 20.GAR-P04620W004 Application (final) docx

Images